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This study proposes to evaluate dosimetrically the feasibility of using rhenium isotopes 
(186Re and 188Re) in the form of perrhenate (which is also a substrate of the sodium iodide 
symporter, NIS) for the treatment of benign nodular thyroid disease and non-thyroidal NIS 
expressing tumours. While radioiodine (131I-NaI) has practical limitations, there is a window in 
which rhenium isotopes might offer greater therapeutic advantages. For instance, 186Re and 
188Re-perrhenate have shorter half-life, higher energy beta particles, longer range and less 
abundant gamma photons thus reducing effective dose to the whole body and members of the 
public and family. Generally, dosimetry in nuclear medicine is considered only at macroscopic 
level with radionuclide uptake assumed to have a uniform distribution throughout the organ. 
However, this assumption is not always correct as radionuclides may or may not get incorporated 
into intracellular structures which, depending on the particular energy transfer mechanisms, may 
be influential. . Therefore, an aim of this thesis was to study the effect of tracer localisation on 
microscopic and macroscopic dosimetry by using the thyroid as a model. 
First, a basic performance evaluation of preclinical imaging systems was carried out. The 
image-based quantification accuracy of SPECT radionuclides (99mTc, 123I and 188Re) and PET 
(18F) with regard to effect of object size, acquisition time and reconstruction parameters (number 
of iterations) were examined with a mouse-size micro-hollow sphere phantom. Quantification 
accuracy in small objects was attempted to be improved using phantom-derived correction factors 
(Chapter 2). Then, a series of in vivo experiments was carried out aimed at spatio-temporal 
quantification with the available SPECT NIS-radiotracers (99mTc-pertechnetate, 123I-NaI, 131I-NaI 
and 188Re-perrhenate) and a forthcoming clinical PET radiotracer (18F-tetrafluoroborate). These 
data demonstrated distinct differences of uptake patterns between metabolised (123I- and 131I-NaI) 
and non-metabolised tracers (18F-tetrafluoroborate, 99mTc-pertechnetate and 188Re-perrhenate), 
and also subtle differences between the non-metabolised tracers. Human-equivalent effective 
dose calculations for diagnostic use of these radiotracers were reported in this study. Dose 
estimations were conducted on the same strain sex- and age-matched animals to allow 
approximate comparison. Dosimetric estimations relevant to treatment of benign nodular thyroid 
disease indicated that rhenium isotopes were equally effective when excluding the highly variable 
uptake in the stomach and urinary bladder. The effective dose per unit of administered activity 
from 186Re and 188Re was lower than conventional radioiodine. Also red marrow absorbed dose 
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was about 1.5 and 3 times (for 186Re and 188Re respectively) lower than that produced by 
radioiodine. In xenograft bearing non-thyroidal NIS adenocarcinoma tumour (human NIS-
engineered model), our data indicated that both rhenium isotopes delivered higher absorbed dose 
to the tumour (6.33 and 8.68 times higher for 186Re and 188Re) compared to 131I-NaI. Additionally, 
the therapy indexes (tumour to effective dose and tumour to thyroid ratio) for both rhenium 
isotopes were greater than 131I-NaI. An investigation of the radionuclide distribution at the 
microscopic level in thyroid tissue with electron microscopy and micro-autoradiography 
techniques illustrated that non-metabolised tracers were only located in thyrocytes whereas 
iodide was detected in the colloid. This information (thyroid geometrical model and tracer 
distribution) were used as an input for small-scale pilot dosimetry using the MCNPx (Monte Carlo 
N-particle extended) platform. The simulation results indicated that the mode of absorbed dose 
when 188Re distributed in thyrocytes was higher and more uniform when compared with 131I being 
located in the colloid.  
In conclusion, dose delivered to the thyroid is dependent on cellular distribution of 
radiotracers. The work presented in this thesis has been an important step for initial dosimetric 
estimates of the therapeutic potential of these radiotracers to inform future translation with pilot 
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Chapter 1 Introduction  
1.1 Introduction 
In nuclear medicine, unsealed radiation sources are administered to patients for 
diagnostic and therapeutic purposes. Dosimetry is intended to predict the risks of radiation in 
diagnosis and also the effectiveness and treatment outcome in therapeutic nuclear medicine. The 
term of dosimetry generally reflects only the macroscopic level but the information at this level is 
not always adequate to explain the complexity of inhomogeneous distribution of radiotracer and 
also the effect of Auger electrons and other secondary emissions (Sgouros, 2005; Stabin et al., 
1999). Thus, it is important to study the distribution of tracer at cellular and subcellular level in 
order to obtain realistic dosimetry maps. Consequently, this knowledge is important in further 
understanding of biological effects from internal emitting radiation in nuclear medicine (Puncher 
and Blower, 1994a). This research will use the thyroid as a model for studying the dosimetry at 
macroscopic and microscopic levels. 
Radioactive iodine treatment (RAIT) is a standard methodology to treat benign and 
malignant disease of the thyroid gland.  The administration of radioiodine (131I-iodide) for 
therapeutic purposes has been commonly accepted for the treatment of benign and malignant 
disease of the thyroid gland since the 1940s and still continues in the therapy of thyroid diseases 
today (Cooper et al., 2006; Tuttle et al., 2010). In the case of benign disease, RAIT is used in 
treatment of hyperthyroidism such as Grave’s disease, toxic nodular goitre or toxic autonomous 
goitre. Additionally, RAIT is also used to decrease the size of nodule and also for suppressing the 
function of thyroid gland in non-toxic diffuse goitre and euthyroid multi nodular goitre. In thyroid 
cancer, RAIT is used to ablate thyroid gland after thyroidectomy and/or to treat metastasis lesion 
(Aschebrook-Kilfoy et al., 2010; Pacini).  
In normal thyroid, the thyroid cells are formed by “colloid” surrounded by a single layer of 
follicular cells (thyrocytes) (as shown in figure 1-1). Radioiodine is trapped into follicular cells via 
the sodium iodide symporter (NIS) glycoprotein. Then, iodide is metabolized to thyroid hormones 
in the colloid. These are the molecular mechanisms of thyroid radioiodine therapy (Lazar et al., 
1999). The disadvantages of radioiodine thyroid treatment can be attributable to the long physical 
half-life of 8.02 days and the beta-particles emitted by 131I-iodide are quite low energy (Eaverage = 
0.18 MeV) which have a mean range in soft tissue of only 0.39 mm (Haymart et al., 2011). In 
particular, the abundant high-energy gamma rays (0.36 MeV, abundance 81.7%) emitted at the 
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same time as the beta emissions cause a large fraction of the whole body radiation dose as well 
as strongly influencing radiation protection associated with RAIT.  
 
In this research, we propose to evaluate novel radionuclide therapy agents 186Re- and 
188Re- perrhenate, which are also a substrate of NIS but not metabolised in processes of thyroid 
hormone production. Radiopharmaceuticals labelled with rhenium isotopes have been proposed 
for therapeutic use of non-thyroidal NIS-expressing tumours, for example palliation of skeletal 
bone pain (188Re-,188Re-HEDP), hepatic tumour (188Re-lipiodol) and neuroendocrine tumour 
(labelled with peptides) (Spitzweg and Morris, 2009). 188Re-perrhenate may offer several potential 
advantages over 131I-iodide for radionuclide therapy of the thyroid. 
The radioactive 188Re-perrhenate is easily eluted from an 188W/188Re generator system 
which has a shelf-life of about 6 months. 188Re-perrhenate has a physical half-life of 16.7 h and 
emits more energetic beta-particles (Eaverage = 0.76 MeV) when compared with I-131 (Eaverage = 
0.18 MeV). The higher beta energy of 188Re may offer more radiobiologically effective treatment 
when treating larger tumours (the mean beta-particle range in soft tissue of 188Re-perrhenate is 
3.10 mm when compared with 131I-iodide of 0.39 mm) and may also enable cross-fire irradiation 
effects. However, the increased range may be also a disadvantage, hence this requires further 
understanding of cellular/subcellular tracer distribution and also small-scale dosimetry. In terms 
of imaging, the gamma photon of 0.15 MeV (15%) emitted by 188Re is less abundant than 0.36 
MeV (81.7%) by 131I-iodide. This means 188Re-perrhenate is still suitable for imaging but imparts 
 
Figure 1-1 Schematic diagram shows section of thyroid gland, thyroid follicular cells are formed from 
“colloid” surround by a shell of follicular cells (Modified from (Champion et al., 2007b; Elbast et al., 2008a)) 
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less whole body radiation dose when compared with conventional 131I-iodide (Chung et al., 2010a; 
Ferro-Flores and Arteaga de Murphy, 2008a; Jeong and Chung, 2003). In the case of 186Re, it 
has a physical half-life of 90.6 h, Eaverage 0.346 MeV, Emax1.070 MeV. Imaging is possible for the 
gamma emission of 0.137 Mev with 9.4 % abundance.186Re can be produced by either cyclotron 
or reactor which make this tracer less available when compared with generator based production 
of 188Re. However, it is still a tracer of choice for therapeutic NIS applications. Also for both 
rhenium isotopes, the cost of radiation protection and management will be reduced due to less 
demanding aspects of shielding and waste management owing to their gentler gamma profiles 
emitted from both rhenium isotopes and shorter half-life.  
According to these potential advantages, the proposed treatment may potentially offer a 
significant therapeutic improvement to patient quality of life and treatment cost effectiveness (Cyr 
et al., 2007; Verburg et al., 2011). However, these issues require further studies in order to confirm 
the radiation dose profiles and clinical advantages. The studies in this thesis are designed to 
assess the hypothesis that rhenium isotopes might offer greater therapeutic advantages for 
treatment of thyroid diseases and non-thyroidal NIS expressing tumour. Hence, the micro-scale 
dosimetry is one way to predict and answer these topics. These clinical relevant therapeutic 
decisions and questions, coupled with the well-defined tissue/cell geometry and uptake 
mechanisms associated with thyroid, make the thyroid therapy model an ideal one to introduce 











1.2 Thyroid  
As mentioned in the introduction, this project aims to use the thyroid as the model to study 
microscopic and macroscopic dosimetry. Thyroid is a good model because there is a lot of clinical 
data available, together with well-defined cell geometry and potential clear cut differences in 
micro-distribution of the various radiotracers. Therefore, these make the thyroid therapy model 
an ideal one to introduce and evaluate the role of small-scale dosimetry. The following part will 
provide the literature research of thyroid anatomy, histology, physiology and the role of nuclear 
medicine in the management of thyroid disease. 
1.2.1 Thyroid Anatomy 
The thyroid gland is part of the endocrine system which secretes hormones into the 
bloodstream. The thyroid gland is composed of two cone-like lobes connected via the isthmus. 
The anatomical form of thyroid is a butterfly-shape located in the anterior of lower neck, below 
the larynx. The posterior side of thyroid is reaching to the oesophagus and carotid sheath. The 
upper border is limited by crico-thyroid muscle to thyroid cartilage. The lower border extends to 




     
 
Figure 1-2 The thyroid gland gross anatomy and blood supply system (Modified from Netter, 1997) 
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1.2.2 Thyroid Histology 
The thyroid gland contains two types of cells: follicular cells, which are responsible for the 
production of thyroid hormones, and C-cells, which synthesize calcitonin, a hormone that controls 
calcium metabolism. The C-cells are greatly outnumbered by follicular cells. The thyroid follicle is 
composed of a layer of simple epithelium follicular cells surrounding a gel-like pinkish material 
called “colloid”. The follicular cell is responsible for synthesizing the thyroid hormones and 
thyroglobulin (Tg). After the synthesis processes, thyroid hormones are stored as part of the 
thyroglobulin in the colloid which serves as a reservoir of materials for thyroid hormone 
production. The variation in follicular size and height depend on cell activity: squamous shape 
cells indicate a relative inactivity whereas cuboidal to columnar cells show more activity in 
removing the hormone from the stored form (McMullen and Delbridge, 2009; Weigel, 2008). 
 
The C-cells (clear cells) are another type of cell in the thyroid gland which usually appears 
large and clear because their cytoplasm and nucleus does not take up stain with H&E 
(hematoxylin and eosin). The C-cells are located in spaces between the follicles, so they are 
sometimes called “parafollicular cells”. Parafollicular cells secrete calcitonin, a hormone that 





Figure 1-3 normal thyroid gland composed of thyroid follicles (follicular epithelial cells and colloid) and 
parafollicular C-cells Modified from (McMullen and Delbridge, 2009; Weigel, 2008) 
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1.2.3 Thyroid Hormones Synthesis and Physiology 
Thyroid hormones are synthesised from tyrosine. The key element in the synthesis of 
thyroid hormone is iodine. There are two thyroid hormones; thyroxine (T4) and 3,5,3'-
triiodothyronine (T3). T4 contains four iodine atoms while T3 is identical to T4, but it has only 
three atoms of iodine per molecule. Thyroid hormones are synthesized by the follicular cells 
together with colloid under regulation by TSH (thyroid stimulating hormone).  
 
There are 5 main steps in synthesis of thyroid hormones. 
“Trapping” – Iodide is trapping from bloodstream into follicular cell by active transport 
via NIS (sodium-iodide symporter). NIS action is stimulated by TSH and can also concentrate 
other ions such as perrhenate, perchlorate, astatide or bromide. In this process, iodide is co-
transported with sodium from basal to apical membrane by ion-gradient. Then, iodide is exported 
into colloid via the exporter protein pendrin. 
“Organification”– Iodide is oxidised to iodine and then iodinated to tyrosyl residues in 
thyroglobulin. According to this process, two molecules are formed: MIT (mono-iodotyrosine) and 
DIT (di-iodotyrosine). This process is controlled by thyroperoxidase (TPO) which is an enzyme 
stimulated by TSH.   
“Coupling” –The linking process of iodotyrosines occurs within the Tg molecule to form 
the thyroid hormones. Linking two molecules of DIT produces T4, whereas, linking one molecule 
of DIT and MIT produces T3. 
 
Figure 1-4 Schematic diagram of thyroid hormones synthesis (Modified from (Häggström, 2014)) 
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“Proteolysis” – After endocytosis to follicular cells, the Tg glycoprotein is digested 
releasing the hormones T3, T4 and iodotyrosine. Thyroid hormones are secreted into the 
bloodstream binding to plasma proteins, only 0.04% of T4 and 0.4% of T3 are free form. 
“Intrathyroidal deiodination” – The deiodination processes of iodotyrosine (MIT or DIT) 
occurs in follicular cell in order to use this iodide again as thyroidal hormones material. This 
process also deiodinate the remaining excess thyroid hormones.  
Thyroid hormones affect almost every cell in our body. The major roles of thyroid 
hormones are: 
Metabolism 
 Increases the basal metabolic rate 
 Increases carbohydrate, lipid and vitamins metabolism 
 Protein synthesis 
 Regulate body temperature 
Growth and Development 
 Neuronal maturation 
 Essential for proper development and differentiation of all cells  
 Long bone growth 
Other System 
 Cardiovascular – increase heart rate and cardiac output 
 Increase sensitivity to catecholamine (e.g. adrenaline) 
In addition, the thyroid gland also produces calcitonin by parafollicular C-cell. The action 
of this hormone is related to calcium and phosphorus metabolism. There are many functions of 
calcitonin such as inhibition of Ca2+ absorption by the intestines, inhibition of osteoclast activity 
in bones, inhibition of resorption of Ca2+ in kidney and vitamin D regulation (McMullen and 








1.2.4  Iodine Kinetics and Sodium Iodide Symporter (NIS) 
 The glycoprotein responsible for iodide transport is the sodium iodide symporter or NIS 
which is located at the baso-lateral plasma membrane of thyroid follicular cells. NIS accumulates 
both Na+ and I- into the cell by active transport. Electrophysiological analysis of NIS indicates 
that it transports a 2:1 ratio of Na+ and I- , which results in a steady-state inward gradient from 
basal to apical membrane. The maintenance of the Na+ gradient is caused by Na+-K+-ATPase. 
Therefore, the iodide transport is energy-dependent. Human NIS is the sodium/iodide co-
transport glycoprotein coded as SLC5A5 which is located on chromosome 19 and codes for a 
protein of 643 amino-acids with a molecular weight of approximately 70-90 kDa and 














1.2.5 Radionuclide Imaging of Thyroid Gland 
The thyroid gland can be imaged with several modalities such as conventional 
radiography, computed tomography (CT), magnetic resonance imaging (MRI) or nuclear medicine 
e.g. planar scintigraphy, positron emission tomography (PET) or single photon computed 
tomography (SPECT).  
In conventional radiography, CT or MRI, thyroid imaging from these modalities accesses 
only the anatomical aspects and some abnormal pathology but does not inform about the function 
of the organ (Filetti et al., 1999).  Nevertheless, the most common cause of thyroid disease occurs 
due to abnormal metabolic function. Therefore, nuclear medicine provides appropriate functional 
imaging based on the physiological properties of radiopharmaceuticals. There are several types 
of radiopharmaceuticals that can be used.  
For SPECT imaging, the most common and practical application is using 99mTc-
pertechnetate. Pertechnetate (99mTcO4−) has physiochemical characteristics similar to iodide but 
is not organified to produce thyroid hormones. (Dadachova and Carrasco, 2004; Dohán and 
Carrasco, 2003a). The 99mTc-pertechnetate produces good quality images thanks to the 
properties of 99mTc but does not indicate all of the aspects of thyroid function. In addition, 99mTc-
sestamibi or -tetrofosmin may help as thyroid tumour seeking tracers in some diseases such as 
differentiated thyroid carcinoma (Giordano et al., 2003).  A better physiological approach of thyroid 
imaging would involve the use of radioisotopes of iodine as it is both trapped and organified by 
thyroid cell. 123I-iodide is ideal tracer for diagnostic imaging, the energy of gamma photons of 159 
keV with abundance of 83.4 % is suited for sodium iodide (NaI) crystal detectors used in SPECT. 
123I-iodide has physical half-life of 13.3 h, which is appropriate for 24 h iodine uptake studies but 
123I-iodide is expensive and not-available worldwide. 131I-iodide has lower cost however it has 
several disadvantages over 123I-iodide. For the same administered activity, 131I-iodide gives more 
radiation dose and lower count rate (lower image quality) when compared with 123I-iodide (Park, 
2002).  
For thyroid PET imaging, most tracers are aimed for use in diagnosis and management 
of thyroid cancer. 18F- fluorodeoxyglucose (FDG) has been used widely in oncology. In thyroid, 
Sundram FX suggested the use of 18F-FDG in patients with high risk disease, adverse histology, 
rising Tg with unknown anatomical source and Hurthle cell carcinoma. Authors also noted that 
combining 18F-FDG PET with 131I-iodide whole body scans had higher diagnostic sensitivity to 
95% (Sundram et al, 2003). Additionally, M. Jauregui-Osiro et al synthesised and evaluated 18F-
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tetrafluoroborate (TFB) for thyroid disease and reported gene imaging of NIS. The preclinical 
evaluation of the tracer in animals has been reported and the work is being translated as a clinical 
study. Hence, 18F-TFB will be another forthcoming PET tracer in thyroid disease (Jauregui-Osoro 
et al., 2010a). For PET iodine isotopes, 124I-iodide can be used for imaging and has presented 
better sensitivity than SPECT. However, 124I-iodide has several disadvantages such as low 
positron yield (23%), long half-life (4.18 days), high positron energy (Emax=2.14 MeV), high energy 
and abundance of gamma emissions (gamma ray abundance exceeds 90% per disintegration) 
(Pentlow et al., 1996). Freudenberg et al suggested that 124I-iodide can be used for improved 
treatment planning and patient specific dosimetry in thyroid cancer of 131I-iodide due to better 























1.2.6 Radionuclide Therapeutic of Thyroid Gland 
For therapeutic purposes, 131I-iodide has been used for therapy of thyroid diseases since 
1940s. As mentioned in previous sections, radioactive iodine treatment (RAIT) is used to ablate 
thyroid remnant after thyroidectomy in thyroid cancer. In addition, RAIT can be used for treatment 
of Grave’s disease, toxic multi-nodular goitre or toxic autonomously thyroid nodule and also for 
suppression of thyroid function in hyperthyroidism. NIS is the fundamental molecular basis for the 
use of radioactive iodine for treatment. Consequently, NIS has also been shown to transport other 
structurally similar anions like ClO3−, SCN−, SeCN−, NO3−, Br−, TcO4− or ReO4−.  
 188Re-perrhenate (188ReO4−) is also a substrate of NIS but not metabolised in processes 
of thyroid hormone production. Radiopharmaceuticals labelled with 188Re have been used for 
therapeutic applications in non-thyroidal tissue. NIS gene transfers for non-thyroidal human 
cancer have been of interest to many groups in cancer researcher. Kogai et al observed NIS 
expression and radioiodine concentration in breast cancer cell line caused by retinoic acid (RA). 
The authors concluded that RA could induce iodide uptake in breast cancer cells and might be a 
potential application for patients whom standard treatments are not effective (Kogai et al., 2000). 
Spitzweg and co-worker also performed experiments in human prostatic adeno-carcinoma cell 
lines (Spitzweg et al., 1999). This study presented another step towards gene therapy of cancer 
with radioiodine. In vivo studies also showed the possibility for this method. Dadachova et al. 
studied the role of 131I and 188Re for treatment of mammary cancer in a mouse model. They 
concluded that NIS expression in the breast cancer animal model is efficient and safe treatment 
with several radionuclides transported by NIS. (Dadachova et al., 2005).  
 In addition, 211At is proposed as new therapeutic radiotracer for thyroid cancer and 
metastatic which emits high energy alpha particles. The physical properties of 211At are promising 
however currently it is only available at a few centres (Chung et al., 2010b). In addition, the 
method to calculate dosimetry for alpha particles must consider energy deposition at the cellular 
and subcellular level as these particles have high linear energy transfer (LET) and high relative 
biological effectiveness (RBE) (Brady et al., 2013).  
 Further details on radionuclide therapy of thyroid diseases are provided in chapter 4 of 





1.3 Microscopic and Macroscopic dosimetry in Nuclear Medicine 
Radiation dosimetry in nuclear medicine aims to estimate radiation risks or benefits from 
unsealed radiation sources that administered to patients. Traditionally, nuclear medicine has been 
focused mainly on a diagnostic radiopharmaceutical. The absorbed dose calculation is based on 
an average organ dose for risks assessment. However with increasing development of new 
radiopharmaceuticals for therapeutic applications, the dosimetry in nuclear medicine needs to be 
determined on a scale comparable to the range of emission and target cell and organelle of 
interest.  
In general, there are 2 levels of dosimetry described in the literature; microscopic and 
macroscopic. Macroscopic dosimetry is considered in non-stochastic approaches while 
microscopic aims to quantify the energy deposited at small scale with stochastic approaches 
(Bardies and Pihet, 2000; Stabin, 2006). Therefore, the following section will provide the general 
overview of macroscopic and microscopic dosimetry in nuclear medicine. 
1.3.1 Macroscopic Dosimetry in Nuclear Medicine  
 Macroscopic dosimetry in nuclear medicine deals with the energy deposited by internal 
emitted radionuclide to organ, tissue or whole body level. To state the macroscopic quantity, the 
absorbed dose is usually used. The absorbed dose for each tissue is the energy absorbed per 
unit mass. The direct measurement of absorbed dose for internalised emitting radionuclide is 
difficult to perform, and the absorbed dose in nuclear medicine is usually determined indirectly by 
calculation (Zanzonico, 2000). Mostly of clinical nuclear medicine dosimetry are relied on 
macroscopic dosimetry with calculated by MIRD (Medical Internal Radiation Dose) method. This 
method is sufficient to estimate absorbed dose by using 2 fundamental quantities; the source-
target geometry factor (also called S-factor) and activity distribution as a function of time (Speer, 
2012). The details of this method, the assumptions and their limitations are extensively discussed 
in chapter 4.    
1.3.2 Microscopic Dosimetry in Nuclear Medicine  
Microscopic dosimetry most generally means measuring the energy deposited on a 
microscopic scale and a sub-millimetre scales which below the resolution of the scanner. More 
distinctively, microscopic dosimetry studies the number, size, spatial, temporal and energy-
spectral distributions of individual energy imparted in cellular and sub-cellular structures (Attix, 
2007; Rossi and Zaider, 1991). Furthermore, dosimetry at microscopic scale takes into account 
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the stochastic fluctuations in the micro volume.  This contrasts with macroscopic dosimetry, where 
the radiation absorbed dose is obtained by dividing the total energy deposited by the mass of that 
volume (i.e. averaging out inhomogeneity within that volume). The calculation does not include 
the stochastic effects because of the large target volume of interest. Consequently, the individual 
cell dose can be over or under estimated due to stochastic nature of radiation and because of the 
inhomogeneous distribution of radionuclides within the volume. 
Another consideration point for macroscopic dosimetry is the assumption of the 
radionuclide distribution is homogeneously to all cells over the entire organ. However, this 
assumption is not always correct as some cell populations in the organ may contain very different 
amounts of radioactivity, and even some cells may not uptake radiotracer. (Farragi et al., 1994; 
Humm et al., 1993a). In addition, the microscopic dosimetry is increasingly of interest because 
the clinical application of high LET radionuclides has become increasingly widespread e.g. alpha 
therapy. The conventional macroscopic dosimetry are inadequate, also, the understanding of 
microscopic dosimetry is important for the diagnostic radiopharmaceutical due to their Auger 
electrons e.g. 67Ga, 99mTc, 201Tl (Humm et al., 1993b; Roeske et al., 2008a). 
The details of microscopic dosimetry including methods for estimation, assumptions and 


















1.4 Thesis Overview  
The major aim of this work is to study the connecting paths of micro- and macro-dosimetry 
using the thyroid as a model. We also aim to evaluate novel radionuclide therapy agents 186Re- 
and 188Re-perrhenate and to compare these radiotracers with conventional radioiodine (131I-NaI) 
using preclinical data. Several experiments have been undertaken for this work. The overview of 
the work is summarised below.   
Chapter 1 contains an introduction and general literature review.  
Chapter 2 investigates the quantification accuracy of preclinical imaging systems 
(nanoScan SPECT/CT and nanoScan PET/CT)  
Chapter 3 explores the capabilities of preclinical imaging systems to quantify the spatio-
temporal distribution of NIS radiotracers (99mTc-pertechnetate, 123I-NaI, 131I-NaI 188Re-perrhenate 
and 18F-tetrafluoroborate) in healthy model and NIS-expressing tumour model (rat 
adenocarcinoma engineered-hNIS). 
Chapter 4 examines the macro-dosimetry of the potential radiopharmaceuticals by using 
MIRD (Medical Internal Radiation Dose) formalism with the OLINDA dosimetry software. The 
kinetic data are based on quantitative preclinical imaging from the previous chapter. We estimate 
the effective dose of diagnostic NIS-radiotracers and also investigate the dosimetric feasibility of 
using 186Re- and 188Re-perrhenate in treatment of benign nodular thyroid disease in comparison 
with conventional 131I-NaI and explore using these new therapeutic radiotracers in NIS-expressing 
tumours. We also examine the impact of quantification accuracy on dosimetry calculations from 
preclinical studies. 
Chapter 5 investigates methods for measurement of tracer distribution at the microscopic 
level. Tracer distribution in thyroid is examined using micro-autoradiography (MAR) and electron 
microscopy (EM) techniques. The distribution and cell geometry are used as input for pilot micro-
scale dosimetry. Then, the micro-scale dosimetry is used to estimate the dose at cellular level 
using the Monte Carlo MCNPx platform.  




Chapter 2 Quantitative Imaging with the nanoScan SPECT/CT 
2.1 Introduction 
SPECT/CT is an essential tool for accessing the distribution of radioactivity in biomedical 
research. The SPECT (Single Photon Emission Tomography) modality offers a tool for 
visualisation of radiotracer accumulation but can also provide quantitative information. In vivo 
image quantification is crucial for many applications, especially for image-based dosimetry, where 
the absolute activity within the tissue/organ permits the calculation of absorbed dose. There are 
many intricate processes and limitations related to SPECT instrumentation and methodology 
which can affect the accuracy of quantification (Franc et al., 2008; Ritt and Kuwert, 2013; Walrand, 
2014). The following figure outlines the factors and correction methods for quantitative SPECT in 
clinical applications. 
 
The main factors limiting the accuracy of quantitative SPECT are photon attenuation and 
scatter of gamma photons as they pass different layers of tissue or surrounding material (e.g. 
collimators) before entering the detector. Additionally, the relatively poor intrinsic resolution of the 
scanner can blur the activity distribution with strong influence on quantification when the 
dimensions of object are comparable or smaller than the spatial resolution of the imaging 
instrument; this called “Partial Volume Effect” (PVE) (Franc et al., 2008; Jaszczak et al., 1981). 
The PVE and its influence on quantification are discussed in more detail in the following sections.  
 
Figure 2-1 The flow chart shows the process of measuring the activity distribution in clinical SPECT. 
Imaged activity distribution is influenced by many factors (attenuation, scatter, Partial Volume Effect 
(PVE) and motion). In SPECT, the pre- or during reconstruction processes can correct for these effects. 
Then, the measured count distribution can be converted to the measured activity distribution via an 
equipment calibration factor. (Modified from Quantitative SPECT) (Ritt and Kuwert, 2013) 
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In preclinical research, high spatial resolution is required for small animal imaging. The 
use of dedicated multi-pinhole collimators enables sub-millimetre resolution in a small field of view 
(due to the small aperture of collimation and high magnification factor) along with preserved 
sensitivity (by the use of multiple apertures per collimator) for in vivo molecular imaging. However, 
the preclinical SPECT is not a scaled down version of clinical SPECT. For example, the PVE in 
preclinical imaging may be a more crucial factor as the size of organs is much smaller when 
compared to the resolution of the scanner. However, less influence from photon attenuation 
characterises small animal imaging due to the shorter track of photons as they pass through 
tissue(Deleye et al., 2013; Franc et al., 2008; Mannheim et al., 2012).     
In this work, we propose to study the magnitude of quantification errors in preclinical 
SPECT with 99mTc, 123I and 188Re. The main goal of this chapter aims to evaluate, quality control 
of preclinical SPECT and to evaluate the accuracy of nanoScan SPECT/CT in quantification, 


















2.2 Pre-clinical Imaging  
2.2.1 System Description of the nanoScan SPECT/CT   
 This work makes substantial use of preclinical imaging systems which are introduced in 
this and the  next section. Preclinical nanoScan SPECT/CT (Mediso, Hungary) is a dual imaging 
modality system which combines the functional SPECT and anatomical CT at high resolution for 
small animal imaging. SPECT is composed of fours NaI(Tl) detectors (215×230 mm2) with pixel 
size less than 1 mm2. The multiplexed multi-pinhole (MMP) collimator magnifies images through 
many pinholes simultaneously with high resolution (1.0 mm-aperture offers FWHM of < 0.75 mm.) 
and high sensitivity levels (≥ 1200 cps/MBq for whole-body imaging with trans-axial field-of-view 
(TFOV) ≥ 30mm.  
 
For reconstruction, all SPECT tomographic projections are reconstructed using 
HiSPECTTM software (supplied with the camera).  An iterative Ordered-Subsets Expectation 
Maximisation (OSEM) algorithm is used in this software. This software does not correct for either 
attenuation or scatter. There are 3 settings for reconstructing the tomographic projections; 
 Fast Reconstruction – 6 iterations with 35% Gaussian Smoothing Filter 
 Standard Reconstruction - 9 iterations with 35% Gaussian Smoothing Filter 
 Phantom Reconstruction - 24 iterations with 25% Gaussian Smoothing Filter 
Images are visualised with VivoQuant image and analysis software. This software has a 
user defined calibration factor (details and methods for obtaining calibration factor in chapter 3) 
to convert image counts to units of radioactivity concentration (MBq or kBq per voxel). VivoQuant 
  
Figure 2-2 (Left) Four detectors NaI (Tl) system surround the animal for fast and dynamic acquisition 
(Right) Multiplexed Multi-Pinhole (MMP) collimator for magnification the image with ultra-high resolution 
(modified from the nanoScan SPECT/CT user manual)   
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also includes software for image quantification, post processing and image co-registration with 
CT (when modalities are not spatially aligned).   
The CT system of nanoScan SPECT/CT is used for scout scanning and anatomical 
imaging. It comprises a standard micro-focus X-ray source (5-8 μm spot size) with an operating 
voltage range of 30 – 90 keV and tube current of 0.09-0.18 mA. The CT system provides a low-




























2.2.2 System Description of nanoScan PET/CT 
Preclinical nanoScan PET/CT is a dual-modality PET and CT system with high resolution 
and high efficiency for in vivo small animal imaging. The PET component comprises twelve 
detector arrays of 85 x 39 LYSO:Ce crystals of 1.12 x 1.12 x 13 mm3 each. The effective FOV is 
123 mm (axial). The trans-axial FOV is 94 mm with the spatial resolution of the system at central 
FOV (CFOV) less than 1.2 mm (for filtered back projection) and sensitivity at CFOV of 8.3 % (for 
250 – 750 keV window). Acquisition is possible in list mode with the option of 3D reconstruction 
using CT for attenuation correction.  
 
The CT images of nanoScan PET/CT are used for scout scanning, anatomical imaging 
and deriving an attenuation map for attenuation correction.  The X-ray CT is acquired using helical 
scanning with volumetric cone-beam technology and a micro-focus source (5-9 μm spot size). 









Figure 2-3 (Left) nanoScan PET/CT (Right) LYSO Detector ring system of PET (modified from nanoScan 
PET/CT user manual)   
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2.3 Tomographic Uniformity with Mouse-Size Phantom 
Tomographic uniformity is a basic test to indicate the overall performance of the imaging 
system (Deleye et al., 2013). Basically, tomographic uniformity is the uniformity of the image after 
reconstruction. Hence, the tomographic uniformity includes the effects of reconstruction as well 
as the attenuation and scatter correction performance of the imaging system.  
2.3.1 Aim  
The aim of this experiment is to evaluate tomographic uniformity of nanoScan SPECT/CT 
with 99mTc, 123I and 188Re. We also analysed the data with all available reconstructing options: 
fast, standard and phantom. In addition, the line profile was obtained to compare the effects of 
attenuation for each isotope.  
2.3.2 Materials and Methods 
2.3.2.1 Phantom 
The 30 ml universal tube (Thermo Scientific, UK) was selected to use as a uniformity 
phantom. This tube has a diameter of 3.1 cm and is 9.4 cm long (as seen in figure 2-2A). The 
phantom was filled with well mixed radionuclide solution with activity range from 37 -74 MBq as 
recommended by the manufacturer. 
2.3.2.2 Experiment Protocol 
The phantom was scanned for 50 s per projection with 40 projections on a sampling 
matrix of 256 × 256 pixels, which resulted in approximately 30 minute scanning time. The scan 
was performed with the following energy-window settings; 99mTc (20% window centred over the 
140 keV photo-peak), 123I (20% window centred over the 159 keV photo-peak) and 188Re (20% 
window centred over the 155 keV photo-peak). All projection data were reconstructed in 
HiSPECT© (Scivis, GmbH, Gottingen, Germany) version 1.4.1876 with; fast (OSEM  - ordered 
subset maximum likelihood expectation maximisation, 6 iterations with 35% smoothing), standard 
reconstruction parameters (OSEM, 9 iterations with 35% smoothing) and ‘phantom’ 
reconstruction parameters (OSEM, 24 iterations with 25% smoothing) 
2.3.2.3 Uniformity Analysis 
Uniformity was quantitatively measured by drawing a cylindrical volume of interest (VOI) 
with diameter of 10% of the diameter of the phantom (diameter of VOI approximately 3 mm.) at 
the centre of uniformity area in the phantom (figure 2-4 right) using the VivoQuant analysis 
software version 2.0 (InVicro, USA). A small VOI was defined (figure 2-4 right) in order to avoid 
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effects related to photon attenuation, however, this could be at the cost of a large standard 
deviation about the mean. The uniformity of the tomographic image was computed using the 
NEMA (National Electrical Manufacturers Association) formula (equation 2-1) (Deleye et al., 
2013).  
                         𝑈𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 (%) =  
𝑀𝑎𝑥 𝐶𝑜𝑢𝑛𝑡−𝑀𝑖𝑛 𝐶𝑜𝑢𝑛𝑡
𝑀𝑎𝑥 𝐶𝑜𝑢𝑛𝑡+𝑀𝑖𝑛 𝐶𝑜𝑢𝑛𝑡
× 100                              Equation 2-1 
We also calculated the coefficient of variation (%CV) using the data from the same VOI. 
Additionally, we compared the uniformity value and %CV for each set of reconstruction 
parameters (fast, standard and phantom). 
                     %𝐶𝑉(%) =  
𝑆𝐷
𝑀𝑒𝑎𝑛
× 100                                                   Equation 2-2 
 The VOI was repeatedly drawn on 3 separate occasions to obtain a measure of deviation 
of the measurement.  
 
2.3.2.4 Line Profile 
The middle axial slices across the Z-axis of the scanner filed-of-view were compressed 
(40 axial planes in total for each data set) using ImageJ software version 1.48v (National Institutes 
of Health, USA) to avoid the noisy signal in each single slice. Line profiles across the X-axis of 
the tomographic image (for standard reconstruction algorithm) were obtained and plotted against 
axial position for each isotope. 
 
 
Figure 2-4 (Left) 30 ml universal tube used as a phantom in this study (Right) Cylinder VOI placed on 
the centre of the uniform area to obtain the uniformity and %CV  
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2.3.3 Results and Discussion 
For the tomographic uniformity, the results were calculated from the mouse-size 
cylindrical phantom. The maximum, minimum, SD and mean values for each VOI were obtained 
from VivoQuant. The uniformity and percentage coefficient of variation were expressed as mean 
± SD in the table 2.1 below. The SD in this experiment was obtained from repeatedly-drawn VOI 
3 times on the same data set. 
 
Syringe Reconstruction Protocol % Non-Uniformity % CV 
99mTc 
Fast 12.71 ± 0.54 5.22 ± 0.40 
Standard 22.00 ± 1.03 8.27 ± 0.12 
Phantom 77.83 ± 5.29 31.57 ± 0.69 
123I 
Fast 12.17 ± 0.68 4.98 ± 1.16 
Standard 19.07 ± 1.66 6.60 ± 0.26 
Phantom 64.79 ± 2.84 22.28 ± 0.18 
188Re 
Fast 18.74 ± 1.40 6.44 ± 0.45 
Standard 29.04 ± 5.38 9.79 ± 0.76 
Phantom 91.92 ± 1.82 44.20 ± 1.96 
 
Based on the results, the tomographic uniformity and %CV changed with the 
reconstruction algorithm. The images were less uniform and %CV increased at high iteration 
numbers (a lower number indicates better uniformity). For the standard reconstruction parameters 
(as we used this reconstruction protocol for all in vivo studies), the tomographic uniformity for 
99mTc (22.00 ± 1.03 %) was found to be similar to 123I (19.07 ± 1.66). Slightly improved uniformity 
with 123I might be due to higher energetic gammas compared with 99mTc, thus slightly reduced 
photon attenuated, although we deliberately chose a small centrally-defined VOI to avoid 
influence from photon attenuation. As this version of nanoScan SPECT/CT reconstruction 
platform does not include correction for attenuation, we can see a drop in the activity at the centre 
of the phantom from uniformity calculations and the line profile (in the following section). The 
tomographic uniformity of 188Re was found to be 29.04 ± 5.38 % with 9.79 ± 0.76 %CV for standard 
reconstruction. The non-uniform result of 188Re (compared with 99mTc and 123I) can be explained 
Table 2-1 Percentage non-uniformity and percentage coefficient of variation (%CV) from tomographic 
image of nanoScan SPECT/CT (mean ± SD) 
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by the high event of Bremsrahlung backscattered caused from high-energy beta (extending up to 
2 MeV), down-scatter from high-energy photons penetrate collimator septa (creating background 
elevated in the image) (Shcherbinin et al., 2014). We did not apply any corrections at this stage 
due to lack of provision for re-importing corrected projection files into the reconstruction platform.  
For the ‘phantom’ reconstruction parameter set, the uniformity and % CV values were 
very high (non-uniform) as expected. Due to the nature of OSEM reconstruction it is widely 
reported that noise in the images increases as iteration increase (Leong et al., 2001).  
Plots of line profiles from the compressed middle axial slides of the uniformity phantom 
are shown in figure 2-5 below. As stated earlier, this version of nanoScan SPECT/CT does not 
include correction for attenuation. To investigate this effect, we compared the line profiles of 99mTc 
and 123I. It can be seen that the drop of activity at the middle of 99mTc phantom was larger than 
123I. In the case of the 188Re line profile, the background counts outside the object are observed 
at around 5000 counts whereas for 99mTc and 123I the background counts outside the object fall to 
almost zero. This poses a difficulty with quantification due to high background for 188Re. 188Re 
quantification also influence by scatter, this will discuss in more detail in quantification section 
with micro-hollow sphere phantom.   
Also, it was important to note that a 99mTc correction flood was used for all studies rather 












                            
                            
                            
Figure 2-5 Line profile plots and line ROIs from uniform area across X-axis of the scanner for 99mTc, 123I 









































2.4 System Calibration  
System calibration is an important step to determine absolute amounts of radioactivity 
from the images. To obtain this, the number of counts per voxel needs to be convert to activity or 
activity concentration. This conversion factor may be referred to as system calibration factor or 
system sensitivity (for example counts/MBq/s). The calibration factor is specific for each 
radionuclide as well as the collimator apertures and thicknesses. Also, the protocol for obtaining 
this factor is specific to the data acquisition and reconstruction parameters as well as any 
attenuation compensation and scatter correction (if available) used in the experimental study.  
 
2.4.1 Aim 
The aim of this experiment was to evaluate the calibration factor of the nanoScan 
SPECT/CT using the radionuclide activity calibrator (Capintec CRC® - 25R, Ramsey, NJ, 
USA) as a standard reference device. The radionuclide activity is annually calibrated against the 
NPL (National Physics Laboratory) as primary standard. Hence, we aim to establish calibration 
factors for 99mTc, 123I, and 188Re with a low energy multi-pinhole collimator aperture of 1 mm and 
for 131I using high energy collimator with aperture of 1 mm. 
 
2.4.2 Materials and Methods 
2.4.2.1 Calibration Phantom 
The mouse-sized quantification phantom is illustrated in figure 2-4. A 3 ml syringe 
(diameter of 9.83 mm) filled with 1.5 ml of the radiotracer solution, aiming for an activity of 37-74 
MBq. The activity was measured in the radionuclide activity calibrator, and the time of the 
measurement noted. Then, the syringe was inserted into a 2.5 cm diameter water-filled Perspex 
cylinder phantom in order to simulate photon attenuation and scattering conditions caused by the 






2.4.3 Experimental Protocol 
The phantom was acquired for a minimum of 50,000 counts per frame according to 
manufacturer recommendations. The scan projections were processed using the standard 
reconstruction protocol. A 3D VOI was drawn using VivoScope© analysis software, then the 
number of counts, time and activity of the syringe measured in the radionuclide activity calibrator 
were inputted to the software for calculation of the calibration factor. 
 
2.4.4 Results   
The quantification factors for the radionuclides used are shown in Table 2-2. The 
quantification factors were dependent on collimator type (thickness), aperture size and isotope 
emissions. These factors were stored for subsequent use to convert count rates to activity in 
mega-Becquerel in the VivoScope© software.  
 
 
Radionuclides Photo-peak (keV) Width (%) 
Calibration Factor 
(Conversion of count to MBq) 
99mTc 140.0 20 0.00304 ± 0.00021 
123I 159.0 20 0.00440 ± 0.00044 
131I 364.0 20 0.01214 ± 0.00112 








 Figure 2 6 Perspex Quantification Phantom with a 3 ml syringe inserted with activity of 37-74 MBq in a 
volume of 1.5 ml for obtaining a calibration factor 
Table 2-2 Calibration factors (± SD) with photo-peak and window width of 99mTc, 123I and 188Re for the low 
energy collimator with aperture 1 mm, 131I for high energy pinhole collimator. 
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2.5 Linearity of nanoScan SPECT/CT 
As this work focused on longitudinal imaging studies, quantitative accuracy over a wide 
dynamic range was critical for following the time course of the tracer from the initially high amount 
of radioactivity injected and over a period permitted by the effective half-life and the animal licence 
restrictions. Since in vivo activity distribution will be followed until the later time-points leading to 
relatively low activity levels, the linearity of the system was tested over the entire intended activity 
range. 
2.5.1 Aim 
The aim of this experiment was to examine the linearity response and dead time 
performance of nanoScan SPECT/CT over a range of activity levels using the decay method.  
2.5.2 Materials and Methods 
The quantification phantom described previously (in chapter 2.3) was used to test linearity 
respond and dead-time correction of the system. A 3 ml syringe was filled with 1.5 ml of 99mTc, 
aiming for a high activity of approximately 200 MBq (similar to the highest activity permitted to be 
injected into the mouse in the lab facility). Higher activity ranges were considered unrealistic for 
the pre-clinical imaging setting both due to associated absorbed radiation dose (e.g. potential 
biological radiation effects, especially in longitudinal studies) and the specific activity and injected 
volume limitations. The activity was measured in the radionuclide activity calibrator, and then the 
syringe was placed into the water-filled Perspex cylindrical phantom. The phantom was scanned 
with an acquisition time of 50 s/projection (40 projections on a sampling matrix of 256 × 256 pixels) 
for a total scanning time of approximately 40 minutes. The activity in the phantom was scanned 
at various time points over 3 consecutive days. All projection data were reconstructed using the 
standard reconstruction protocol (OSEM, 9 iterations with 35% smoothing). The images were 
viewed and analysed using VivoQuant© software.  
2.5.3 Results and Discussion 
The linearity and count rate tests on the nanoScan SPECT/CT were performed by 
scanning a 1.5 ml syringe inserted into a plexiglass quantification phantom. The activity in the 
phantom was measured and recorded with the radionuclide activity calibrator prior to scan, with 
total activity in the syringe of 208.80 MBq. Data were acquired over a period of about 3 days in 
order to allow activity in the phantom to decay to approximately 1 MBq. Activity measured in the 
radionuclide activity calibrator was decayed for the isotope’s physical half-live and plotted against 
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the quantification results obtained from the nanoScan SPECT/CT in a semi-logarithmic scale 
(Figure 2-5). 
 
From the results, it can be seen that the relationship between the quantified activities 
from nanoScan SPECT/CT with 99mTc was within 10% from the radionuclide activity calibrator 
derived radioactivity over the range assessed. At high activities, the quantified activity showed 
the highest discrepancy at approximately 10 % (relative quantified value 0.915 ± 0.005). The 
quantified activity was within reasonable range from the measured activity from the radionuclide 
activity calibrator at lower activities with underestimated to within 5 – 6 %, the quantified value 
deviated from the unity line at 0.933 ± 0.005, 0.943 ± 0.007 and 0.949 ± 0.003 for 0.530, 1.072 
and 17.904 MBq respectively. These activity levels up to 100MBq represent a realistic range of 
small-animal scans from the full maximum injected activity in the scanner field-of-view to decayed 
levels in longitudinal dynamic imaging studies. It should be noted that other non-instrumentation 
related limitations, such as those related to the achieved specific activity injected into small 




 Figure 2-6 Linearity of nanoScan SPECT/CT obtained with 99mTc by using quantification phantom. The 
relative quantification activity were the measured activity from nanoScan SPECT/CT normalised to initial 

































2.6 Accuracy of nanoScan SPECT/CT in Quantification of Small 
Objects 
 Image quantitative accuracy in emission tomography (PET and SPECT) is hampered by 
the finite spatial resolution capability of the scanner which results in blurring the activity distribution 
and limiting tissue sampling (each individual voxel can in principle contain 2 or more tissue types 
at the boundary of regions). This is called the partial volume effect or PVE. This problem can be 
more severe when quantifying small objects/organs with size less than 2-3 times the scanner’s 
spatial resolution, which is measured in terms of the full width at half maximum (FWHM) (Hoffman 
et al., 1979; Hwang et al., 2008; Soret et al., 2007). 
 
The quantification of activity in the region can be either under- or overestimated, 
depending on the cause of spill-in or spill-out effects (Soret et al., 2007). In case of spread of 
activity from outside the region of interest (ROI), then the derived value inside the ROI is 
overestimated and this effect is called “spill-in”. On the other hand, “spill-out” refers to activity 
spreading out of the region, consequently the activity inside the ROI is erroneously decreased 
(underestimated). These effects (spill-in and spill-out) can happen at the same time, for example 
(as illustrated in figure 2-7) spill in to structure X from background (fig C) occurred at the same as 
spill-out from background to structure X (fig B). Hence, the resulting image is the sum of spill-in 
and –out (also termed as “spill-over”) and typically it is not balanced and difficult to predict. The 
 
 Figure 2-7 Graph demonstrating the relationship between the recovery coefficient and diameter of the 
cylindrical object in terms of units of FWHM of the emission scanner. There is not a linear relationship 
between the image-derived and true activity concentration when object size is less than 2 times of system 
FWHM (modified from (Hoffman et al., 1979)) 
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equilibrium is seen only if the object has similar activity concentration to background (Erlandsson 
et al., 2012; Mannheim et al., 2012; Soret et al., 2007).    
 
 
Furthermore, the PVE is related to the finite dimensions of the voxel. A larger voxel size 
has a high chance to contain mixed type of tissues. Thus, the displayed signal will be composed 
of the average of mixed confounding signals. This effect can be better observed at the boundary 
of the organ/tissue. It is also called “tissue fraction”. This effect can be improved by decreasing 
the voxel size of the imaging facility (Soret et al., 2007). 
 There are several existing techniques to correct partial volume errors published in the 
literature. These techniques have been applied with different strategies and implementation. 
Correction methods can be categorised in 3 main strategies (a) anatomical based correction (b) 
reconstruction based correction and (c) phantom based correction. 
 First approach, the anatomical based partial volume correction method uses the 
anatomical information from other available modalities (CT, MRI) to correct the emission data. 
Since most of modern imaging facilities are equipped with high spatial resolution anatomical 
imaging systems such as in dual-modality SPECT/CT, PET/CT, SPECT/MRI, PET/MRI or tri-
modality SPECT-PET/MRI. Basically, this correction method utilises the anatomical information 
by assuming that those images are perfectly registered and segmented into physiological 
compartments. Then the magnitude of the spill-over between the regions can be mathematically 
calculated and used to correct the partial volume error in the emission images. However, a major 
limitation of this method is that it only uses the anatomical information at a snapshot of the 
functional process assuming uniform activity and equilibrium partial volume effect within each 
region. 
 
 Figure 2-8. Image A is the actual activity distribution (value of 10 is lesion and 5 is background). The 
measured image D is the sum of spill-out B (spilling out of lesion to background) and spill-in C (spilling 
of background to lesion) from the imaging system (Modified from (Soret et al., 2007)) 
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For reconstruction-based correction, the reconstruction algorithms together with PSF 
(point spread function) modelling are performed to resolve PVE. The basic concept of this 
approach is an improved overall spatial resolution of the scanner, thus the partial volume error 
can be limited. For instance, Rapisarda E et al (2010) implemented the 3D OSMLEM (ordered 
subset maximum likelihood expectation maximisation) reconstruction with modelling of PSF 
incorporated in image space, thus the result of this technique found high contrast, lower noise 
and improved the quantitative accuracy (Rapisarda et al., 2010). For details of reconstruction 
based during- and post-reconstruction of SPECT, the review by Erlandsson et al. described many 
techniques from several groups, mostly applied to clinical imaging (Erlandsson et al., 2012). We 
have also investigated the effects of HiSPECTTM iterative OSEM reconstruction which is 
commercially supplied together with the nanoScan SPECT/CT camera. The details are described 
in the following section.    
 Another approach to diminish the partial volume error is multiplication of image-derived 
measurements by pre-defined correction factors (also called “recovery coefficient”). The 
correction factor can be derived and measured from a relevant physical phantom. Principally, this 
factor is the ratio of apparent activity from the measured image to true activity in the object. Once 
phantom measurements of standard shape geometries (sphere, cylinder) are experimentally 
performed, then the recovery coefficient over a range of physical dimensions of those objects can 
be plotted (also called “recovery curve”). Subsequently, the recovery coefficient can then be 
applied and consequently used to estimate the true activity in such objects. This concept of 
recovery coefficient was first introduced by Hoffman EJ et al. (1979). Based on Hoffman’s report, 
the effect of object size and the quantitative capability of PET were measured. This work reported 
the recovery curve of simple test objects, for example line, cylinder, bar and wedge in low-activity 
background. The work by Kessler et al. (1984) extended Hoffman’s concept by investigating the 
effects of neighbouring activity, and also defined the terms HRSC (hot lesion in a cold 
background), CSRC (cold lesion in a hot background) and CRC (contrast recovery coefficient-
ratio of image to object contrast). However, this methodology has some limitations; for example, 
the simple geometrical shape may not always be a suitable approximation for all anatomical 
structures. Furthermore, the uniformity of the activity distributed in the target and background is 
not always a valid assumption. However, this approach is simple to achieve and can be used as 




The aim of this experiment was to understand the magnitude of error in quantification of 
small-objects/organs with nanoScan SPECT/CT. We also intended to plot the recovery curve and 
calculate the recovery coefficient for 99mTc, 123I and 188Re with the micro hollow sphere (MHS) 
phantom in order to correct the in vivo data in the following chapter. Additionally, this study also 
aims to investigate the effects of acquisition time and reconstruction protocol on quantification 
accuracy.  
 
2.6.2 Materials and Methods 
2.6.2.1 Micro Hollow Sphere Phantom 
A fillable micro hollow sphere (MHS) phantom (Bartec Tech, UK) was selected to use in 
this study as the only commercially available option for object dimensions considered in the in 
vivo studies. The MHS phantom consists with 4 micro-spheres with the nominal volumes of 31.3, 
62.5,125 and 250 µl. These micro-spheres correspond to diameters of 3.9, 4.8, 6.0 and 7.8 mm 
with the wall thickness approximately 1 mm (diagram in figure 2-8). The details are given below. 
  
 
Sphere Volume (µl) Diameter (mm) Outside Diameter (mm) Inside Diameter (mm) 
250 7.8 9.86 7.86 
125 6.0 8.23 6.23 
62.5 4.8 6.95 4.95 
31.3 3.9 5.95 3.95 
 
The micro-spheres can be mounted onto the cylinder phantom with approximately rat size 
dimensions (diameter of 51 mm and length of 114 mm). However, our in vivo experiments only 
used mice. Therefore, we adjusted this phantom to mount the spherical inserts into a mouse size 
cylinder (manufactured by King’s College London Workshop, London, UK) with diameter of 25 
mm and length of 50 mm. The picture of the phantom and set of microsphere inserts are shown 

























 In this experiment, the MHS phantom was filled with different amounts of 99mTc, 123I or 
188Re. The amount of radioactivity in each sphere was measured using a radionuclide activity 
calibrator (CRC-25R Capintec, USA) prior to imaging. The details of activity are tabulated in the 
following table. In addition, the amount of radionuclide in the MHS phantom was similar to the 
activity typically injected to mice in our in vivo experiments (see next chapter) in order to 
investigate performance aspects of the scanner (effects of count rate, acquisition time and/or 











 Figure 2-9 (Top Left) Set of microspheres. From left to right, the volumes are 31.3, 62.5, 125 
and 250 µl (Bartec Ltd, UK) (Bottom Left) Diagram for each sphere indicates inside and outside 
diameter as tabulated in table 2-3 (Right) Mouse Size Micro Hollow Sphere Phantom (KCL 

















































2.6.2.3 Experimental Protocol 
To study the partial volume error on quantitative measurements, the MHS phantom was 
filled with radionuclide with water in the surrounding cylinder (no activity in cylinder). (The term 
partial volume error is used loosely here to describe object size dependency as typically the term 
partial volume effect refers to activity concentration).The partial volume error for different contrast 
ratios was not determined in this work. The MHS phantom was positioned and scanned in the 
middle of the axial FOV of the scanner. SPECT was acquired using the low energy multi-pinhole 
collimators (1 mm aperture and 9 pinholes). The acquisition was run in step-and-shoot mode for 
25 projections with default acquisition time of 20 seconds per projection. 
To study the effects of acquisition time, the time per projection was varied from 5, 10, 20, 
50 and 100 seconds per projection. The total accumulated counts from DICOM information noted 
for each acquisition time and tabulated in the graph.  
To study the effects of reconstruction, all data sets from the nanoScan SPECT/CT were 
reconstructed using HiSPECT OSEM iterative reconstruction software (supplied with the camera). 
This software does not correct for photon attenuation and there were only 3 optional sets of 
reconstruction parameters: 
 Fast Reconstruction – 6 iterations with 35% Gaussian Smoothing Filter 
 Standard Reconstruction - 9 iterations with 35% Gaussian Smoothing Filter 
 Phantom Reconstruction - 24 iterations with 25% Gaussian Smoothing Filter 
All MHS phantom projection data were reconstructed with these 3 reconstruction options, 
and the quantification accuracy was calculated and compared to examine its effect.     
 
 
Table 2-4 Amount of radionuclide filled in MHP phantom 
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2.6.2.4 Data Analysis 
All images were displayed and analysed using VivoQuant© software (VivoQuant, 
USA). A large 3D VOI (much larger than observed activity) was manually defined around each 
microsphere to obtain the total count of radiotracer in each sphere (as illustrated in following 
figure). This also called “integral method”. We defined a large VOI to include total object activity 
by setting a threshold of 10% of the maximum count to exclude background. The aim to include 
all activity in the organ/object was because the main purpose of this work was to study the 
dosimetry of radiotracer. Consequently, we were interested in the total accumulation of 
radiotracer in each organ in terms of percentage of injected dose (%ID) and percentage of injected 
dose per gram of tissue/organ (%ID/g) at a particular time-point. Likewise, we used these values 
to compare the ratio of tracer accumulated between different organs and also comparing uptake 
of one tracer with another. This would be a different approach (likely a different VOI definition) to 
SUV-led (Standard Uptake Value) quantification which relies on activity concentration rather than 
total activity, hence definition of uniform areas of uptake and avoiding cross boundary effects are 




In this study, the total activity in each sphere was taken from VivoQuant© software, all 
measured data were decay corrected to the radionuclide activity calibrator’s time (as we used the 
measured activity from radionuclide activity calibrator as a standard). The percentage error (%) 
and percentage quantification accuracy (%, as a measure for inter-comparison of different 
reconstruction and acquisition parameters) were calculated using the following formulae where 
 
           
Figure 2-10 (Left) Actual activity of MHS phantom consists 4 spheres (Right) Large VOI defined (by setting 




AN and AD are the activity in units of MBq measured from nanoScan SPECT/CT and radionuclide 
activity calibrator respectively; 
 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑄𝑢𝑎𝑛𝑡𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 (%) = 100 −  𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑄𝑢𝑎𝑛𝑡𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝐸𝑟𝑟𝑜𝑟 (%)     Equation 2-4 
 
To calculate relative error, the VOIs were repeatedly drawn in 3 separate occasions one 
week apart. The mean of measurement and standard deviation (SD) were calculated and plotted 
(mean ± SD) in order to appreciate the inconsistency of defining the volumes of interest.  
 In this chapter, we also evaluated effects of the object size on quantification. As 
mentioned earlier, we used the integral method in our study. However, there is another approach 
for reporting outcome of biodistribution study. The method is based on the standardised uptake 
value (SUV) and it is also referred to the dose uptake ratio. In this study, we selected the SUVmax 
(also called “maximum method”) which calculates the SUV based on the highest image pixel in 
the tumour region (Bailey and Willowson, 2013). 
To access SUVmax, we used the maximum pixel concentration instead of SUVmax. The 
maximum pixel value was taken from VivoQuant. For SUVmean analysis, VOI was automatically 
drawn using the AMIDE (AMIDE is a Medical Image Data Examiner) software (version 1.0.4, 
http://amide.sourceforge.net) with 42% of the maximum value set as a threshold (Hong et al., 
2007). Then, these values (taken from VivoQuant and AMIDE in units of MBq) were divided by 
the pixel size which it is 0.3 × 0.3 × 0.3 mm3 (for nanoScan SPECT/CT, aperture 1 and standard 
reconstruction algorithm) in order to obtain the maximum pixel concentration and SUVmean in unit 
of MBq/mm3. For reference value, the radiotracer concentration was calculated from the stock 
activity with which we filled in the MHS phantom using the radionuclide activity calibrator as a 
standard (MBq per volume of tracer in unit of MBq/mm3). Then, the percentage error (%) and 
percentage quantification accuracy (%) were calculated as in the integral method using the above 
equations (Bai et al., 2013). 
2.6.3 Results and Discussion 
2.6.3.1  Effects of Object Size 
For effects of sphere size, the results were analysed by plotting the mean of percentage 
quantification accuracy as a function of the microsphere diameter (figure 2-10). The percentage 
quantification accuracy was calculated based on the above equation from the large VOI (integral 
                         𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑄𝑢𝑎𝑛𝑡𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝐸𝑟𝑟𝑜𝑟 (%) =  
(𝐴𝑁−𝐴𝐷)
𝐴𝐷
× 100                                     Equation 2-3     
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method) and compared to the measured activity from radionuclide activity calibrator. We used the 
radionuclide activity calibrator as the standard as it was annually calibrated to the National 
Physics Laboratory (NPL) – details of this calibration are provided in appendix A. We also tested 
for any geometry effects in the radionuclide activity calibrator by filling the same activity 
concentration in each microsphere. It was found that the measured activities across the 4 
microspheres agreed within 1.74 %. Therefore, we further assumed that geometric uncertainty 
due to different diameters and sizes of microspheres would be negligible.  
 
These results show that the measurement of smaller objects suffered larger partial 
volume errors therefore had lower quantification accuracy when compared with larger objects. 
Based on the results, the quantification accuracy varied also across isotopes. The mean 
quantification accuracy of 99mTc and 123I were over 90 %, compared with 82 - 87 % for quantified 
activity from188Re. The larger errors of 188Re quantification might be a result of the scattered 
photons contaminating the acquired energy window and also septal penetration from broad 
spectrum of Bremsstrahlung radiation (up to 2 MeV) and also the higher energy photon emissions 
of Re-188 (478 and 632 keV). Interestingly, we observed a high variation (SD) in the 188Re small-
object quantification. This might be a result from poor signal to noise ratio (low count from only 
15% abundant of gamma emission).  
 
 Figure 2-11 Effects of object size: the mean percentage quantification accuracy obtained by integral 
method (mean ± SD) plotted against diameter of microspheres in millimetres. MHS phantom acquired with 
20 seconds per projection and standard reconstruction using nanoScan SPECT/CT. The activity in each 








































For 123I, the results of the two largest spheres (diameters of 7.8 and 6 mm) were 
overestimated about 2 % which is within the tolerance of the calibrator though it may also reflect 
differences due to photon attenuation (less attenuated for higher energy gamma of I-123) because 
this version of reconstruction software does not allow for attenuation correction. In addition, it is 
unclear whether the PSF and flood uniformity corrections of this preclinical scanner are isotope-
specific rather than only based on 99mTc. Such factors might also influence the quantification of 
other isotopes. It is important to note that these results may include influence by other factors due 
to different isotopes (photon energy, attenuation, scatter, PSF model). However, it is important to 
understand these because in the next chapter we compare the in vivo quantification data across 
isotopes. To eliminate the influence of isotope-related factors, the quantification accuracy was 
normalised to the value obtained with the largest sphere under the assumption that the effect of 
photon attenuation (not corrected for SPECT in this implementation) will be of comparable scale 
across all spheres (similar depth) for the same isotope. The normalised results are plotted in 
figure 2-12.  
 
From this graph, the errors due to size of the object can be clearly seen. The results 
indicate comparable PVE effects across the isotopes. These findings are in keeping with the work 
of McElroy DP et al. which reported that PVEs and spatial resolution were not considerably 
changed when changing isotopes (McElroy et al., 2002). Also, the septal penetration of the 
collimator was not significantly changed for those isotopes as primary photon peaks were very 
similar (99mTc 140 keV, 123I 159 keV and 188Re- 159 keV). Interestingly, the normalised results 
 
 
Figure 2-12 Plot of mean of the normalised value to the measured activity in the largest sphere (Mean ± 
























indicated that PVE affected 99mTc, 123I and 188Re imaging by about 8%, 5% and 4% respectively. 
The quantification accuracy variation in figure 2-10 likely resulted from other factors such as 
system calibration factor, scatter and attenuation correction as well.    
2.6.3.2 Effects of Object Size on SUVmax and SUVmean 
The effects of object size on quantification accuracy were additionally examined with 
SUVmax, as this is also used in reporting preclinical imaging data, using the maximum value pixel 
taken from a large VOI (integral VOI method) and SUVmean using a threshold of 42% of the 
maximum value. In both cases (SUVmax and SUVmean), the initial VOIs were drawn with the size 
larger than the actual size of the sphere. As mentioned above, quantification accuracy was 




Figure 2-13 Effects of object size and SUVmax. The mean percentage quantification accuracy and SD 
































As seen from the results, quantification accuracy using SUVmax appears excessed 
overestimated, the quantified values were overestimated about factor of 1.6 to 1.9 from the 
standard activity measured by radionuclide activity calibrator for 123I and 188Re. For 99mTc, the 
SUVmax result was overestimated by a factor of about 1.2. Theoretically, it has been reported by 
many studies that SUVmax is robust and less affected by PVE compared to the integral method. 
However, the weaknesses of maximum SUV method is that it appears more sensitive to noise 
(Bai et al., 2013). Additionally, this method relies on only the maximum value from one single 
pixel. This may introduce errors in the preclinical scanner as there may be relatively high levels 
of noise often in small size structures. For 188Re, the quantified result of the smallest sphere was 
overestimated about 100%. This might be affected by random noise due to high levels of scattered 
photons from secondary Bremsstrahlung radiation. 
In contrary, the SUVmean results were underestimated by about 20% for 99mTc and 188Re 
when using SUVmean with a 42% thresholding. This method has a tendency to underestimate the 
quantification results because by setting the counting threshold at 42%, some radioactivity below 
the threshold will be uncounted. 
In the same manner as in the integral method, we eliminated other isotope-specific effects 
(scatter, attenuation, photon energy etc.) by normalising results from each sphere with the value 
obtained from largest sphere and then plotting as the function of the radius of the diameter of 
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Figure 2-14 Effects of object size and SUVmean (42% thesholding of the maximum value). The mean 









Figure 2-15 SUVmax using maximum intensity voxel in VOI. The quantification results were 
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Figure 2-16 SUVmean  using 42% thresholding of maximum intensity voxel in VOI. The quantification 






As expected, we did not observe a dependency of the PVE for SUVmax and SUVmean when 
decreasing the size of the sphere as we did with the integral method. The quantification accuracy 
from SUVmean and SUVmax seem to be random and difficult to predict whereas the PVE with 
integral method can be addressed and corrected using this standard phantom.  
However, the advantages of these methods are that they are quick and reproducible 
compared with the more manually-intensive and user-dependent integral method. So, these 
methods (SUVmean and SUVmax) can eliminate the intra- and inter-analyser viability on defining 
VOI. Whereas, the integral method had an operator-dependent aspect when defining a VOI 

























2.6.3.3 Effects of Acquisition Time 
The effects of acquisition time were studied by varying the time per projection at 5, 10, 
20, 50 and 100 seconds per projection. The nanoScan SPECT/CT was set to acquire the standard 
SPECT mode (25 projections/detector), so these time-varying projections corresponded to total 
scanning times of 2.08, 4.17, 8.33, 20.83 and 41.67 minutes respectively. This study was 
performed with 3 isotopes (99mTc, 123I and 188Re). All projection data were reconstructed with the 
standard reconstruction parameter set (OSEM, 9 iterations, 35 % smoothing). The graphs of the 
mean percentage quantification accuracies with SD were plotted versus the time per projection. 
The total accumulated counts from the DICOM header are also noted for each time-varying 
condition.  
  
                            
Figure 2-17 Graphs plotted of the mean percentage quantification accuracy (mean ± SD) against the time 
per projection (sec/p). Top Left: MHS Phantom with 99mTc; Top Right: MHS Phantom with 123I; Bottom: 



























































































































As shown in figure 2-16, the quantification accuracy for 99mTc and 123I were not 
significantly affected when changing the acquisition time. Even for the smallest microsphere (3.9 
mm diameter), the quantification accuracy changed less than 2 % for 99mTc or 123I. However, the 
188Re quantification data were most affected when changing the acquisition time. Especially in 
the smallest microsphere, the observed accuracy changed from 75.81 ± 4.90 % for 5 s/projection 
to 83.68 ± 5.11 % for 100 s/projection. The effect of acquisition time was much less influential for 
larger microspheres. Furthermore, the variation of 188Re quantification accuracy was quite high 
when compared with 99mTc and 123I. Therefore, these errors might be related to limited photon 
counts, as the total accumulated counts of99mTc and 123I were much higher when compared with 
188Re. The total accumulated counts for 188Re were only 0.22 million counts compared with 2.61 
and 1.29 million counts for 99mTc and 123I when acquired for 5 seconds per projection. Low counts 
can lead to non-Poisson statistics which may introduce bias to the quantification as part of the 
OSEM reconstruction which is based on the assumption of Poisson statistics.  
These results agreed with the study by Finucane CM et al. Their work investigated the 
accuracy of nanoScan SPECT/CT in quantifying low-count samples. Finucane et al. stated that 
low counts led to higher levels of deviation and a minimum of 10,000 counts per frame is required 
for deviation of 10% from true activity values (Finucane et al., 2011). These findings were very 
important as the dynamic acquisitions of time-activity series for dosimetry are related to a wide 
dynamic count range. Understanding the quantification errors for different time settings and count 
levels was necessary for this study. Consequently, this problem is more complicated for in vivo 
(rather than phantom) data as these involve wide dynamic range as tracer distribution changes 
between organs. However, this study can be applied as a guide protocol for in vivo studies in 










2.6.3.4 Effects of Reconstruction Protocol 
 All SPECT projections were reconstructed using HiSPECT© software supplied with the 
camera as the only available option for multi-pinhole collimators. This iterative reconstruction 
software uses the accelerated version of the maximum-likelihood expectation maximisation 
(MLEM) method, the ordered subsets expectation maximisation (OSEM) for reconstruction of the 
raw projection data (Hudson and Larkin, 1994). There are only 3 reconstructing parameters 
available as stated earlier: fast (6 iterations with 35% Gaussian smoothing), standard (9 iterations 
with 35% Gaussian smoothing) and phantom (24 iterations with 25% Gaussian smoothing).  
Plots of mean percentage accuracy against the number of iterations for each microsphere 




Figure 2-18 Mean of percentage accuracy (mean ± SD) plotted with the number of iterations for 99mTc, 






















































































































































































































































Figure 2-19 Mean of percentage accuracy (mean ± SD) plotted against the number of iterations for 123I, 




Figure 2-20 Mean of percentage accuracy (mean ± SD) plotted against the number of iterations for 























































































































250 µl Sphere (7.8 mm Ø)
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The overall results indicate that the quantification accuracies improved when increasing 
the iteration number from 6 to 9 iterations, probably reflecting a good convergence of the 
algorithm. However, when increased to 24 iterations, accuracies depended on the scanning time 
as the quantification was more accurate when the acquisition time per frame was longer (i.e. 
increased number of counts). As previously mentioned, the reconstruction of nanoScan 
SPECT/CT is limited to the HISPECT system with only 3 parameters available (fast, standard and 
phantom). Therefore, a choice from the limited standard reconstruction parameters was made 
asa compromise between noise and spatial resolution. Furthermore at high number of iterations, 
the quantification in small objects was affected more by the reconstruction parameters and 
scanning times, presumably reflecting the influence of both PVE and number of counts in the 
projections. Interestingly, the variation (SD) observed was larger at higher iterations. This 
increase of noise levels with increasing iterations is a well-established effect in MLEM/OSEM 
reconstruction. Therefore, at this particular reconstruction setting, the data were increasingly 
biased for an image with a lower number of counts. However, there are only 3 option of 
reconstruction parameters available for this system (fast, standard and phantom). This is 
important to note as a limitation in this study. Other platforms for reconstructing multi-pinhole 
projection data may need to be developed in future for further investigation, for example as part 
of a future extension of the open source STIR software (Fuster et al., 2013) which is currently 
















2.7 Accuracy of nanoScan PET/CT in Quantification of Small Objects: 
A Comparison with nanoScan SPECT/CT 
In our study, we aim to estimate the dosimetry profile for a forthcoming clinical PET 
radiotracer, 18F-tetrafluoroborate [BF4-]. The initial estimation is to be based on preclinical data 
and we also intend to compare the effective dose with other well-established NIS imaging 
radiotracers. Hence, we need to compare the quantitative data from different modalities and 
isotopes; nanoScan PET/CT (18F-BF4) and nanoScan SPECT/CT (99mTc-pertechnetate, 123I-
iodide and 188Re-perrhenate). Additionally, our main organ of interest is the thyroid which is 
particularly small in size and subject to suffer from PVE. It is therefore crucial to understand the 
magnitude of error and quantification accuracy across these two imaging modalities.  
 
2.7.1 Aim 
This experiment aims to evaluate the quantification accuracy for small objects of the 
nanoScan PET/CT and compare it with the nanoSPECT/CT using the standard MHS phantom.   
 
2.7.2 Materials and Methods 
In this experiment, we used the MHS phantom as described in previous sections. The 
phantom was filled with 18F-NaF, the total activity of phantom was kept below 10 MBq due to 
limitations of the dead-time correction of the nanoScan PET/CT. The phantom was placed at the 
centre of the FOV and PET data were acquired for one bed-position in list mode, within a 400-
600 keV energy window, a coincidence ratio 1:3 for 30 min followed by CT for attenuation 
correction. The projection data were reconstructed with 3D Teratomo (supplied with the PET 
camera) with 0.4 × 0.4 × 0.4 mm3 voxel size and 8 iterations. Decay, dead-time, attenuation and 
scatter corrections were applied as part of the reconstruction.   
All images were displayed and analysed using VivoQuant following the processing steps 
described in previous sections in which large VOIs were drawn in order to obtain the activity with 
the integral and maximum method. The percentage error (%) and percentage quantification 
accuracy (%) were calculated by equation 2-3 and 2-4 using the radionuclide activity calibrator as 
the standard. VOIs were repetitively defined for 3 separate occasions to obtain the intra-analyser 
variability. The SUVmean technique was not employed for PET data due to a technical problem 
with incomplete header information when transferring DICOM PET data to the AMIDE© software.  
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2.7.3 Results and Discussion 
Based on the graph (as shown in figure 2-20), the quantification results were 
overestimated for defining VOI with both integral and maximum methods. The quantified result 
with integral method overestimated 5 - 15 % across all sizes of sphere compared to the activity 
measured by radionuclide activity calibrator. While, the maximum method generated an error of 
about 20 – 40%. For the integral method, the smallest compartment (3.90 mm diameter sphere) 
suffered the largest PVE and the quantification accuracy improved and reached plateau at 6 mm. 
sphere. The error from the maximum method was difficult to address as this method is very 




To compare with SPECT, we used the SPECT data obtained with 20 s/frame with 
standard reconstruction to compare with PET quantification (as explained earlier). The figures 2-
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Figure 2-21 Quantification Accuracy of 18F nanoPET/CT with MHS phantom, data showed with 2 different 





Figure 2-22 Comparison of the quantification accuracy (Integral method) from nanoScan SPECT/CT and 







Figure 2-23 Comparison of the quantification accuracy (Maximum method) from nanoScan SPECT/CT and 
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Results with the integral method demonstrated that PET quantification with 18F was less 
accurate when compared with SPECT. The mean error from PET quantification of the largest 
sphere (where we assume less PVE influence) was about +16 % for 18F, whereas results from 
SPECT were +2, -2.5 and -12 % for 123I, 99mTc and 188Re respectively. As expected, for smaller 
objects the quantified activities decreased; however we can use the recovery coefficient to 
compensate and correct for this phenomenon. On the contrary, the results from the maximum 
method were difficult to predict. Furthermore, the SUVmax method provided a higher error when 
compared with the integral method.  
The nanoScan SPECT/CT has a better spatial resolution than nanoScan PET/CT: 
according to the scanner specifications, 0.7 mm FWHM at CFOV 99mTc for nanoScan SPECT/CT 
vs. 1 mm FMHM at CFOV 18F for nanoScan PET/CT (Szanda et al., 2011). Hence, the 
quantification of small objects from nanoScan PET/CT might be subject to stronger PVE than 
nanoScan SPECT/CT. However, the results were seen the other way around. This might mainly 
result from the correction processes of attenuation, scatter and dead-time, which are employed 
only in nanoScan PET/CT (as the Teratomo reconstruction software in nanoScan PET/CT is also 
a more advanced and updated software suite compared to HiSPECT in nanoScan SPECT/CT) 
















It has been demonstrated in this chapter that the nanoScan SPECT/CT can be used for 
quantitative imaging. For general system performance, we have compared the tomographic 
uniformities with all available reconstruction options. The tomographic uniformity for 99mTc (22.00 
± 1.03 %) was found to be similar to that for 123I (19.07 ± 1.66) whereas uniformity for 188Re was 
found to be 29.04 ± 5.38 % for standard reconstruction. The non-uniform result of 188Re 
(compared with 99mTc and 123I) can be explained by the high amount of backscattered 
Bremsrahlung and high-energy photons penetrating collimator septa (creating elevated 
background in the image).  
The linearity of this preclinical SPECT with 99mTc was found to be within 10 % over the 
range of activity that we inject into animals in the lab (up to 210 MBq). Deviation was observed at 
low activity (less than 1 MBq) which might be resulted from a low count. However, discrepancies 
were still within 10% of radionuclide activity calibrator measurements.    
The quantification accuracy is strongly influenced by attenuation and scatter corrections. 
Unfortunately, our system does not employ these corrections in this current version, however, 
they have been included and addressed in this study in terms of the quantification accuracy. The 
MHS phantom was used in this study with 3 SPECT radioisotopes; 99mTc, 123I and 188Re. We have 
investigated the effects of object size, acquisition time and reconstruction parameters (number of 
iterations) on the quantitative accuracy of nanoScan SPECT/CT using the mouse size micro-
hollow spheres phantom.  
For the effects of object size, we determined the quantification accuracy with 3 different 
methods; (a) large VOI (by setting a threshold of 10% of the maximum count to exclude 
background) with integral activity (b) large VOI with SUVmax and (c) automatic VOI with 42% 
thresholding SUVmean. Different methods provided significantly different results for quantification 
accuracy. However, large VOI with integral activity is the most suitable method for our in vivo 
experiment aiming at relative organ uptake and is aided by the fact that the organs/tissues of 
interest for the particular tracers are well delineated from each other. Also, it is important to note 
that the integral approach is only suitable for a low-background situation which is appropriate for 




Furthermore, the PVE from this method can be addressed and corrected for using 
phantom-derived correction factors. For the effects of sphere size with the integral method, the 
PVE and perhaps photon attenuation and photon scatter had a strong influence on the accuracy 
of quantification (although the last two were not directly assessed but assume that these are the 
cause of the observed variation). In the smallest compartment (3.9 mm diameter sphere) which 
is still larger than mouse thyroid, the quantification accuracy with the integral method was found 
to underestimate uptake by about 18%, 10% and 3% for 188Re, 99mTc and 123I respectively. 
Interestingly, the normalised values indicated that changing isotopes does not affect the PVE.  
Changing the acquisition time did not alter the quantification accuracy for 99mTc and 123I. 
However, 188Re was more affected when acquiring shorter time frames (fewer counts) and the 
effect was stronger in smaller spheres. These errors are likely to be related to the influence of 
number of counts per projection on the performance of the EM algorithm. 
The effect of reconstruction iterations was also examined in this work. The quantification 
accuracy improved when changing from 6 to 9 iterations. For changing from 9 to 24 iterations, the 
accuracies depended on acquisition time (count levels). Also, the quantification accuracy in the 
smallest microsphere was affected more when changing the reconstructing parameters and 
acquisition times.  
Additionally, we did not perform the quantification accuracy for 131I because our 
department not own high-energy multi-pinhole collimator and this collimator was not available at 
the time of phantom study. As we also investigated the in vivo kinetic of 131I in next chapter, this 
is also important issue and need further investigate.       
In the last part of this chapter, quantification results from nanoScan SPECT/CT were also 
compared with the18F data from nanoScan PET/CT. For the integral method, PET quantification 
with 18F was less accurate when compared with SPECT. The quantification result of nanoScan 
PET/CT was overestimated about 16 % for 18F, while most of quantification results from nanoScan 
SPECT/CT were underestimated at -2.5 and -12 % for 99mTc and 188Re, except for 123I which was 






Chapter 3  Comparative Spatio-Temporal Quantification of 
Sodium Iodide Symporter (NIS) Radiotracers in Healthy and 
Tumour-Bearing Animals 
3.1 Introduction 
Sodium iodide symporter (NIS) is a membrane glycoprotein responsible for iodide 
transport which is important for thyroid hormone production. NIS is located at the baso-lateral 
plasma membrane of the thyroid follicular cells. For the transportation of iodine, NIS pumps 2 
sodium ions (Na+) together with 1 iodide (I-) using the transmembrane sodium gradient generated 
by the oubaine-sensitive Na+/K+ ATPase pump as the energy source for this transfer (Ahn, 2012). 
The activity of NIS at thyroid primarily is controlled by thyroid stimulating hormone (TSH) from the 
pituitary gland through a dedicated negative feedback loop from the hypothalamus.  Intense NIS 
expression is also normally found in other cell compartments in extra-thyroidal tissues/organs 
such as gastric lumen/mucosa in stomach, salivary acini/duct lumens in salivary gland, lactating 
breast and small intestine. However, these expression of NIS in extra-thyroidal tissue are not 
controlled by TSH (Dohán and Carrasco, 2003b; Portulano et al., 2013).  
 In research NIS has been important for many years as a molecular target for tracking the 
distribution, migration, metastasis and survival of cells in vivo. Furthermore, NIS has been 
investigated and used as a reporter gene in several systems such as respiratory, haematopoietic, 
and neurological systems and for cancer metastasis tracking as well as monitoring treatment 
response in many preclinical studies (Fruhwirth et al., 2014; Khalil et al., 2011).      
In clinical applications several NIS radiotracers are proved as diagnostic 
radiopharmaceuticals for thyroid diseases in nuclear medicine. For instance, 99mTc-pertechnetate 
and 123I-iodide are well known SPECT imaging tracers while PET radiotracers for studying NIS 
have so far been limited to124I-iodide. However, when compared with 18F, 124I-iodide has several 
disadvantages such as poor image quality due to low positron yield and higher effective dose due 
to long physical half-life. 18F-tetrafluoroborate is a forthcoming PET diagnostic agent for thyroid 
disease and NIS-expressing organs (Jauregui-Osoro et al., 2010b). 
In therapeutic applications transport of iodide by NIS, combined with the metabolic 
trapping of radioiodine into thyroid hormone, is the fundamental molecular basis for the use of 
radioactive iodine in treatment of thyroid diseases. 131I-iodide has been used for thyroid therapy 
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since the 1940s and continues to be a stronghold therapeutic agent (Verburg et al., 2011). 
Additionally, targeted radioiodine therapy has been researched for the treatment of extra thyroidal 
tumours post-transcriptional NIS gene transfer (Klutz et al., 2009). However, high dose131I 
treatment has a number of limitations and disadvantages. In particular, the abundant high-energy 
gamma rays emitted at the same time as the beta emissions cause a large fraction of the total 
radiation dose. Therefore, many groups of researchers have been interested in using alternative 
radiotracers for NIS expressing tumours. 
186Re- and 188Re-perrhenate are also substrates of NIS (but not of subsequent metabolic 
steps) which have been examined for therapeutic purposes of NIS-bearing tumours in preclinical 
research such as thyroid, breast or prostate cancer (Dadachova et al., 2005; Ferro-Flores and 
Arteaga de Murphy, 2008a). Nevertheless, further in vivo information is still required for clinical 
translation.  
In addition, Astatine-211 (211At) is a new therapeutic candidate for cancer which emits 
high energy alpha particles. The physical properties of 211At are promising, however it is currently 
available at only a few centres worldwide.  
The physical characteristics of available NIS radiotracers and production tabulate in 





























633.5 keV/511 keV Cyclotron 
99mTc 
(pertechnetate) 



































(free astatine or 
astatide) 
7.2 h Alpha, X-ray 7500 keV/77-92 keV Cyclotron 
 
Non-invasive in vivo pre-clinical imaging is a useful tool to study the distribution and 
kinetics of radiotracers in biomedical research. While single time-point imaging in planar or 
tomographic (SPECT or PET) mode has been used to obtain static information (or “snapshot”) 
about tracer distribution at particular time after injection, dynamic in vivo imaging is more 
advantageous for tracer development as it enables accessing information about the organ 
kinetics, the metabolic pathways and the physiological processes while the animal is alive (albeit 
under general anaesthetic). For dosimetric studies, time-activity curves (TACs) derived from 
dynamic data are key to determine the cumulated activity, effective half-life, tracer residence time 
and dosimetry for therapeutic nuclear medicine. In diagnostic nuclear medicine applications, 
dynamic data can be used to find the optimal time to image the organ of interest (Franc et al., 
2008; Johnström et al., 2012; Matthews et al.).    
 A key advantage of dynamic in vivo imaging is that it allows the acquisition of image data 
over a series of time-points to complete the dynamic sequence using a single animal. Quantitative 
imaging using a single animal reduces the variability when compared with ex vivo bio-distribution, 
which has several disadvantages. The recent work (2012) by Brandt et al. has used preclinical 
 
Table 3-1 NIS radiopharmaceuticals with the physical characteristics 
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imaging to image the thyroid and salivary glands in mouse, investigating variable parameters that 
affect the 99mTc-pertechnetate and 123I-iodide image. The authors concluded that the potential 
advantages of whole-animal imaging can reduce inter-experimental variability of thyroid and 
salivary glands uptake in contrast to using a set of animals sacrificed at different time-points to 
derive tracer kinetics (Michael P. Brandt, 2012). Ex vivo bio-distribution requires sacrifice of many 
animals for each time-point. Also, the ex vivo measurement combines the radiation 
measurements from difference modalities (dose calibrator and gamma counter) which differ in 
measurement unit and counting efficiency. Also the self-absorption, geometry and dead-time 
difference between organs are also sources of errors in the gamma counter. Furthermore, the 
human errors such as dissection skill (excess/loss of tissue and body fluid e.g. blood during 
dissection), weighing error, and time synchronisations are also the main source of errors for ex 





















3.2 Aims  
In this chapter, we aim to compare the in vivo behaviour of NIS radiotracers in normal 
healthy Scid/Beige mouse with different radiotracers available; 99mTc-pertechnetate (99mTcO4-), 
123I-iodide (123I-NaI), 131I-iodide (131I-NaI), 188Re-perrhenate (188ReO4-) and 18F-tetrafluoroborate 
(18F-BF4). We also set out to examine the in vivo kinetics of NIS radiotracers in mice bearing NIS-
expressing tumours in the murine xenograft adenocarcinoma model (MTLn3E34CXCR4-hNIS). 
In tumour-xenografted mice, we evaluated the kinetics with 99mTc-pertechnetate, 123I-NaI and 
188Re-perrhenate. So, iodide is expected to be different to others because it is metabolised and 
trapped in thyroid while the pertechnetate, perrhenate and tetrafluoroborate are not. 
The distribution of the radiotracers in NIS-expressing organs/tissues and temporal 
change over time (Spatio-Temporal quantification) were quantitatively investigated in this chapter. 
In small animal imaging, the spatial resolution is an important concern due to the small size of 
organs/ tissues. It is therefore necessary to use appropriate imaging devices with high spatial and 
temporal resolution and high sensitivity. The dedicated small-animal nanoScan SPECT/CT 
(Mediso, Hungary) and nanoScan PET/CT (Mediso, Hungary) were used as the imaging systems 
















3.3 Materials and Methods 
3.3.1 Animal Experiments  
All animal experiments were performed according to the licence requirements under the 
United Kingdom (UK) Home Office and the Animal (Scientific Procedure) Act 1986 (ASPA). The 
study protocol was approved by the local ethics committee. Age- and sex-matched female healthy 
Scid/Beige mice were purchased from Charles River Breeding Laboratory (London, UK). Animals 
with age between 4-8 weeks were used in this experiment. All mice were kept in standard BSU 
(Biological Service Unit) conditions with autoclaved water bottle and normal food at King’s College 
London BSU unit, St Thomas Hospital (London, UK). 
3.3.2 Healthy Model and Tumour Xenograft Model  
 Animals were randomly divided into 2 main groups; healthy and tumour xenograft. 
Healthy female mice (n=3 for each radiotracer) were used to serve as the control in this study. 
The mammary adenocarcinoma cell line (MTLn3E) was chosen to use in this study. MTLn3E was 
engineered to uniformly express human sodium iodide symporter (hNIS). This cell line was also 
engineered by overexpressing truncated CXCR4 to become highly metastatic; the cell line is 
known as MTLn3E34CXCR4-hNIS (Fruhwirth et al., 2014). Mice were housed for one week 
before tumour initiation. 5×105 cells in sterile 0.9% saline were subcutaneously initiated at the 
lower left side flank of the mouse mammary fat pad. Tumour growth and mice health were closely 
monitored and recorded. Xenograft mice were imaged when the tumour could be palpable 
(usually between days 9 and 19 after the tumour initiation), with tumour diameter not exceeding 
12 mm according to the Home Office project license and local ethic rules. The details for 
engineering of stable cell lines, cell culture, radionuclide in vitro uptake and specific information 
of this animal model were previously described and published by colleagues (Dr. G Fruhwirth and 
Dr. S Diocou) (Fruhwirth et al., 2014).  
3.3.3 NIS Radiotracers 
Clinical standard radiopharmaceuticals 99mTc-pertechnetate, 123I-NaI and 131I-NaI were 
kindly supplied by the Radiopharmaceutical Unit, Guy’s Hospital (Guy’s & St Thomas’ Hospitals 
NHS Foundation Trust, London, UK). 99mTc-pertechnetate was eluted as per clinical routine at 
Guy’s Hospital, 123I-NaI was purchased from Mallinckrodt Pharmaceutical (Petten, Netherlands) 
and 131I-NaI was purchased from GE Healthcare (Amersham, Buckinghamshire, UK). 188Re-
perrhenate was eluted from our on-site W-188/Re-188 generator (ITG-Isotope Technologies, 
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Germany) using sterile normal saline for injection (Baxter Healthcare, Newbury, UK). The 
radiochemical purity of 188Re-perrhenate was tested by radio-TLC (Thin Layer Chromatography) 
using saline as a solvent and ITLC-SG (Agilent Tech, Berkshire, UK) as a stationary phase.  
18F-BF4 was produced at the cyclotron in the Clinical PET Centre, St Thomas’ Hospital 
(London, UK). The method of synthesis was published by colleagues with the specific activity of 
10 GBq/mg (Jauregui-Osoro et al., 2010b). GMP (Good Manufacturing Practice) standard 
analysis and quality controls were performed before the product was released for use.  
The radiotracers were intravenously injected at required levels of activity for each mouse 
with a volume of approximately 150 µl (Table 3-2). All injections were performed under 








                    Table 3-2 Activity of radiotracer injected to the animal (mean ± SD) 
Animal Model - Radiotracer Injected Activity (MBq) 




123I- Sodium iodide 
18F- Tetrafluoroborate 
 
199.53 ± 2.95 
36.99 ± 3.47 
37.34 ± 2.96 
15.15 ± 0.29 
5.11 ± 0.14 
Tumour Xenograft Mice (n=3 for each radiotracers) 
99mTc-Pertechnetate 
188Re- Perrhenate 
123I- Sodium iodide 
18F- Tetrafluoroborate 
 
20.27 ± 0.80 
36.77 ± 0.40 
15.00 ± 0.25 
4.98 ± 0.21 
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3.3.4 Imaging Protocols 
3.3.4.1 Imaging Protocols for Healthy Group  
After injection under anaesthesia, animals were immediately transferred to the scanner 
bed with anaesthesia maintained using 1.5 - 2% isoflurane gas in O2 air. In all scans, 
anaesthetised animals were monitored for breathing signal and bed warming was operated to 
preserve body temperature. Whole body dynamic SPECT commenced about 3-5 minutes after 
tracer administration (depended on transferring process from induction box to scanner bed). The 
photopeak windows of nanoScan SPECT/CT were set at 20% window width (ww) centred over a 
140 keV photopeak for 99mTc-pertechnetate, 20% ww centred over a 159 keV photopeak for 123I-
NaI, 20% ww centred over a 364 keV photopeak for 131I-NaI and 20% ww centred over a 155 keV 
photopeak for 188Re-perrhenate. SPECT projections were acquired using a low energy multi-
pinhole collimator with pinhole aperture of 1 mm except for 131I-iodide where a high energy 
collimator was used with aperture 1 mm. For dynamic imaging, the frame duration was set at 10-
12 minute per frame (exact frame rate slightly varied with axial field extend) per time frame with 
continuous scanning for 4 hr. Then, static SPECT was performed again at 8 hr, 24 hr and 48 hr 
after tracer administration (latter for 131I-iodide only). At the end of the scan, a whole-body CT 
scan (55 keV X-ray, exposure time 1000 ms and 180 projections and pitch 1) was performed for 
anatomical localisation.   All SPECT tomographic data were processed by HISPECTTM iterative 
reconstruction software using “standard reconstruction” reconstruction parameters. 
For PET acquisition, 18F-tetrafluoroborate was injected intravenously under anaesthesia 
(as previously described). Then, the mouse was transferred to scanner bed were anaesthesia, 
bed warming and vital signs monitoring were maintained as described above. Dynamic PET was 
continuously acquired for 4 hr on the nanoScan PET/CT in list mode using 400-600 keV energy 
window and coincidence relation of 1:3 followed by CT (55 keV X-ray, exposure time 1000 ms 
and 360 projections and pitch 1) for anatomical localisation and attenuation correction. All PET 
projection data were processed with the 3D reconstruction Tera-tomo® software package 
(supplied with the system) with attenuation, scatter and dead-time corrections applied.  
3.3.4.2 Imaging Protocols for Tumour Xenograft Mice 
For 123I-NaI, the data were collected using the same protocol as for healthy mice with 
dynamic scanning for 4 h after injection and static SPECT at 8 and 24 h after injection. In case of 
99mTc-pertechnetate and 188Re-perrhenate, the whole-body dynamic data were acquired only for 
4 h with no additional SPECT at later time-point due to technical limitations (low count levels). 
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18F-tetrafluoroborate for xenograft were scanned for 2 h. All data were reconstructed and 
managed as describe for the healthy mice experiments (Krisanat Chuamsaamarkkee, 2013a). 
3.3.5 Image Quantification  
The VivoQuant© (InviCro, Boston, USA) software was used to view and quantify the data. 
Volumes of interest (VOIs) were drawn on the tracer accumulating organs using the CT as a guide 
to resolve areas not clear on the radionuclide images. The VOIs (integral method by setting a 
threshold of 10% of the maximum count to exclude background) were drawn over the thyroid, 
salivary glands, stomach, bladder, left-ventricle (for blood), and muscle (for background) with 
additional VOI at tumour for the xenografts (figure 3-4). The whole body VOI was drawn on the 
initial whole body (WB) SPECT (first time frame, about 12-14 min post injection). This initial WB 
activity was considered to be equal to the injected activity and this was used instead of the 
radionuclide syringe dose-calibrator reading mainly to avoid any errors due to tissue activity in 
the animal tail or other remnant activity (injection needle and tubing). The percentage uptake per 
injected dose (%ID) in each organ was calculated as the activity in the VOI (in units of MBq) 
divided by the injected activity (units of MBq) from the whole-body VOI with decay correction 
(eq.3-1) (Krisanat Chuamsaamarkkee, 2013a, b). The conversion of image counts to radioactivity 
in units of MBq is based on a calibration process for a user-defined quantification factor in 
VivoQuant©. The method for obtaining these quantification factors is described in chapter 2.   
 
 
The percentage uptake per organ weight (%ID/g) for all tracers (eq.3-2) were computed 
in 3 NIS-expressing organs; thyroid, salivary glands and stomach. For the healthy mice, we used 
the mean organ weight (n=14) to divide the percentage uptake. The mean organ weight was 
collected from the dissected organ of healthy mice after imaging session, these masses were not 
derived from whole group of mice due to technical problem. The average body weight (mean ± 
SD) of mice in this group was 22.71 ± 2.38 g. The average thyroid tissue (not including the 
Figure 3-1 VOIs in lateral view of MIP image T-thyroid, SG-salivary glands, LV-left ventricle, SM-stomach, 
M-muscle and BD-bladder  
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trachea) when dissected under microscope had mass of 0.0169 ± 0.0052 g. Dissecting mouse 
thyroid was very challenging due to their small size. So, the associated error in weighing is high. 
For this reason, the average group value is a good compromise in order to limit the inaccuracies. 
In addition, the average weights of salivary gland, stomach and urinary bladder from the same 
batch of animals were also used with mass of 0.1165 ± 0.0255 g, 0.2613 ± 0.0709 g and 0.0818 






For the tumour xenograft mice, the mass of organs for individual mouse including actual 
dissected tumour mass were used to calculate the percentage uptake per weight of organ. The 
mass of tumours ranged from 0.348 to 0.548 g (average 0.452 ± 0.064 g for n = 9) (average 0.432 
± 0.046 g for n = 12), with the average weight of mice 23.91 ± 3.05 g (23.58 ± 2.95 g).    
3.3.6  Statistical Analysis 
 A tracer uptake was presented as mean ± standard deviation (SD). The significance of 
changes in tracer uptake was determined by using a two-tail paired t-test for same animal and a 
two-tail unpaired t-test when compared to different animal. P-values of less than 0.05 were 












      𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝐼𝑛𝑗𝑒𝑐𝑡𝑒𝑑 𝐷𝑜𝑠𝑒 (%𝐼𝐷) =  
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑖𝑛 𝑡ℎ𝑒 𝑉𝑂𝐼 (𝑀𝐵𝑞)
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑖𝑛 𝑡ℎ𝑒 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑊𝐵 (𝑀𝐵𝑞)
× 100                         Equation 3-1 
  𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝐼𝐷 𝑝𝑒𝑟 𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑂𝑟𝑔𝑎𝑛 (%𝐼𝐷/𝑔) =  
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝐼𝑛𝑗𝑒𝑐𝑡𝑒𝑑 𝐷𝑜𝑠𝑒 (%𝐼𝐷)
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑂𝑟𝑔𝑎𝑛 (𝑔)




3.4.1 In vivo Spatio-Temporal Quantification in healthy mice 
In this chapter, radiotracer distributions in NIS-expressing organs were identified, with 
clearly distinguished activity in thyroid and salivary glands as we also used anatomical information 
from CT to verify the tissue border between these organs. All images were displayed and 
analysed using VivoQuant© software. Decay-corrected time activity curves (TAC) based on VOIs 
over thyroid, salivary glands, stomach, urinary bladder, left ventricle (for blood pool) and muscle 
(for background) are illustrated in figure 3-6 and 3-7.  
For SPECT radiotracers, the highest uptake was found in the stomach from initial time 
point with widely variable uptake values (high SD) from one animal to another and also varied 
across radiotracers. The stomach uptake reached its maximum at 4 hr for both iodine isotopes 
(123I-iodide and 131I-NaI), then continuously decreased over time and almost completely vanished 
at later time-points. On the other hand, stomach uptake of pertechnetate and perrhenate 
continuously increased and peaked at 8 hr after injection, then uptake gradually declined. By 24 
hr after injection, stomach uptake of pertechnetate and perrhenate was found to be still high at 
26.79 ± 3.03 %ID. Correspondingly at this time point, the pertechnetate excreted by saliva and 
gastric mucosa were transited and appeared in the gastrointestinal tract, As the activity in small 
and large bowel were seen at 24 hr time-point in representative mouse (matched coronal views 

















The uptake of non-metabolised radiotracer in thyroid increased gradually over time and 
peaked early at 1.22 hr (3.27 ± 0.29 % ID) for pertechnetate. The maximum uptake for perrhenate 
observed at about 3 hr after injection (1.39 ± 0.31 % ID). The different of peak times and uptake 
values of non-metabolised radiotracer could be resulted from imaging artefact which are 
discussed later in next part. In contrary for metabolised radiotracer iodine isotopes, peak activities 
for 123I and 131I were observed at 8 hr. The maximum uptake for iodine was comparatively high 
(14.80 ± 0.98 % ID and 11.04 ± 1.62 % ID for 123I and 131I respectively) when compared with non-
organified tracers (pertechnetate and perrhenate). The iodine uptakes in thyroid slowly decreased 
but still remained fairly high when compared to uptake in other organs even at 24 h (for 123I) and 
48 h (for 131I). This presumably resulted from iodine organification in thyroid hormones synthesis. 
Figure 3-2 Matched coronal images of 99mTc-pertechnetate for each time points (A) 10 min (B) 45 min (C) 
90 min (D) 4 hours (E) 8 hours and (F) 24 hours after injection 
A B C 





Thyroid uptake in non-organified tracers (pertechnetate and perrhenate) fell faster and almost 






















































































Figure 3-3 Time-Activity Curves demonstrate the uptake of NIS radiopharmaceuticals 99mTc-pertechnetate, 
188Re-perrhenate, 123I- and 131I-NaI in normal mouse (n=3). The data were analysed and presented as the 






In salivary glands, a similar pattern was seen for all radiotracers, in which the uptake 
increased slowly overtime followed by a plateau phase and gently washed out at later time-points. 
The activities in the urinary bladder indicated the excretion of radioisotopes via the genitourinary 
system. For the first 4 hr phase of the dynamic study, the bladder activities were characterised by 
a similar pattern for all radiotracers, in which bladder uptake increased gradually for 4 hr then 
animals were awakened from anaesthesia and urinated. Hence, this process caused the 
maximum activity mostly observed at 4 hr post injection and bladder activities were negligible at 
later time-points. Activity in tissues that do not express NIS (muscle) and the left ventricle 




















































Figure 3-4 Time-Activity Curves (same data as figure 3-3 with expanding scale) demonstrate the uptake of 
NIS radiopharmaceuticals 99mTc-pertechnetate, 188Re-perrhenate,123I- and 131I-NaI in normal mouse 
(n=3) in thyroid and salivary glands.  The data were analysed and presented as the mean of percentage 




For 18F-BF4 (as illustrated in figure 3-5), whole body PET was dynamically acquired in list 
mode continuously for 4 hr after injection followed by CT for anatomical localisation and 
attenuation correction. Data were re-binned and reconstructed into a series of 30 min time 
frames. Based on the graph, it can be seen that the uptake pattern of 18F-BF4 was similar to 
non-organified SPECT tracers (99mTcO4- and 188ReO4-). The uptake was highest in stomach and 
continued to increase for 4 hr post injection. TACs showed a fast accumulation of 18F-BF4 in 
thyroid and salivary glands then the rate of uptakes slightly decreased. The activity in the 
salivary glands was higher than thyroid which is a pattern not seen in other tracers. The uptake 
in thyroid reached its maximum (1.06 ± 0.05 %ID) at 1 hr after injection while uptake in salivary 
glands approached its maximum (6.65 ± 1.42 %ID) at about 2.5 hr after injection. Interestingly, 
images showed tracer accumulation in lateral parts (not observed this in SPECT radiotracers) 







Figure 3-5 (A -Top Left) Time-Activity Curve shows the uptake of PET 18F-BF4 in normal mouse (n=3). The 
data were analysed and presented as the mean of percentage injected dose (%ID) ± SD (B-Top Right) 
Maximum Intensifying Projection (MIP) of 18F-BF4 accumulated in normal mouse. Tracer was accumulated 
in NIS-expressing organs (thyroid, salivary glands, stomach, urinary bladder) and also uptake in lateral part 
of chest (arrow) which might indicate mammary tissue (C – Bottom Left) Time-Activity Curve with expanding 




























bladder activity represented renal excretion of radiotracer, the activity continue to increase to 4 
hr due to the effect of anaesthesia as previously observed in other SPECT radiotracers. Activity 
in the left ventricle (representing blood pool) and muscle (representing background) remained 
low over time.   
The percentage uptake per organ weight for all tracers is shown in the following figures 
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Figure 3-6 Time-Activity Curves demonstrate the uptake of SPECT NIS radiopharmaceuticals 99mTc-
pertechnetate, 188Re-perrhenate,123I- and 131I-NaI in normal mouse (n=3). The data were analysed and 








When comparing uptake in thyroid and salivary glands for non-metabolised tracers 
(pertechnetate, perrhenate and tetra-fluoroborate), the percentage uptake per injected activity 
was slightly higher in salivary glands. However when comparing the normalised activity per gram 
of tissue, thyroid showed higher values than salivary glands. This pattern was observed over time 
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Figure 3-7 Time-Activity Curve shows the uptake of PET 18F-BF4 in normal mouse (n=3). The data were 
analysed and presented as the mass normalised of percentage injected dose (%ID/g) ± SD 
Figure 3-8 Bar graph of uptake per gram of tissue in thyroid (Mean ± SD) for all radiotracers 
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respectively. Thyroid uptake of 123I- and 131I- were much higher (about 20 folds at 8 hr after 
injection) than that observed in non-metabolised tracers and continued to increase through the 8 
hr time-point then decreasing by 24 and 48 hr post injection (as illustrated in figure 3-8), 
presumably as a result of a hormone production process.   
 We additionally analysed the percentage injected dose per tissue mass ratio of uptake 
in thyroid divided by salivary glands for all radiotracers in the dynamic phase (first 4 hr after 
injection) (Figure 3-9). At 15 min post injection, the uptake ratios of all radiotracers were similar 
except for that of BF4 which was lower than other tracers. Then, the uptake ratios of iodide 
radiotracers (123I- and 131I-NaI) were starting to increase while other decreased.  The thyroid to 











Figure 3-9 The percentage injected dose per tissue mass ratio of uptake in thyroid divided by salivary glands 
show clearly differences of uptake pattern for each radiotracers 
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3.4.2 In vivo Spatio-Temporal Quantification in Xenograft mice 
Xenograft bearing breast adenocarcinoma cell line (MTLn3E) overexpressing truncated 
CXCR4 and human sodium iodide symporter (hNIS) was selected to examine the kinetics of 
radiotracers in this study. Time-activity curves of NIS radiotracers accumulated in xenograft are 
presented in figure 3-10. In vivo dynamic imaging showed similar pattern of NIS-expressing 
organs as seen in normal subjects.  Interestingly, uptake in tumours was higher than thyroid and 
salivary glands in all tracers. For 123I-NaI, activity in tumour was higher than stomach. The tumour 
uptake in 123I-NaI elevated over time and peaked at 4 hr post injection (21.90 ± 0.98 % ID). 
However, the tumour uptake for 123I was remained only about 0.6 % ID at 24 hr after injection. A 
similar pattern was found in pertechnetate with tumour activity higher than that observed in the 
stomach for the first 2.5 hr, before reaching its maximum at about 26 % ID at plateau and still 
remaining high at 4 hr after injection. For 188Re-Perrhenate, the tumour uptake was remarkably 
low when compared with pertechnetate and iodide. Rhenium tumour uptake reached a maximum 
(5.64 ± 1.42 % ID) at approximately 3 hr and still accumulated in tumour about 5 % ID until 4 hr 
after injection. For 18F-BF4 PET radiotracer, tumour uptake was low when compared with SPECT 
radiotracer. At 2 h , the uptake of BF4 was still not reached its peak yet, the data at this time-pint 
shown the uptake at 3.25 ± 1.98 % ID)  
 
 
After imaging all mice were dissected to obtain the tumour weight. Then, the percentage 
uptake per gram of tumour (% ID/g) was calculated as shown in figure 3-11, 18F-tatrafluoroborate 
accumulated in tumour at about 4-8 % ID/g, compared with SPECT radiotracers approximately 5-
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Figure 3-10 shows the tumour uptake in NIS-radiotracers per gram of tissue (% ID/g) in xenograft (n=3). 
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Figure 3-11 Time-Activity Curves demonstrate the uptake of NIS radiopharmaceuticals 99mTc-pertechnetate, 
188Re-perrhenate and 123I-NaI in mouse bearing rat adenocarcinoma xenograft tumour expressing hNIS 
(n=3). The data are presented as the mean of percentage injected dose (%ID) ± SD 
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3.5 Discussion  
In this chapter, in vivo spatio-temporal quantification of NIS radiotracers in normal healthy 
and tumour bearing xenograft mice was studied. TACs were graphically plotted in terms of 
percentage injected dose (%ID) over time after injection as well as normalised percentage 
injected dose per organ/tissue weight. This information afforded a side by side comparison of 
pharmacokinetics. 99mTc-pertechnetate and 123I-NaI are well known SPECT imaging agents. 131I-
NaI has long been recognised as a therapy agent in the management of thyroid diseases. 188Re-
perrhenate is another NIS substrate whose physical properties appealed for therapeutic purposes 
but have not been assessed clinically. In addition, 18F-Tetrafluoroborate is a forthcoming 
diagnostic PET imaging agent for thyroid disease (clinical trial currently underway) and NIS 
reporter gene imaging. All these NIS radiotracers have been examined and compared in this 
chapter. 
The availability of preclinical imaging allows an assessment of radiotracer behaviour with 
high spatio-temporal resolution throughout the whole body of the animal which enables us to 
localise and quantify the uptake of radiotracer in small organs of laboratory animals. The sub 
millimetre resolution from multi-pinholes allows the high resolution imaging of thyroid with both its 
lobes clearly resolved and the ability to distinguish and quantify the radiotracer accumulated 
between thyroid and the salivary glands.  
For pharmacokinetics in normal healthy mice, the thyroid, salivary glands and stomach 
were the main organs that accumulated the radiotracers. Uptake in urinary bladder showed the 
excretion of radiotracer via kidneys. The uptake in those organs was found to be varied across 
radiotracers. A large proportion of radiotracer was accumulated in the stomach when compared 
with other organs (thyroid, salivary glands, and urinary bladder) in all radiotracers for first 4 hours 
of the dynamic phase after injection. However, as the mass of the salivary glands and stomach 
are much greater than the mass of thyroid in this species, the normalized uptake (%ID/g) was 
highest in thyroid followed by salivary glands or stomach. However, this pattern was difference in 
18F-BF4. Thyroid to salivary gland uptake ratios were 1.59 and 1.23 at 30 minutes and 1 h after 
injection, then decreased to 0.94 and 0.83 at 2 h and 4 h respectively. Our study found that 
normalized uptake of 18F-BF4 was highest in thyroid only for the first hour after injection then the 
stomach and salivary gland activity were greater than the activity accumulated in thyroid. 
However, there appeared to be some difficulty when comparing SPECT and PET data. As 
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nanoScan SPECT/CT has a spatial resolution better than that of nanoScan PET/CT (about 0.7 
and 1.2 mm FWHM at CFOV for 99mTc with nanoScan SPECT/CT and 18F with nanoScan PET/CT 
respectively), small organ quantification in PET may be subject to stronger influence by partial 
volume effects (PVE) than in SPECT.   
Furthermore, in this study we have shown data for a potential for new therapeutic agent 
(188Re-Perrhenate) for comparison with conventional 131I-NaI. As mentioned above, the uptake 
patterns in thyroid can be categorised into metabolised (iodide) and non-metabolised (perrhenate, 
pertechnetate, tetrafluoroborate) group. For 188Re-perrhenate, the maximum uptake in thyroid 
was about 2 hr after injection and subsequently decreased at later time points, where both iodide 
radiotracers continued to increase and reach maximum at 8 hr (for 123I-NaI) and 24 hr (for 131I-
NaI) after injection. Interestingly, the thyroid uptake value of 123I- was higher than 131I- which could 
due to stunning effect. The stunning effect is defined as a temporary defeat of iodine and trapping 
function of the thyrocytes as a result of the radiation given off by the 131I. 
Based on the dynamic TACs in figure 3-6, it can be seen that the pharmacokinetics 
pattern of 188Re-perrhenate and 99mTc-pertechnetate were very similar. However, the uptake 
values of NIS-expressing organs in 188Re-perrhenate were quite low when compared to images 
obtained with 99mTc-pertechnetate. This might be influenced also by the elevated background 
counts observed in 188Re images (as shown in figure 3-12) from a strong Bremsstrahlung 
component which has a boarding spectrum up to MeV (with the subject and the camera), septal 
penetration from high-energy lines (478 and 632 keV) and also a random noise from low-
abundance of 155 keV gamma photons (about 15% gamma abundance). According to study by 
Manjunatha HC, the Bremsstrahlung radiation spectrum of 188Re was estimated using Bethe and 
Heitler’s analytical formula. Manjunatha HC showed that Bremsstrahlung spectrum of 188Re 
interacted with bone and muscle has a continuous spectrum from 0.1 up to 2 MeV. Also, high-
energy photons (0.487 MeV – 0.62 % abundance and 0.632 MeV – 1 % abundance) can 
penetrate collimator septa, then creating significant background elevated in the image (as 
observed in figure 3-12). The combination of all these effects may result in elevated background 
and hence high “whole body” activity in the denominator contributing to inaccuracies 






The kinetic comparison of NIS radiotracers (perrhenate, pertechnetate and iodide) in 
healthy CD mice also has been reported by Zuckier et al (Zuckier et al., 2004). However, the 
kinetic results from Zuckier et al were based on the ex vivo bio-distribution from a different sets 
of mice and at different time-points (20 min, 2 h and 19 h post injection). We consider that time-
activity curves derived by ex-vivo bio-distribution (rather than single animal kinetics) are subject 
to strong influence by inter-animal variability and organ dissection errors. This variation confirmed 
by the study by Brandt et al in 2012. In this study, the inter- and intra-experimental viability of 
thyroid and salivary uptake of 99mTc-pertecnetate was evaluated. Brandt’s study concluded that 
the magnitude of variability among different animals were greater than the inter-experimental 
variability in the same mouse (Brandt et al., 2012). Furthermore, Traditional ex vivo bio-
distribution needs to sacrifice many animals. The substantial expense of animal lives, costs, and 
time are constrained the number of time-points of time-activity curve. In our study, In vivo imaging 
with preclinical SPECT/CT and PET/CT are offered series of imaging of live mice. The full time 
course of pharmacokinetics was measured on the same animals. This reduces biological 
variability over the time course of the radiotracers and avoids errors from ex vivo bio-distribution 
which may be quite large and difficult to address (Franc et al., 2008). However, there are still 
pitfalls for comparing in vivo data resulting from imaging instrument (previously described in detail 
Figure 3-12 Maximum Intensity Projection (MIP) at 90 min post injection (Left) 99mTc-Pertechnetate and 
(Right) 188Re-Perrhenate. These images demonstrate differences in background values (potentially due to 
Bremsstrahlung, septal penetration and a random noise from low-abundance of gamma photon when 









in Chapter 2) such as, calibration factor and different artefacts (e.g. scatter) from different 
isotopes, also different in  physical properties (low abundance of gamma photons, positron range, 
bremsstrahlung).     
To compare uptake in thyroid and salivary glands, Zuckier et al showed only the 2D planar 
quantification from representative mice. Interestingly, Zuckier et al reported that uptake pattern of 
iodide (125I-NaI), pertechnetate (99mTc-pertechnetate) and perrhenate (188Re-perrhenate) in mice 
salivary glands were similar in which remained elevated for initial 2 h PI and then washed out. For 
thyroid, Zuckier et al showed a similar bio-distribution pattern of 188Re and 125I for initial phase (20 
min and 2 h post injection), then at later time-point (19 h PI), perrhenate uptake was decreased 
while iodide decreased by organification process. However, in vivo imaging from Zuckier’s study 
was unable to show this because ROIs were drawn at the neck region where thyroid and salivary 
glands are indistinguishable in the planar views. A publication by Grewal RK et al stated that the 
salivary gland is the critical organ for using high dose 131I-iodide treatment(Grewal et al., 2009). 
The understanding of dynamic accumulation of NIS radiotracers might lead to better clinical 
outcome in high dose radioiodine treatment.  
Our study demonstrated the capability of preclinical tomographic imaging and specifically 
its superior ability to distinguish the thyroid from the salivary gland. Based on literature data, each 
lobe of the mouse thyroid is about 1 × 0.3 mm and it alights closely to the salivary glands, the 
approximately distance is around 2-5 mm from CT images (Franken et al., 2010). The images 
have shown the ability of emission tomography to identify each lobe of the thyroid clearly in the 
sagittal planes. Furthermore, the superimposition of CT images can additionally help to define the 
boundary of the salivary glands and thyroid.  
In other work using 3D SPECT, Franken et al. published the SPECT dynamic assessment 
of 99mTc-pertechnetate using clinical SPECT equipped with pinhole collimator. Franken’s work 
has shown dynamic data only over 2 hours after injection with the tomographic area limited only 
to the neck region. The additional whole body planar view was acquired separately for the 
stomach uptake(Franken et al., 2010). Franken’s work showed that pertechnetate uptake reached 
its maximum in thyroid within 20-40 min whereas uptake in salivary glands still not reached its 
peak after 100 min. This was similar to our finding that thyroid reached its peak rapidly followed 
by the salivary glands (thyroid 75 min and salivary glands 120 min after injection) (Spitzweg et 
al., 1998). Franken’s et al discussed that there were many complex factors related with the NIS 
uptake such as level of NIS (expression, transporting efficiency, number, size), organ (passive 
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diffusion, physiological influx, efflux and size of cell compartment of each organ - cell compartment 
of salivary glands are much larger than follicular cells in thyroid) and also the level of regulation 
and action of hormones that control NIS in among different animals (Franken et al., 2010; Michael 
P. Brandt, 2012). 
The variation in uptake patterns of NIS radiotracers can be further explained by an 
assumption of anion selectivity however all published studies were performed in vitro (Eskandari 
et al., 1997b; Van Sande et al., 2003). Eskandari et al (1997) performed electrogenicity of Na+/I- 
symporter to evaluate the inward currents induced by various anions in Xenopuslaevis oocytes. 
From this study, the best transported substrate was iodide (I-) which the relative Imax value equal 
to 1. The anion group of ClO3-, SCN-, SeCN- and NO3- were intermediate high (Imax value between 
0.5 to 1) while Br-, BF4- and IO4- were categorized in the intermediate low anion selectivity group. 
Interestingly, authors found perrhenate (ReO4-) to be an effective blocking agent for NIS (Imax 
value nearly approached zero), second only pertechnetate (ClO4-) which did not induce an 
appreciable inward current in their study (Eskandari et al., 1997b). Furthermore, another in vitro 
study by Van Sande et al (2003) reported different order of affinity in FRTL-5 in NIS-transfected 
COS cells. Authors concluded that the order of blocking affinity was ClO4− > ReO4− > I− ≥ SCN− > 
ClO3− > Br− (Van Sande et al., 2003). In our study, the normalised uptake of thyroid at early phase 
(15 min after injection) was 99mTcO4->123I-iodide >131I-iodide >18F-BF4->188ReO4−whereas for 4 h 
after injection the order was 123I-iodide ≥131I-iodide >99mTcO4->188ReO4−>18F-BF4-. However, the 
thyroid uptake of both iodide isotopes was not statistically different as described in previous 
section.  
Considering of pharmacokinetics in xenografts, we performed the whole-body dynamic 
in vivo study in mice with rat adenocarcinoma (34CXCR4-hNIS). All radiotracers detected the 
tumour with high target to background ratio. In our study, perrhenate uptake in tumour was 
significantly low when compared with pertechnetate or iodide. Our findings were similar to the in 
vivo study of 188Re-perrhenate in a prostate cancer cell expressing NIS (Willhauck et al 2007) and 
study by Kang et al (2004) in a liver cancer xenograft transplant model.  However, these data 
showed higher uptake of 188Re-perrhenate when compared with published work by Dadachova et 
al. (2002) where the bio-distribution in xenografts with mammary adenocarcinoma showed only 3 
– 4 % ID/g of 188Re-perrhenate accumulated in tumour at 2 hr post injection. Also, this could be 
due to different expression levels of NIS, so, the mammary tumours were not transfected with 
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engineered NIS, only endogenously expressing at low level (Kang et al., 2004; Willhauck et al., 
2007).  
In addition, the tumour uptake can be increased by blocking or decreasing the NIS uptake 
in other NIS-expressing organs such as thyroid, salivary glands and stomach. This is also called 
the “sink” effect (Dadachova et al., 2002; Dadachova et al., 2005; Zuckier et al., 2004). The study 
by Dadachova et al. (2005) demonstrated that eliminating or blocking the uptake of radiotracer in 
thyroid by pre-treating them with T3 thyroid hormone which reduces the thyroid uptake, it can 
contribute to elevated uptake of rhenium in tumour. This can also reduce radiation damage to the 
thyroid (Dadachova et al., 2005).  
Since the study by Eskandari et al. (as explained above) in rat thyroid NIS using 
electrophysiological measurement reported that ReO4- is a potent blocking agent for NIS and is 
inferior (for blocking) to only perchlorate (KClO4-) (Eskandari et al., 1997a).  The significant finding 
from this study demonstrated that there may be a window for using perrhenate for the treatment 
of NIS-expressing tumours.  
Also, it should be noted that our animal model is initiated with genetically engineered 
(hNIS) which is unlike the endogenous mouse sodium iodide symporter or mNIS that is expressed 
in thyroid, salivary glands and stomach. Therefore, this might partly explain the variation of tumour 














3.6 Conclusion  
In this chapter, we have used high resolution preclinical imaging to quantify the spatio-
temporal distribution of the available NIS-radiotracers. In healthy model, this experiment has 
demonstrated distinct differences in uptake patterns between metabolised and non-metabolised 
tracers, and also subtle differences between the putatively non-metabolised tracers. The uptake 
of radiotracers in thyroid can be categorised into 2 assemblies: metabolised (123I- and 131I- sodium 
iodide) and non-metabolised tracers (18F-tetrafluoroborate, 99mTc-prtechnetate and 188Re-
perrhnate). In salivary glands, similar patterns of uptake were observed for all tracers which 
uptake increased gradually over time then remained steady and slowly decreased. The activity in 
thyroid can be distinguished from salivary glands along with high spatial resolution imaging of 
other NIS-expressing organs. Stomach uptake was high compared with other organs, the uptake 
in stomach peaked at 4 h for metabolised radiotracers. In contrary, peak uptake in stomach found 
at 8 h for non-metabolised radiotracers, except with 18F-BF4 which showed peak values at around 
3 h after injection (as we collected data only 4 h). Activity in muscle (not expressing-NIS) and left 
ventricle (representing blood activity) were low and remained so over time for all tracers. 
In xenograft model, all radiotracers (18F-tetrafluoroborate, 99mTc-prtechnetate, 123I-sodium 
iodide and 188Re-perrhnate) detected the tumour with high target to background ratio. This work 
demonstrated the capability of 188Re-perrhenate with appealing therapeutic and imaging 
properties (high energetic beta and imaginable gamma emission). However, perrhenate uptake 
in tumour was significantly low when compared with pertechnetate or iodide the percentage 
uptake per gram of tumour about 5 - 12 %ID/g for 188Re-perrhenate, 45-55 % ID/g for 99mTc-
pertechnetate and 42-62 % ID/g for 123I-NaI). This work also showed kinetic data of forthcoming 
PET radiotracer (18F-BF4) for imaging of NIS-expressing tumour, 18F-tatrafluoroborate 
accumulated in tumour at about 4-8 % ID/g. 
Regarding to imaging artefact of 188Re, the images of 188Re-perrhenate showed in this 
study had a problems from (1) a continuous spectrum of Bremsstrahlung radiations (energies 0.1 
up to 2.0 MeV), (2) septal penetration cause by down scatter from the higher energy photons 
creating significant background in the image, (3) scattered photon corresponding to the 0.478 and 
0.632 MeV and (4) a random noise from low-abundance of 155 keV gamma photons (about 15% 
gamma abundance). The combinations of all these effects are resulted in elevated background, 
contamination of counts in main photo-peak and hence contributing to inaccuracies in 
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quantification of 188Re-perrhenate. As the complexity of multi-pinhole, we cannot employ the triple-
windows correction to 188Re data at this stage. These will be very important things 
to investigate further for future work.  
In conclusion, the data showed the capability of pre-clinical imaging for spatio-temporal 
quantification. Such data can be used to determine optimal imaging times to maximise image 
quality in diagnostic studies and allowing accurate quantitative in vivo analysis for the dosimetry 
























Chapter 4 Human-Equivalent Dosimetry of NIS Radiotracers in 
Healthy and Tumour Model Mice Based on Preclinical Spatio-
Temporal Data 
4.1 Introduction 
4.1.1 Nuclear Medicine Dosimetry 
In general, radiation dosimetry aims to estimate risks and benefits of using ionizing 
radiation. In nuclear medicine, radionuclides are administered for a variety of diagnostic and 
therapeutic applications. Specifically, nuclear medicine dosimetry deals with the energy deposited 
by internally emitted radionuclides into organs, tissues or the whole body. The energy absorbed 
per unit mass in terms of “absorbed dose” is used to indicate the effects of radiation on the tissue 
or organ. The direct measurement of absorbed dose for internalised emitting radionuclides is 
difficult to perform, hence in nuclear medicine this quantity is usually indirectly determined by 
calculation. The methodology and associated assumptions are discussed below.    
 
4.1.1.1 Medical Internal Radiation Dose (MIRD) 
Historically, the first formalism for dose calculations from internal deposited radionuclides 
was defined and published by Marineli et al (1948) and Quimby and Feitlberg (1963)(Stabin, 
2006). After that in 1968, the Medical Internal Radiation Dose (MIRD) committee of the Society 
of Nuclear Medicine (SNM) was established. The MIRD committee contributes to defining the 
methods, equations and models for dosimetry calculation in nuclear medicine. MIRD has provided 
an extensive body of data for several radionuclides to assist in dose estimation. The estimation 
of absorbed dose is based on assumptions of biological distribution, clearance and the physical 
decay properties of the radiotracers. The cumulated activity (𝐴)𝑖̃ is proportional to the total number 
of disintegrations that take place and can be calculated by integrating the time-activity curve for 
each organ (this also called the time-integrated activity in the MIRD primer) (see figure 4-1). Time-
activity curve is decreased exponentially (in its simplest form) with an effective half-life (Teff) which 
results from the combination of both physical decay of the radionuclide and bio-kinetic clearance. 
The cumulated activity can be obtained with a counting probe, quantitative imaging (planar 
imaging, SPECT, PET) or excretion sampling (urine, faces, blood) at different time points after 
tracer administration.  
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The mean absorbed dose, ?̅?, within the 𝑘𝑡ℎ target from the 𝑖𝑡ℎ source is denoted in 
equation (4-1). The unit of absorbed dose is the Gray (Gy), which refers to absorbed energy of 
one Joule of ionising radiation in one kilogram (1 Gy = 1 J/kg). 
 
  
where 𝐴?̃? is the cumulated activity (µCi.h or MBq.s) in the 𝑖
𝑡ℎ source, ∆𝑗 is the mean energy emitted 
per nuclear transition from the 𝑗𝑡ℎ transition, ∅𝑗 is the absorbed fraction representing the fraction 
of energy emitted from the 𝑖𝑡ℎ source which is absorbed by the 𝑘𝑡ℎ target, and 𝑚𝑘  is the mass of 
the target (Howell et al., 1999). 
 
 
The absorbed fraction term ( ∅𝑗) depends on the emission type and energy and also the 
geometry of the source and target organ. Generally, this term is determined by Monte Carlo 
simulations. The photons (gamma rays and X-rays) take into account that some of the emitted 
energy will escape from the source organ due to their high penetration with variation due to the 
dimensions of tissue or organ. For therapeutic tracers (Auger electrons, beta and alpha particles), 
most energy is typically absorbed (non-penetrating emission), so the absorbed fraction from 
source to source organ ( ∅𝑠←𝑠) is set to 1 and for source to target organ ( ∅𝑡←𝑠) is set to 0. However, 
this assumption is only valid at macroscopic level when the size of organ is greater than the 
                                                         ?̅? = 𝐴?̃? ∑ ∆𝑗
∅𝑗(𝑘←𝑖)
𝑚𝑘
                                                   Equation 4-1 
Figure4-1 Example time-activity curve for calculating the cumulated activity. From the graph, the 
cumulated activity is the area underneath or mathematical integration of the time-activity curve – Adapted 




particle track length (Stabin, 2006). The tissue absorbed fraction of photon versus electron or 




The MIRD equation (eq. 4-1) can be simplified by defining the S-factor which is the mean 
absorbed dose per unit of cumulated activity. The S-values can be obtained by using analytical 
or computer (Monte Carlo) methods. The selection of method depends on the complexity of 
source-to-target geometry, and in some cases the S-value is not constant e.g. tumour dose with 
changing size during treatment.  
In 1975, the MIRD committee published the S-values for 117 radionuclides with various 
pairs of source-target organs based on a mathematically defined adult anthropomorphic phantom. 
The reference phantom in MIRD pamphlet no. 5 was limited by data from planar imaging, with 
organ configurations based on geometric shapes (sphere, cylinder, cone etc.) as showed in figure 
4-3. The S-values were computed by using data from the MIRD standard man phantom. The 
atomic composition and density were based on the report of ICRP reference man in 1975.  
 
Figure 4-2 Gamma photons can irradiate distant organs while electrons/alpha particles will be absorbed 
within source tissue. However, it also depends on the energy, range and size of source organ – Adapted 





The mathematical expression of the S-factor is described in the following equation. 
 
  
Where ∅𝑗(𝑘 ← 𝑖) is the absorbed fraction for particular target organ (k) and source organ 
(i), mk is mass of the target organ. Using the S-value, the equation (4-1) can be simplified as 
follows: 
                                                               ?̅? = ∑ 𝐴?̃? 𝑆(𝑘 ← 𝑖)                       Equation 4-3 
 
4.1.1.2 Calculation Tools and Models  
Many dosimetry programs have been developed from the MIRD formalism, for example 
MABDOSE (University of Colorado), INDOSE (Nuclear Energy Agency), MIRDOSE3 and 
OLINDA/EXM (Oak Ridge and RADAR) (Sgouros et al., 2010; Stabin, 2006). MIRDOSE is the 
most widely used software for medical internal dose calculations. MIRDOSE was first established 
in 1984 at Oak Ridge National Laboratory (ORNL). MIRDOSE 1 (Watson and Stabin 1984) was 
implemented in a Tektronix-PC.(2004; Stabin, 1996; Stabin and Siegel, 2003; Stabin et al., 1999). 
MIRDOSE 2 (Stabin 1987) migrated to DOS-PC. MIRDOSE 3 and 3.1 (Stabin 1996) run in the 
Windows PC (the software is not associated with the MIRD Committee of the SNM). The S-values 
in MIRDOSE 3.1 were calculated using the phantom series of Cristy and Eckerman. The six 
phantoms from this series allowed users to calculate dose estimates for children and adults of 
both genders. The pregnant female series by Stabin was also added to MIRDOSE 3.1. The table 
Figure 4-3 Reference Man Phantom from MIRD pamphlet no. 5 in 1975 
    𝑆(𝑘←𝑖) =  
∑ ∆𝑗∅𝑗(𝑘←𝑖)
𝑚𝑘
                                             Equation 4-2 
110 
 
of S-values for numerous radionuclides (>200 radionuclides) and about 25 source-target organs 
was made available in this software (Stabin, 1996). MIRDOSE was later replaced by the new 
generation software OLINDA/EXM (Organ Level Internal Dose Assessment/Exponential 
Modelling) in 2005 (Stabin et al., 2005). The OLINDA/EXM is written in the Java programming 
language and the Java Development Kit environment. There are several new features that have 
been developed from MIRDOSE software such as applications with alpha and beta emitters (over 
800 radionuclides) and the programme (EXM part) consists of a multi-exponential curve fitting 
tool which allows the user to calculate the cumulated activities from measured bio-distribution 
data. OLINDA/EXM has incorporated new physical models such as the Stabin prostate gland 
model, the Watson & Stabin peritoneal cavity model, the Evans et al. spinal cord model, the MIRD 
head and brain model, the MIRD dynamic bladder and distribution of electrons in small spheres 
model. The dose agreement between MIRDOSE3.1 and OLINDA/EXM was within 1-2% for most 
cases. The OLINDA/EXM is the first computer dosimetry calculation software to receive US FDA 
approval (Stabin, 2007; Stabin et al., 2011; Stabin et al., 2005). In this chapter, the OLINDA/EXM 
was used to estimate absorbed doses, with details of calculations provided in the next sections.    
 
4.1.2 Dosimetry for NIS Radiotracers  
4.1.2.1 Effective Dose of NIS Radiotracers for Diagnostic Use 
According to ICRP (International Commission on Radiological Protection), the effective 
dose is the summed radiation-risk weighted equivalent to organ and tissue (WT), representing the 
potential risks from stochastic (mainly lethal cancer and serious hereditary disorder) from 
exposure to radiation. Primarily, this quantity was used for radiation protection of occupationally 
exposed persons. Nevertheless, the concept of effective dose is useful in nuclear medicine as 
this value can be used to compare the stochastic effects and relative risk from different 
examinations e.g. comparing dose to a patient injected with 123I-NaI SPECT or 124I-NaI PET 
imaging.(Charles, 2008; Johansson et al., 1984; Mattsson et al., 2011) 
Radiation doses from diagnostic use of radiopharmaceuticals have been published in 
ICRP publication 53, 80 and 106. Basically, the ICRP report contains the absorbed doses to 
organs/tissues and the effective dose per unit of administered activity. Since ICRP 53 was 
published in 1988, the tissue/organ weighting factors have been revised twice and the quantity 
changed from “effective dose equivalent” to “effective dose”. The differences between the tissue 
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weighting factors of ICRP 60 and ICRP 103 are illustrated in the following table (Andersson et al., 
2014; Charles, 2008; Mattsson et al., 2011). 
 
Tissue/Organ 
Tissue/Organ Weighting Factor 














































a - Shared by remainder tissues (14 in total, 13 in each sex) adrenals, extrathoracic tissue, gall bladder, 
heart, kidneys, lymphatic nodes, muscle, oral mucosa, pancreas, prostate (male), small intestine, 
thymus, uterus/cervix (female) 
b – Shared by the five most highly exposed  
 
For NIS radiotracers, a range of isotopes has been used in nuclear medicine as 
mentioned in previous chapter. In 2011, a task group within ICRP published the effective dose in 
adults for commonly used radiopharmaceuticals (Mattsson et al., 2011). All doses have been 
calculated based on the MIRD formalism using published bio-kinetic data with the mathematical 
Cristy and Eckerman phantom. The S-values and tissue weighting factors were taken from MIRD 
pamphlet 11 and ICRP publication 60 respectively. The effective doses per unit administered 
activity (mSv/MBq) for adults with ICRP publication references for bio-kinetic models are 
















99mTc-pertechnetate without thyroid blocking 
99mTc-pertechnetate with thyroid blocking 
123I-iodide, 35% thyroid uptake 
123I-iodide, After ablation 1 % thyroid uptake 
131I-iodide, 35% thyroid uptake 














More recently, the development of medical imaging techniques offered high resolution 
images (e.g. CT, MRI) together with the advanced nuclear medicine modalities and new 
generation of computer algorithms. In 2009, ICRP/ICRU published new adult reference voxel 
phantoms for male and female with more realistic details for organs size and shape.  Recent work 
by Anderson M et al. (2014) published the effective dose using the new ICRP/ICRU phantom, 
updated radionuclide decay data (ICRP 107), the new human alimentary tract model and the 
latest tissue weighting factor from ICRP 103. Anderson M et al. also compared the results with 
the conventional data (Cristy & Eckerman Phantom with ICRP 60 tissue weighting factor-as 
displayed in table 4-3). The effective dose per unit administered activity from Anderson’s work is 









WT-ICRP 60 (%) 
99mTc-pertechnetate without thyroid blocking 
99mTc-pertechnetate with thyroid blocking 
123I-iodide, 35% thyroid uptake 
123I-iodide, After ablation 1 % thyroid uptake 
131I-iodide, 35% thyroid uptake 


















Table 4-2 (Wrixon, 2008)Effective Dose per Administered Activity for Adults (Adapted from ICRP 2011) 
Table 4-3 Effective dose from ICRP/ICRU phantom and tissue weighting factor ICRP 103 (Wrixon, 2008) 
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4.1.2.2 Dosimetry for NIS Radiotracers for Therapeutic Use 
The administration of radioiodine (131I-NaI) for therapeutic purposes has been commonly 
accepted for the treatment of benign and malignant disease of the thyroid gland since the 1940s 
(Lee et al., 2006).  
The common indications of RAIT are classified in two types: benign nodular thyroid 
disease and thyroid malignancy according to EANM guidelines (Stokkel et al., 2010). RAIT is 
used for treatment of hyperthyroidism, and the effects of excessive action of thyroid hormone. 
Hyperthyroidism includes the following: (I) Grave’s disease, (II) solitary hyper-functioning thyroid 
nodule, (III) Plummer’s disease (toxic multi nodular goitre), (IV) silent and acute thyroiditis. 
Additionally, RAIT is also used to decrease the size of thyroid nodules and also for suppressing 
the function of the thyroid gland in non-toxic diffuse goitre and euthyroid multi-nodular goitre. In 
thyroid cancer, RAIT is used to ablate thyroid cancer and/or metastasis at local or systemic level 
after partial or complete thyroidectomy (Stokkel et al., 2010).  
The fundamental molecular mechanism behind RAIT is the sodium iodide symporter 
(NIS) which is an intrinsic plasma membrane glycoprotein located at the baso-lateral plasma 
membrane of thyroid follicular cells. In normal thyroid, the thyroid follicle is formed from “colloid” 
surrounded by a single layer of follicular cells called “thyrocytes” (as shown in figure 4.4a and 
4.4b). 131I radioiodine (in the form of iodide ion) is trapped into follicular cells by NIS. This 
symporter co-accumulates both Na+ and I- into the cell with a 2:1 ratio of Na+ to I-. Then, iodide is 
moved apically into the colloid via the exporter protein pendrin and iodide is oxidised to iodine 
and then incorporated into tyrosyl residues in thyroglobulin. It then remains in the colloid until 
exported (fig 4.4c) (Champion et al., 2007a; Chung, 2002). 
RAIT has a number of limitations and disadvantages. The 131I radioiodine has a long 
physical half-life of 8 days and the abundant high-energy gamma rays (0.36 MeV, abundance 
81.7%) cause a large fraction of the whole body radiation dose. These also irradiate other 
individuals especially medical staff, family and members of the public. Consequently, the treated 
patient needs isolation in a specially designed shielded ward for several days, and lifestyle 
restrictions for a further several weeks, causing great cost to health services and disruption of 
family life. Furthermore, the beta-particles emitted by 131I-NaI are of relatively low energy (Emean = 





                 (a)                                              (b)                                                      (c) 
Figure 4-4 (a) Follicle of normal thyroid imaged by SIMS (secondary ion mass spectroscopy) (b) 
geometrical model, the thyroid follicles are formed from “colloid” surround by a shell of thyrocyte (c) 
digitised image with phosphorus (red) and iodine (green), Image shows that iodine is almost entirely 
located in the colloid and not thyrocytes. No corresponding micro-distribution data for perrhenate (ReO4-
) are available but it is expected to localise in thyrocytes. Images were taken from Champion et al 
(Champion et al., 2007a) 
 
In this study, we propose to evaluate a novel radionuclide therapy agent using rhenium 
radioisotopes (186Re- and 188Re-perrhenate). Perrhenate is also a substrate of NIS but not 
metabolised in processes of thyroid hormone production and hence once trapped in thyrocytes 
can slowly leak out rather than being semi-permanently trapped in the colloid. This means that 
whilst remaining in the thyroid, the perrhenate remains within thyrocytes rather than extracellular 
(in colloid). The radiobiological consequences of the different emission properties and the 
different location and shorter residence time would be interesting to ascertain; it is not obvious 
whether the effectiveness per emission would be greater or less than that of 131I as a result. 
Several studies have reported the therapeutic application of other rhenium labelled compounds 
in systems that do not involved iodine metabolism, for example palliation of skeletal bone pain 
(using labelled HEDP), hepatic tumour (using labelled lipiodol) and neuroendocrine tumour (using 
labelled peptides) (Ferro-Flores and de Murphy, 2008; Jeong et al., 2001; Li et al., 2001). 
However, after the cloning of NIS followed by the development of the NIS gene transfer technique 
into various cancer cells, rhenium has become appealing for treatment of NIS-expressing tumours 
of non-thyroidal origin such as breast, prostate, liver and colon cancer (Dadachova, 2010; 
Dadachova et al., 2002; Dadachova et al., 2005; Willhauck et al., 2007).  
188Re-perrhenate is easily eluted from tungsten-188/rhenium-188 (188W/188Re) 
generators, which have a high elution yield (75 to 80% of the available 188Re) and long shelf-life 
(more than 6 months for generator size of 7.4 GBq). The long shelf-life of generators may 
contribute to cost effectiveness for treatment in areas where 131I is not available. The 188W/188Re 
generator can reach a 62% of equilibrium activity at 24 h after previous elution. Therefore, the 
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generator can be eluted every day with the breakthrough of W-188 kept generally very small 
within (<10-3 %) over an extended shelf-life with further elimination by simple removal using an 
alumina column (Argyrou et al., 2013; Jeong and Knapp Jr, 2008a; Jeong and Knapp Jr, 2008b). 
Regarding the physical properties, 188Re has a physical half-life of 16.7 h (compared to 192 h for 
131I) which is a good match to its biological half-life in non-organifying tumours. The long half-life 
of 131I radioiodine results in increases radiation dose to organs and whole body as well as thyroid 
tissue. Also, Re-188 emits more energetic beta-particles (E mean = 0.764 MeV) when compared 
with I-131 (E mean = 0.182 MeV). The higher beta energy of 188Re may offer improved radio-
biological effectiveness when treating larger benign disease or tumours as the mean beta-particle 
range in soft tissue of 188Re is 3.10 mm when compared with 131I-NaI is 0.39 mm. The gamma 
photons of 0.15 MeV (15% abundance) emitted by 188Re offer a more gentle profile for imaging 
than the 0.36 MeV (82% abundance) emitted by 131I-NaI (Argyrou et al., 2013; Ferro-Flores and 
Arteaga de Murphy, 2008b). Also attractive is the dosimetric profile of another rhenium isotope, 
186Re which has a half-life of 90.6 hours, medium energy beta particles (E mean 0.346 MeV and 
Emax1.070 MeV), and photon emissions suitable for gamma camera imaging (0.137 Mev with 9.4 
% abundance). 186Re is produced by nuclear processing using thermal reactor or cyclotron. The 
physical properties of 186Re appear to be intermediate between 131I and 188Re, therefore it can be 
a therapeutic radionuclide of choice for benign thyroid disease or NIS-expressing tumours 
(Moustapha et al., 2006).  
Regarding radiation protection, the dose contribution from gamma radiation emitted 
promptly with high energetic beta particles from both rhenium isotopes is of considerably lower 
energy and lower abundance than that form 131I. Rhenium gamma photons are still detectable by 
a gamma camera for planar or SPECT (Single Photon Emission Tomography) imaging but 
imparts less whole body radiation dose when compared to conventional radioiodine. 
Consequently, the cost of radiation protection will be reduced due to lower demand on shielding 
and radioactive waste management provision. Furthermore, this may alleviate the need for 
isolation and hospitalisation of patients in specialised shielded rooms after treatment unlike 
patients treated with 131I-NaI. Therefore, this will be a substantial cost saving for the healthcare 


























in soft tissue 
(mm) 
Maximum 
range in soft 
tissue (mm) 
131I 192 0.364 [82] 0.182 0.610 0.39 2.30 
188Re 16.9 0.155 [15] 0.764 2.120 3.10 11.00 
186Re 90.6 0.137 [9] 0.346 1.070 1.10 4.50 
 
Owing to these potential advantages, rhenium is an excellence candidate for internal 
radionuclide therapy and we hypothesised that 188Re- and 186Re-perrhenate may offer several 
benefits over 131I-NaI for radionuclide therapy of benign nodular thyroid disease and NIS-
expressing tumours with better patient quality of life and treatment cost effectiveness in term of 



















          Table 4-4 Comparison Physical Characteristics of 131I, 188Re and 186Re  
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4.2 Chapter Aims 
The aims of this chapter are three-fold. The first part of this chapter aims to estimate and 
compare the human-equivalent effective dose of NIS radiotracers (99mTc-pertechnetate, 123I-
iodide 131I-iodide and 188Re-perrhenate and 18F-BF4) for diagnostic use based on preclinical 
spatio-temporal data from mice presented in the previous chapter. The dose comparison studies 
were conducted on the same strain, sex- and age-matched animals to allow for dosimetric 
comparison to approximate radiation dose for diagnostic clinical use of these tracers. 
Secondly, this chapter aims to evaluate the potential of rhenium (186Re- and 188Re-) in the 
form of perrhenate (ReO4-) as alternative therapeutic agent compared with conventional (131I-) 
radioiodine, with the primary intention to examine the dosimetric feasibility in the treatment of 
benign nodular thyroid diseases and NIS-expressing tumours based on mouse model bio-kinetic 
data. The absorbed doses in critical organs together with whole-body and effective doses were 
computed on the basis of extrapolated animal data from the previous chapter using the OLINDA 
dosimetry software package.  
Thirdly, this chapter aims to examine the impact of the partial volume effect (PVE) on 
dosimetry calculation from preclinical imaging data. The recovery coefficient obtained earlier from 
the multi-hollow sphere phantom in Chapter 2 will be applied to the in vivo kinetic data in Chapter 
3. This correction would allow us to investigate the impact on the dosimetric error of small-













4.3 Materials and Methods 
The details of animal experiments, radiotracers, image acquisition, and data analysis for 
spatio-temporal quantification were described in chapter 3. In our study, we used the healthy 
animal data without a thyroid-blocking agent or exogenous thyroid hormone to represent the 
uptake of benign nodular thyroid disease. For NIS expressing tumours, the data from xenografted 
mice bearing breast adenocarcinoma cell line (MTLn3E) overexpressing truncated CXCR4 and 
human sodium iodide symporter (hNIS) discussed in previous sections were used to calculate 
dosimetry in this chapter. 
4.3.1 Dosimetry Calculations 
To extrapolate the human dose from the preclinical data, the linear mass scaling by 
Kirschner originally published in 1973 was applied to account for uptake differences between 
animal and human (Kirschner et al., 1973). In this work, equation 4-4 was used to convert 
percentage uptake per gram of organ (%ID/g) in mice to percentage uptake in organ (%ID) in 
human (Chang et al., 2012; Chung et al., 2010b).  
 
 
All measured pre-clinical mouse values were extrapolated to human values using the 
above equation. Effectively, this model assumes preservation of standard uptake values (SUV) 
across species. The human organ weights were extracted from the Cristy-Eckerman and Stabin-
Siegal standard phantom series for the total body mass of a reference adult male (73700 g) and 
female non-pregnant (56912 g) which were implemented and used in the OLINDA/EXM human 
dosimetry software version 1.1 (Vanderbilt University, Nashville, TN, USA). Animal organ masses 
in this study were taken from age- and sex-matched groups as discussed in the previous chapter. 












Mice (n=14) Standard Phantom in OLINDA 
Weight (g) SD Male (g) Female (g) 
Thyroid 
(dissected under microscope) 
0.0169 0.0052 20.7 17 
Salivary Glands 0.1165 0.0255 n/a n/a 
Stomach 0.2613 0.0709 158 140 
Urinary Bladder 0.818 0.0189 47.6 35.9 
Whole-Body 22.71 2.38 73700 56912 
 
The human extrapolated time-activity curves (TACs) were generated as the function of 
time post injection (h) and non-decay-corrected human data (%ID). The source organ cumulated 
activity (?̃?) was estimated by integrating TACs using MATLAB software version R2011b 
(MathWorks Inc., USA). The area under the curve beyond the last measured point was 
extrapolated to infinity using a single exponential based on the effective half-life from the last 2 or 
3 measured points (Behr et al., 1997). Consequently, the total accumulated activity (A) in each 
source organ was defined as: 
 
From the cumulated activity, the residence times for each source organ, which can be 
called “normalised cumulated activity”, were obtained and input into the OLINDA/EXM software 
version 1.1. The MIRD principal equation (equation 4-3) was simplified as follows: 
 
 Where N is the number of disintegrations that occur in the source organ and DF is 
mathematically the same as S-factor which is defined by the MIRD committee (Stabin et al., 
2005). 
 The outputs of OLINDA/EXM are the organ absorbed dose (mGy) per administered 
activity for source and target organs and the effective dose (mSv) based on the tissue weighting 
factor from ICRP publication 60. In this study, we also introduced the therapeutic dose ratio , i.e. 
thyroid absorbed dose to effective dose ratio (mGy/mSv), a tumour absorbed dose to effective 
dose ratio (mGy/mSv) and a tumour absorbed dose to thyroid absorbed dose ratio in order to 
compare therapeutic efficiency. The details are described in the following section.   
 
Table 4-5 Size of selected relevant organs in mouse and standard phantom 
                                                                 ?̃? = ∫ 𝐴(𝑡)𝑑𝑡
∞
0
                                           Equation 4-5 
                                                     D =  N ×  DF                                             Equation 4-6 
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4.3.1.1 Source Organ 
In this study, thyroid, salivary glands, stomach, urinary bladder and the remainder of the 
body were designated as the source organs. The uptake for the remainder of body was calculated 
as the whole-body uptake after subtracting all other evaluated organs. Also, it is important to note 
that the radioactivity was assumed to be uniformly distributed in all source organs and throughout 
the remainder of the body. Also, OLINDA/EXM provided the ICRP 30 GI (gastro-intestinal) and 
urinary voiding model to estimate the dosimetry in the excretory organ but we did not include 
these models in our calculation after considering the variation from anaesthetised mice to awake 
human physiology in these systems. 
 
4.3.1.2 S-values for Salivary Gland and Tumour 
As the current version of OLINDA/EXM software has not included the salivary glands 
which appears to be a major uptake organ for NIS radiotracers in humans and also in laboratory 
animals, the radiation absorbed doses to salivary glands were estimated by using a spherical S-
value typically used for interpolating self-dose for tumour in OLINDA. The mass of the human 
salivary gland was assumed to be 77 g for both male and female (Chin et al., 2014; Coleman et 
al., 2009). 
The tumour S-values were computed based on considering tumour to be a sphere. The 
OLINDA sphere-model was assumed with uniformly distributed activity. For calculation of tumour 
dosimetry, the standard human phantom was assumed to be bearing a 2 g tumour. Therefore, 
the actual dissected tumour mass from each xenograft mouse was extrapolated to a 2 g tumour 
so that a TAC was generated for use in dosimetry based on the method described for other 
organs. It is important to note that, the dosimetric calculations were performed without accounting 
for changes in tumour size (Coleman et al., 2009; Stabin et al., 2005) or taking into account 
differences of levels of NIS expressed in tumours across species.   
4.3.2 Statistical Analysis 
For the statistical analysis, every dynamic TAC was considered separately and the 
residence time from each mouse was individually input to the OLINDA software. The mean and 
standard deviation (SD) were considered across all time-points in the scan. All of %ID, %ID/g, 
organ absorbed dose, tumour absorbed dose, effective dose and all therapeutic index were 




4.4  Results 
4.4.1 Effective Dose of NIS Radiotracers for Diagnostic Use 
To estimate the effective dose, the spatio-temporal data from healthy mice from the 
previous chapter were used for human dosimetry calculation in this chapter. The animal data were 
extrapolated to human by the commonly used Krischer’s linear mass scaling equation in order to 
predict the human-equivalent bio-distribution. The extrapolated human-equivalent uptakes 
derived from preclinical data are shown in the following figures 4.6. In this study, the human-
equivalent of standard male and female were computed from female mouse data, assuming that 
the percentage injected dose multiplied by the body weight is constant across species. 
Figures 4-5 below illustrates extrapolated human-equivalent percent injected dose in 4 
source organs; thyroid, salivary glands, stomach and urinary bladder. The values in each graph 
















































































































99mTc-pertechnetate standard female 
Figure 4-5 Extrapolated human-equivalent percentage uptake using Krischer’s mass scaling method, data 
were expressed as mean and standard deviation (Top Left) 18F-[BF4] standard male, (Top Left) 18F-[BF4] 









Based on the human-equivalent uptake, the time-activity curves were constructed then 
the tracer residence times for humans in 4 source organs (thyroid, salivary glands, stomach and 
bladder) and remainder of the body were calculated. The area under the TAC from initial time-
point (t=0) to infinity is equivalent to residence time (also called “time-integrated activity 
coefficient” by MIRD pamphlet 21) and these values were input to OLINDA in order to estimate 
the human-equivalent doses. The mean tracer residence times and standard deviations are 


















































































































































Figure 4-6 Extrapolated human-equivalent percentage uptake using Krischer’s mass scaling method (A 
and B) 123I-NaI standard male and female (C and D) 131I-NaI standard male and female (E and F) 188Re-




Radiotracers – Source Organs 








Remnant of the Body 
 
0.008 ± 0.001 
0.030 ± 0.010 
0.097 ± 0.017 
0.035 ± 0.012 
3.150 ± 0.580 
 
0.009 ± 0.001 
0.039 ± 0.013 
0.111 ± 0.019 
0.034 ± 0.011 






Remnant of the Body 
 
0.083 ± 0.022 
0.079 ± 0.014 
0.596 ± 0.169 
0.087 ± 0.057 
7.178 ± 0.733 
 
0.089 ± 0.024 
0.103 ± 0.018 
0.683 ± 0.194 
0.085 ± 0.056 






Remnant of the Body 
 
0.722 ± 0.011 
0.039 ± 0.009 
0.378 ± 0.073 
0.146 ± 0.090 
8.875 ± 0.914 
 
0.767 ± 0.012 
0.050 ± 0.012 
0.433 ± 0.084 
0.143 ± 0.088 
8.766 ± 0.908 
131I-NaI 
        Thyroid 
        Salivary Glands 
        Stomach 
        Bladder 
        Remnant of the Body 
 
1.649 ± 0.099 
0.039 ± 0.008 
0.694 ± 0.056 
0.067 ± 0.008 
18.916 ± 0.626 
 
1.779 ± 0.066 
0.050 ± 0.010 
0.797 ± 0.064 
0.066 ± 0.008 
18.675 ± 0.595 
188Re-perrhenate 
       Thyroid 
       Salivary Glands 
       Stomach 
       Bladder 
       Remnant of the Body 
 
0.072 ± 0.022 
0.037 ± 0.014 
0.751 ± 0.098 
0.069 ± 0.020 
9.133 ± 0.167 
 
0.077 ± 0.024 
0.048 ± 0.018 
0.861 ± 0.112 
0.067 ± 0.020 






Table 4-6 Human equivalent residence times (mean ± SD, in Becquerel-hour per Becquerel administered) 
of NIS radiotracers (n=3 for each radiotracer) 
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In our dosimetric calculations, the residence times from each mouse were input 
separately into OLINDA. Therefore, the variation in mean effective doses resulted from the dose 
variation stemming from bio-kinetic variation across animals. The effective dose comparison 
shown below was conducted from the same strain-, sex- and age-matched animals to allow 
proper dosimetric comparison. The organ weighing factors used in the calculations were based 




The mean of human-equivalent effective dose from the PET radiotracer18F-BF4 was 0.024 
± 0.001mSv/MBq for the standard adult male model and 0.030 ± 0.002mSv/MBq for the standard 
adult female model. The mean effective doses for established SPECT radiotracers were: for123I-
iodide 0.046 ± 0.002mSv/MBq and 0.059± 0.002mSv/MBq for male and female model, and for 
99mTc-pertechnetate 0.009 ± 0.001mSv/MBq and 0.011 ± 0.001mSv/MBq for male and female 
model respectively. The effective doses from therapeutic agents were higher as expected for 131I-
iodide: 0.543 ± 0.026mSv/MBq and 0.707 ± 0.021 mSv/MBq for male and female model, and for 
188Re-perrhenate 0.206 ± 0.012mSv/MBq and 0.266 ± 0.021mSv/MBq for male and female 
respectively. 
As mentioned earlier, the effective dose calculated by OLINDA software version 1.0 (as 










F18 BF4 I123 NaI Tc99m
Pertechnetate


















Figure 4-7 Mean human-extrapolated effective dose per unit administered activity (mean ± SD) in units of 
mSv/MBq (n=3 for each radiotracer); data comparison for 5 NIS-radiotracers based on weighting factors 
from ICRP 60 
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latest tissue weighting factors from ICRP (103) were announced by ICRP in 2007. In this study, 
we also calculated the effective dose based on the new ICRP guideline from the output of 
OLINDA. Furthermore, we included the dose from the salivary gland into the effective dose using 
the S-value from sphere as described above. Therefore, the sum of tissue-weighting factors for 
these calculations was 0.93, instead of 1 because some organs contributing to effective dose 
were not listed in OLINDA. For comparison, the effective dose calculations were performed for 
each NIS radiotracer in 3 different ways (a) original OLINDA (WT-ICRP 60, salivary gland included 
in remainder of the body), (b) WT-ICRP 60 with salivary glands excluded from remainder of the 
body and assuming S-value of salivary glands from the sphere model and (c) ICRP 103 weighting 
factors excluding salivary glands from remainder of the body and assuming S-value of salivary 




Mean Effective Dose Male (mSv/MBq) 
Original 
OLINDA (a) 
ICRP 60 and 




ICRP 103 and 




18F-BF4 2.37E-02 2.35 E-02 -0.56 2.40 E-02 1.51 
99mTc-Pertechnetate 8.63E-03 8.59E-03 -0.46 8.52E-03 -1.29 
123I-NaI 4.57E-02 4.65 E-02 1.75 4.16 E-02 -9.06 
131I-NaI 5.43E-01 5.42E-01 -0.06 4.79E-01 -11.80 
188Re-Perrhenate 2.06E-01 2.06E-01 -0.16 2.05E-01 -0.54 
 
 
Mean Effective Dose  Female (mSv/MBq) 
18F-BF4 2.98 E-02 2.96 E-02 -0.67 2.96 E-02 -0.70 
99mTc-Pertechnetate 1.11 E-02 1.10 E-02 -0.90 1.07 E-02 -2.94 
123I-NaI 5.93 E-02 5.93 E-02 0.00 5.28 E-02 -11.09 
131I-NaI 7.07 E-01 7.07 E-01 0.00 6.21 E-01 -12.25 
188Re-Perrhenate 2.66E-01 2.66 E-01 0.00 2.61 E-01 -1.60 
  
The effective doses were slightly changed (approximately in the range of ± 1%) when 
excluding the salivary glands from the remnant of the body and assuming a specific S-value of 
salivary glands from the sphere model. Interestingly, the effective doses were decreased by about 
10% for iodide isotopes (123I- and 131I-NaI), whereas, the estimated effective doses were a little 
bit lower when calculated with the most recent tissue weighting factors (ICRP 103),  
 
 
Table 4-7 Mean human-equivalent effective doses from NIS radiotracers determined using 3 different 
methods, the effective dose shown as the mean effective dose per unit administered activity (mSv/MBq) 




4.4.2 Dosimetry and Potential Use of 188Re and 186Re-perrhenate in benign nodular thyroid 
diseases and NIS-expressing xenograft model 
The second part of this chapter was intended to examine the dosimetric possibility of 
using 186Re- and 188Re-perrhenate in treatment of benign nodular thyroid disease and breast 
adenocarcinoma expressing NIS tumour by using preclinical data for comparison with 131I-NaI. 
4.4.2.1 Benign Nodular Thyroid Disease 
In our study, we used the healthy animal data without a thyroid-blocking agent and 
exogenous thyroid hormone to represent the uptake of benign nodular thyroid disease. As 
mentioned in the discussion part of chapter 3, the pharmacokinetics of 188Re-perrhenate and 
99mTc-pertechnetate were characterised as very similar but the uptake values of 188Re were fairly 
low when compared to 99mTc. These might be influenced by the elevated background counts from 
septal penetration and a strong Bremsstrahlung component which has a broad spectrum and by 
random noise from low-abundance of gamma photon of 188Re. Hence, all these effects contributed 
to high background counts in the image with consequent effects in image quantification. In a 
clinical setting, the correction of this effect could be performed using scatter correction techniques 
such as triple energy window (TEW) together with a medium energy collimator to limit septal 
penetration, or a reconstruction based method that includes a model for such background 
photons. However, this is still problematic for a multi-pinhole acquisitions with the nanoScan 
SPECT/CT because at this stage, the system does not allow users to re-import raw projection 
data after processing (e.g. subtraction of energy windows) or intervene with the image 
reconstruction in the HISPECT reconstruction software.  
The estimated organ absorbed doses to thyroid, salivary glands, stomach, red marrow, 
urinary bladder and total body (mGy), as well as effective dose (mSv) based on ICRP 60 for the 
standard male and female, are listed in table 4-8. The table shows the human-equivalent 
dosimetry calculated based on the 188Re-perrenate.  
Furthermore, since our study indicated that pharmacokinetics of perrhenate and 
pertechnetate were characterised as similar but the relative uptake of 188Re was relatively low, 
possibly due to systemic error explained earlier, we therefore attempted to recalculate using 
pertechnetate kinetic data with applied 188Re physical half-life to perform the human-equivalent 
dosimetry. The key assumption here was that changing isotope does not alter the bio-distribution 









(based on 99mTcO4- kinetics) 
I-131 
Thyroid 1.512 ± 0.465 3.087 ± 0.716 9.453 ± 0.564 
Salivary Glands 0.212 ± 0.079 0.892 ± 0.249 0.063 ± 0.013 
Stomach Wall 0.697 ± 0.082 1.253 ± 0.276 0.227 ± 0.016 
Urinary Bladder Wall 0.131 ± 0.021 0.241 ± 0.073 0.074 ± 0.004 
Red Marrow 0.077 ± 0.062 0.023 ± 0.003 0.045 ± 0.001 
Whole-body Dose 0.059 ± 0.001 0.035 ± 0.004 0.054 ± 0.002 
Effective Dose (mSv/MBq) 
ICRP 60 WT 
0.206 ± 0.014 0.339 ± 0.030 0.543 ± 0.026 
Thyroid to Effective Dose 
Ratio  
7.340 9.106 17.410 
Thyroid to Whole-body 
Dose Ratio 




(based on 99mTcO4- kinetics) I-131 
Thyroid 1.950 ± 0.601 3.980 ± 0.923 12.367 ± 0.451 
Salivary Glands 0.275 ± 0.103 1.155 ± 0.322 0.081 ± 0.016 
Stomach Wall 0.905 ± 0.109 1.623 ± 0.355 0.295 ± 0.020 
Urinary Bladder Wall 0.168 ± 0.027 0.305 ± 0.092 0.088 ± 0.005 
Red Marrow 0.049 ± 0.001 0.026 ± 0.004 0.055 ± 0.002 
Whole-body Dose 0.076 ± 0.001 0.045 ± 0.006 0.068 ± 0.002 
Effective Dose (mSv/MBq) 0.266 ± 0.018 0.437 ± 0.038 0.707 ± 0.021 
Thyroid to Effective Dose 
Ratio  
7.331 9.108 17.492 
Thyroid to Whole-body 
Dose Ratio 
25.658 88.444 181.868 
 
The estimated doses were higher in female than in male subjects as expected. The 
largest mean absorbed dose was received by thyroid which is our target treatment organ for both 
radiotracers. By using actual 188Re kinetics, the thyroid absorbed doses were calculated to be 
1.512 ± 0.465 mGy/MBq for adult male and 1.950 ± 0.601 mGy/MBq for adult female. The 
estimated thyroid absorbed doses from 188Re (based on 99mTc-pertechnetate kinetics) were 3.087 
± 0.716 and 3.980 ± 0.923 mGy/MBq for male and female respectively while for I-131, the thyroid 
absorbed doses were 9.453 ± 0.564 mGy/MBq for male and 12.367 ± 0.451 mGy/MBq for female. 
The thyroid to effective dose ratio for conventional radioiodine (131I) was still found to be greater 
than 188Re-perrhenate (about 7.34 for actual 188Re, 9.10 mGy/mSv for 188Re based on 99mTc 
kinetic and 17.45 mGy/mSv for 131I). In the same manner, the thyroid to whole-body dose ratio for 
131I-NaI was also higher than 186Re- and 188Re-perrhenate.  
Table 4-8 Estimated human equivalent dose (mGy/MBq), effective dose (mSv/MBq) and thyroid to 
effective dose ratio from 188Re-Perrhenate, 188Re-Perrhenate (based on 99mTc-pertechnetate kinetic) and 




Based on the dynamic animal data as described in chapter 3, the uptake in stomach and 
urinary bladder were very variable across animals and these factors strongly influenced uptake 
in other NIS expressing organs. The biological factors affecting tracer uptake (such as diet, fluid 
intake, voiding of bladder and anaesthesia) are very difficult to control in animal studies whereas 
for clinical application such factors may be possible to control. For example for urinary bladder, 
patients can be encouraged to have high fluid intake and to frequently void, also administration 
of diuretic drug is possible in order to accelerating renal clearance (Seabold et al., 1993). Thus, 
we also analysed the data by eliminating/removing the activity in the urinary bladder. As explained 
earlier about image noises and artefacts with 188Re, these dosimetric results for rhenium isotopes 
(186Re- and 188Re-perrhnate) were calculated using pertechnetate kinetics whereas actual 131I-NaI 


























By removing urinary bladder, the conventional radioiodine also showed superior ratio 
(thyroid to effective dose ratio) over 186Re- and 188Re-perrhenate. In addition, EANM guideline 
suggested that medication such as H-2 blocker and liberal oral hydration can be used to decrease 
stomach activity (Luster et al., 2008). Furthermore, invasive methods such as gastric lavage have 
also been reported in a US patent by Dadachova (Dadachova, 2010). Hence, we analysed the 
data again by eliminating and removing the activity in both stomach and urinary bladder to 
anticipate such clinically controlled conditions. The data were shown in table 4-10. The dosimetric 






Table 4-9 Human equivalent organ absorbed dose (mGy/MBq) and effective dose (mSv/MBq) from 131I-NaI 
versus 188Re-, 186Re-Perrhenate based on 99mTc-pertechnetate kinetic in adult male and female. These data 
were modified from previous table by eliminating the urinary bladder. Dosimetric data were extrapolated from 
normal mouse without hormone supply and thyroid blocking agent representing conditions relevant to 
























































































































Thyroid to Effective 
Dose Ratio  
17.543 8.415 9.607 17.453 9.171 9.679 
Thyroid to Whole-
body Dose Ratio 








Table 4-10 Human equivalent organ absorbed dose (mGy/MBq) and effective dose (mSv/MBq) from 131I-NaI 
188Re-Perrhenate and 186Re-Perrhenate in reference adult male and female. These data set were modified 
from previous table by eliminating the stomach and urinary bladder Data were extrapolated from normal 
mouse without hormone supply and thyroid blocking agent representing conditions relevant to the 



























































































































18.208 18.112 17.510 18.257 18.112 17.547 
Thyroid to  
Whole-body Dose 
Ratio 
















































Thyroid to Effective Dose Ratio
 
Figure 4-8 Thyroid to Effective Dose Ratio calculated from normal mouse of 131I-NaI and 188Re-Perrhenate and 







By eliminating the stomach and urinary bladder activity, the thyroid to effective dose ratios 
for rhenium (as illustrated in figure 4.8) were found identical to iodine demonstrating that the same 
thyroid absorbed dose from rhenium results in equal effective dose (based on ICRP 60). 
Furthermore, the red marrow, stomach, whole-body and bladder absorbed doses from rhenium 
were less than that produced by conventional radioiodine. However, the thyroid to whole-body 
dose ratio for conventional radioiodine (131I) was still found to be greater than 186Re- and 188Re-
perrhenate. 
In addition, we also calculated the thyroid to effective dose ratio using the current tissue 
weighting factors from ICRP publication 103 (2007) with and without thyroid listed on the radiation 
weighted dose quantity (showed in table 4-11). As in this study, thyroid is the main treatment 
target. According to ICRP publication 103, the radiation weighted dose quantity for thyroid is 0.04 
























Figure 4-9 Thyroid to Whole-body Dose Ratio calculated from normal mouse of 131I-NaI and 188Re-
Perrhenate and 186Re-Perrhenate (based on 99mTc-pertechnetate kinetic) after eliminating the stomach and 
urinary bladder activity 



























ICRP 60 (original 
OLINDA) 




20.885 20.648 18.704 21.037 19.355 18.835 
ICRP 103 (removed 
thyroid from WT) 
192.393 105.800 89.652 206.650 109.268 93.931 
  
Thyroid to effective dose ratios were increased when the effective dose were calculated 
based on tissue weighting factors from ICRP 103. As from this ICRP publication, the calculated 
effective doses gave lower values than that computed using weighting quantity from ICRP 60. 
With ICRP 103 weighting factors, the ratios for 186Re were still equalled to 131I, whereas 188Re 
ratios were presented a little bit lower. Additionally, the ratios of 131I-NaI were much higher than 
both rhenium isotopes when not including thyroid in tissue weighing factors.  
 
4.4.2.2 Xenografts Mice and NIS-bearing Tumour 
Rat adenocarcinoma (34CXCR4-hNIS) tumour was selected to graft to scid/beige mice. 
The pharmacokinetics of NIS radiotracers (123I-NaI, 99mTc-pertechnetate and 188Re-perrhenate) 
and tumour uptakes were explored in chapter 3. Again, the tumour pharmacokinetic pattern of 
188Re-perrhenate and 99mTc-pertechnetate were similar but the uptake fraction of 188Re-
perrhenate was significantly lower when compared with pertechnetate. The potential role of partial 
volume effects, image noises and scatter were discussed in the previous section. Hence the 
pertechnetate kinetics were used instead of perrhenate for dosimetry calculation. For iodine 
isotopes, the kinetics of 123I-NaI were used and then adapted to the physical half-life of 131I (i.e. 
TACs were decay corrected for 123I and then decayed for the half-life of 131I) to estimate the tumour 
dosimetry of conventional radioiodine. The dosimetry for xenografts was calculated without 




Table 4-11 Thyroid to effective dose ratio based on effective dose calculated with ICRP 60 and ICRP 103 
(with and without thyroid included in tissue weighing factor) 
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Table 4-12 lists human-equivalent tumour absorbed doses, organ absorbed doses and 
effective doses estimated from mouse xenografts bearing adenocarcinoma tumour. The 
calculation of tumour absorbed dose was performed using a sphere S-value with the assumption 
that tumour mass in human is 2 g for both standard male and female and that the standard uptake 






Male  Female 
I-131 Re-186 Re-188  I-131 Re-186 Re-188 




(± 0.692)  
1.597 
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0.965 
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0.406 
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0.017 
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3.717 
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0.393 




































The tumour absorbed doses from 188Re were 1.597 ± 0.361 mGy/MBq and 2.080 ± 0.453 
mGy/MBq for male and female respectively, while for 186Re the tumour absorbed doses were a 
bit lower with 1.164 ± 0.962 mGy/MBq for male and 1.512 ± 0.902 mGy/MBq for female. The 
tumour absorbed doses from radioiodine (131I-NaI) were found to be 0.184 ± 0.055 mGy/mSv and 
0.238 ± 0.071 for male and female due to the combination of similar transit times to Re isotopes 
(unlike the thyroid where iodine is organified) and physical characteristics of the particle emissions 
(lower energy betas). The tumour absorbed dose from rhenium isotopes (186Re- and 188Re-
perrhenate) were about 6-8 folds higher than conventional radioiodine (131I-NaI). In addition, the 
highest organ absorbed dose was received by the thyroid gland with 131I inducing 2.927 ± 0.548 
Table 4-12 Human-equivalent tumour, organ absorbed dose (mGy/MBq) and effective dose (mSv/MBq) from 
131I-NaI, 188Re-Perrhenate and 186Re-Perrhenate in reference adult male and female. Data were extrapolated 
from mouse bearing xenografted rat adenocarcinoma (∆34CXCR4tumour. Values were expressed as mean 
± SD (n=3 for each radiotracer) 
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and 3.783 ± 0.709 mGy/MBq for male and female, 186Re inducing 2.240 ± 1.845 mGy/MBq for 
male and 2.900 ± 2.391 mGy/MBq for female with 188Re thyroid absorbed dose of 3.717 ± 1.835 
and 4.830 ± 2.310 mGy/MBq for male and female respectively. In contrast, the red marrow 
absorbed dose delivered by rhenium isotopes were lower than radioiodine (~ 0.27 times for 186Re 
and 0.5 times for 188Re). The mean whole-body absorbed doses delivered by rhenium isotopes 
and iodide (131I-NaI) are also illustrated in table 4-12 with highest values for radioiodine (0.041 ± 
0.003 and 0.051 ± 0.004 mGy/MBq for male and female), followed by 188Re (0.027 ± 0.003 and 
0.033 ± 0.004 mGy/MBq for male and female) and 186Re (0.015 ± 0.002 and 0.018 ± 0.002 















































































Tumour to Thyroid Ratio
 
 
Figure 4-10 (Top) tumour to effective dose ratio (mGy/mSv) calculated from mouse xenografts. Ratios 





The therapeutic ratios in 3 radiotracers are shown in figure 4-10 and 4-11. Tumour to 
effective dose ratios were shown as mean ± SD (n=3). For 131I, ratios were 0.949 ± 0.279 and 
0.956 ± 0.279 mGy/mSv for male and female. 188Re were 6.048 ± 1.146 mGy/mSv for male and 
6.064 ± 1.106 mGy/mSv for female. 186Re were 7.634 ± 2.061 mGy/mSv for male and 7.660 ± 
2.107 mGy/mSv for female. The tumour to effective dose ratio of both rhenium isotopes were 
greater when compared with conventional radioiodine so for the same effective dose to the whole-
body, rhenium can deliver more dose to the tumour. Tumour to thyroid ratios were 0.063 ± 0.019 
and 0.062 ± 0.029 mGy/mSv for male and female for 131I-NaI, 0.507 ± 0.252 and 0.502 ± 0.241 
mGy/mSv for male and female for 188Re-Perrhenate and 0.587 ± 0.190 and 0.589 ± 0.194 
mGy/mSv for male and female for 186Re-Perrhenate. In the same manner, the tumour to whole-
body dose ratio of both rhenium isotopes were greater when compared with conventional 
radioiodine (131I-NaI) so for the same whole-body dose, rhenium can deliver more dose to the 
tumour. Hence, these data are indicate that rhenium produced a lower fraction of dose to the 
thyroid when treating the NIS-expressing tumour compared with 131I.     
 
4.4.3 Impact of Partial Volume Effects in Preclinical Dosimetric Calculation 
As mentioned earlier in this chapter, the main purpose of this work was to study the 
feasibility of new therapeutic NIS radiopharmaceuticals for thyroid disease (benign and malignant) 
and other NIS-expressing tumours. We used pre-clinical tracer kinetics scaled by Krischer’s 
equation to estimate human dosimetry. Hence, a critical challenge in this process was the 
accuracy of quantification of the radiotracer uptake in small-organs (e.g. thyroid and salivary 
glands) with preclinical SPECT and PET. It is well known that tracer quantification in organs of 

















Figure 4-11 Tumour to whole-body dose ratio calculated from mouse xenografts. Ratios were shown as 
mean ± SD (n=3) 




accuracy and the influence of PVE using the MHS phantom with the nanoScan SPECT/CT. Based 
on the phantom study, we examined the relation between percentage quantification accuracy 
versus volume of sphere in 3 SPECT radiotracers; 99mTc, 123I and 188Re. We defined VOI using 
integral method by setting a threshold of 10% of the maximum count to exclude background. The 
image quantification was performed in InVivoQuant software. Then, we fitted these curves with 
the second order polynomial equations. The equations and polynomial regressions are displayed 




Figure 4-12 MHS phantom acquired with 20 second per projection and standard reconstruction with second 
order polynomial curve fitting 
  
The second-order polynomial function used to fit the data and polynomial coefficients are 





a b c 
99mTc 0.9697 -1.00E-04 7.25E-02 8.84E01 
123I 0.9822 -6.00E-05 3.76 E-02 9.67E01 
188Re 0.9826 -4.00E-05 3.00 E-02 8.19E01 
 
The polynomial regressions showed a good correlation between the volume of sphere 
and quantification accuracy (R2 = 0.9697, 0.9822 and 0.9826 for 99mTc, 123I and 188Re 
respectively). These equations were used to calculate volume-specific correction factors in order 
y = -0.0001x2 + 0.0725x + 88.449
R² = 0.9697
y = -4E-05x2 + 0.03x + 81.935
R² = 0.9826





























Volume of Sphere (ul)
Tc99m Re-188 I-123
                                                          𝑌 = 𝑎𝑥2 + 𝑏𝑥 + 𝑐                                                    Equation 4-7 




to correct our original in vivo data. The organ volumes were obtained from VOI analysis based on 
the high resolution CT images (n = 15) of the same strain as in the kinetic experiments. The mean 
volume of the organs with SDs and the correction factors derived from MHS phantom and 
equation 4-7 are tabulated below.   
 
Organ 
Volume from CT (µl) 
Tc99m I-123 Re-188 
Mean SD 
Thyroid 22.07 3.99 1.099 1.022 1.207 
Salivary Gland 95.71 8.36 1.072 1.006 1.188 
Stomach 348.57 62.08 1.021 0.976 1.150 
        Bladder 197.50 26.55 1.037 0.986 1.162 
 
Based on our results, the volume of the mouse thyroid was approximately about 22.07 ± 
3.99 µl. The VOI for thyroid was drawn together as one VOI for both lobes with included the 
isthmus. This volume was smaller than the volume of the smallest sphere (31.3 µl) of the MHS 
phantom which is smallest possible compartment among the commercially available phantoms. 
The mean volumes of stomach and urinary bladder were based on the CT images at the end of 
the dynamic phase (approximately 4 hours after injection). Hence, these volumes showed large 
variations due to the different contents in stomach and bladder across animals. Organ volumes 
of the particular mouse strain (female scib/beige, 4-8 weeks old) were not found to be reported 
elsewhere. Hence, it was difficult to compare our volumes with other published data. 
 
4.4.3.1 Influence of Volume-specific PVE Correction Factor to in vivo Kinetic Data 
The volume-specific PVE correction factors were applied to the in vivo kinetic data 
described in chapter 3 for 99mTc, 123I and 188Re. To analyse the impact on dosimetric calculation, 
the corrected in vivo kinetics were used to calculate the tracer residence time using equation 4-
5. According to the mathematical integral property, the tracer residence times were changed by 
the same factor as we applied to in vivo kinetic. In this study, we calculated the percentage 
difference from the healthy animal data, the mean percentage difference (mean ± SD) in thyroid, 
salivary glands, bladder, red marrow and whole-body effective dose (based on ICRP 60) are 
illustrated in the following table. (The percentage difference calculated using the original non PVE-
corrected dose as reference values)  





Male (%) Female (%) 
















































































After application of PVE CFs and re-calculation of the dose, the thyroid absorbed doses 
showed the highest impact, with doses increasing by approximately 20% for 188Re, 10% for 99mTc 
and 2% for 123I. Similarly, the salivary gland absorbed doses were raised by a similar magnitude. 
For the absorbed dose to the stomach, the absorbed doses were increased by 13.6 % for 188Re, 
1.7% for 99mTc whereas decreased by approximately 2% for 123I. Similar findings were observed 
for the bladder with absorbed dose most effected for 188Re (increased by approximately 8%), with 
minimal effect for 99mTc (increased about 1.5%) and 123I (decreased about 1%). Red marrow 
absorbed dose was not much affected for 99mTc and 123I, while for 188Re dose increased by about 
2% (indirect effect from other ROIs). For effective dose (based on ICRP 60), overall values were 











Table 4-15 Percentage difference (Mean ± SD) of PVE-corrected absorbed doses for each organ with 




In the first part of this chapter, we estimated the effective dose of NIS radiotracers (18F, 
BF4, 99mTc-pertechnetate, 123I-NaI, 131I-NaI,188Re-perrhenate) for diagnostic use. In the second 
part, the feasibility of using rhenium isotopes (186Re and 188Re-perrhenate) for therapeutic 
applications in benign thyroid diseases and NIS-expressing tumours was examined for 
comparison with conventional radioiodine (131I-NaI). In the third part, we used the quantification 
accuracy results from the phantom study in chapter 2 to correct the in vivo kinetic data to 
investigate the impact of volume-specific PVE correction on the dosimetric calculations. 
In our study, murine organ uptakes were extrapolated to human using the Krischer’s 
linear mass scaling equation which assumes that SUVs remain constant across species. Then, 
the human-equivalent dosimetry was performed using the OLINDA/EXM internal dosimetry 
software package. This software was intended to estimate the internal dosimetry for standard 
human models. Criticism has previously been raised over the mass scaling method, the size and 
mass of organs as well as the extent of physiological differences between two species (Stabin, 
2008). However, as Stabin proposed, “Extrapolation to human values of uptake and clearance is 
far from certain, but these preliminary data provide a basis for going forward with clinical trials if 
the results are generally favourable” (Stabin, 2003). 
 
4.5.1 Effective Dose of NIS Radiotracers for Diagnostic Use 
In the ICRP publications (ICRP 53, 80 and 106), the effective dose values were calculated 
based on the published bio-kinetic data. However, as was discussed in ICRP 106 there were 
several problems in finding and selecting good bio-kinetic data for dosimetry. Published kinetic 
data in literature are often reported by workers interested only in the initial phase of the tracer 
distribution, are often restricted to imaging a particular section rather than providing whole-body 
data and lack information about tracer retention at later time-points which can strongly influence 
dosimetry calculation (ICRP, 2008).In some cases, kinetic data acquisition was largely simplified 
due to limitations of the imaging technology at that time and no recent data have been revisited. 
For instance, the iodine model from ICRP 53 is mono-exponential developed from the Berman’s 
early compartmental model in 1972 (Berman et al., 1975; Johansson et al., 2003).  
In terms of comparison of data, it is also difficult to compare dosimetric results calculated 
from studies referring to different size, age, strain and gender (Pradhan et al., 2012). In our study, 
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the estimation of effective dose was based on a side-by-side comparison of available NIS-
radiotracers from in vivo studies of the same strain, sex and age-matched animals. 
 To compare our effective dose calculations, the table below showed the comparison of 
our estimated values with the dose published by ICRP. For effective dose of iodine isotopes 
published in ICRP 53 & 60, the effective doses per unit administered activity were proposed on 
the maximal uptakes of thyroid at 0%, 5%, 15%, 25%, 35%, 45% and 55% (Andersson et al., 
2014; Mattsson et al., 2011). Consequently, we fitted a linear function from these ICRP data and 
then the effective dose according to our maximal human-equivalent uptake value was calculated 
from the graph. For 99mTc-pertechnetate effective dose, the values were calculated based on the 
intravenous administion of radiotracer and no thyroid blocking agent given.   
 
Radiopharmaceutical 





Our Study ICRP 53/80 
123I - NaI 
(3.67% thyroid uptake) 
4.57E-02 3.86E-02 18.54 
Maximum uptake 
at 8 h 
99mTc - Technetium 
pertechnetate 




(4.05% thyroid uptake) 
5.43E-01 2.97E+00 -81.71 
Maximum uptake 
at 8 h 
  
Estimation of effective doses from our study varied from the ICRP and this can be 
attributed mainly to the bio-kinetic models used as a basis for the calculations. Also, the urinary 
voiding and GI tract model were not included in our dosimetric calculation. It should also be noted 
that the values for effective dose in the various publications vary from each other and really 
depend on their selected method and kinetic model. For instance, the recent work by Andersson 
et al (2014) recalculated and compared the effective dose using conventional ICRP bio-kinetic 
data but Anderson used the new ICRP/ICRU computational reference phantoms (instead of the 
MIRD phantom published in ICRP 53/80/106). The recalculated value for 99mTc-pertecnnetate (IV 
administration, no thyroid blocking) changed from 1.30E-02 to 1.55E-02 mSv/MBq (+19 %) and 
when applying the new phantom combined with new ICRP weighting factors (ICRP 103, 2007), 
the effective value increased by approximately 22% when compared with the original value 
(Andersson et al., 2014). In this study, we demonstrated the difference when applying the new 
Table 4-16 Comparison of effective dose (male model) from our estimation (human-equivalent derived 
from preclinical data) and effective dose published in ICRP 53/80 
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ICRP 103 weighting factors and excluding the salivary glands from the remainder of the body 
applying an S-value of salivary glands from a 77 g sphere model. The OLINDA version 1.1 
effective dose calculations are based on ICRP 60 with the salivary gland not listed in the Cristy-
Eckerman’s phantom series. Two main differences in this revised WT weighting factors that may 
influence our study are the inclusion of tissues not previously listed (brain, salivary glands) and 
also the thyroid WT slight decrease from 0.05 to 0.04. Hence, it can be seen from table 4-7 that 
our recalculated values (with ICRP 103) decreased by about 10 % for metabolised tracers (123I 
and 131I-NaI) while these modifications of WT did not substantially affect non-metabolised tracers 
(18F-BF4, 99mTc-pertechnetate, 188Re-perrhenate).  
With the above points in mind, these values can still be practically useful for initial 
estimates and dosimetric comparison in the development of new radiotracers. For example, this 
study estimated the effective dose for 18F-BF4 as an initial approach with a forthcoming clinical 
trial for this PET radiotracer for clinical use in thyroid cancer due to start in 2015, with the ability 
to verify dosimetry based on the updated patient-derived kinetics. Based on the preclinical results, 
the effective dose from this new PET tracer was lower than conventional imaging agents (123I-
iodide and131I-iodide). However, the 18F-BF4 estimated dose was still higher when compared 
with99mTc-pertechnetate, a long-established single photon tracer (Krisanat Chuamsaamarkkee, 
2014). Obviously, such pilot data cannot easily be achieved directly from injecting the tracer to 
humans at early stages of research, hence this human-equivalent dosimetry and data evaluation 
is still very important and practically useful as a guiding tool for clinical translation.   
 
4.5.2 Dosimetry and Potential Therapeutic Use of 186Re- and 188Re-perrhenate in benign 
nodular thyroid disease and NIS-expressing xenografts model 
In this work, we investigated the feasibility of using rhenium isotopes (186Re- and 188Re-
perrhenate) in treatment of benign nodular thyroid disease and NIS-expressing tumour using 
preclinical data for comparison with conventional 131I-NaI.  
For benign nodular thyroid disease, the normal healthy mouse without thyroid blocking 
was used to estimate the dose. As mentioned earlier, the kinetics of 99mTc-pertechnetate was 
used to estimate the dose of rhenium isotopes for this calculation. The dosimetry estimation in 
table 4-8 demonstrated that 131I-NaI produced the highest dose per unit administered activity to 
thyroid among all tracers at about 3 times that of 188Re, and a thyroid to effective dose ratio nearly 
2 times higher for 131I-NaI compared to 188Re-perrhenate. After modification of the uptake by 
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eliminating urinary bladder, the treatment efficiency of 131I-NaI (thyroid absorbed dose, thyroid to 
effective dose ratio) were still higher than rhenium isotopes. However, we have also recalculated 
the thyroid dose by eliminating the activity in the stomach and urinary bladder as uptake in these 
organs fluctuated widely across the mice while this can be potentially controlled in a clinical 
setting. After updating dosimetry calculations, the thyroid to effective dose ratios were almost 
identical for 131I-NaI, 186Re- and 188Re-perrhenate while the absorbed dose to stomach, urinary 
bladder, red marrow, whole-body and effective dose from both rhenium isotopes were considered 
lower than conventional 131I. Even therapeutic equivalence of 186Re, 188Re and 131I are 
demonstrated in this study, however, the logistic and cost benefits and reduced adverse impact 
on quality of life would justify for further scientific evaluation of 188Re.  
In this work, we used the mean weight of each organ to calculate the percentage injected 
dose per gram for dosimetric calculations. The mean organ masses were obtained from dissection 
of animal after in vivo imaging. The thyroid was dissected under a microscope to isolate the 
thyroid gland without the trachea. The average mass of thyroid from our study was 0.0169 ± 
0.0052 gram. However, the mass of thyroid (without trachea) from similar strain or same sex- or 
age-matched animals has not previously been reported in literature. As the organ was very small 
and the mass value was important in dosimetry calculations, this could be a potential source of 
error in this study. 
Further investigation ideally with human-derived kinetics and the influence of thyroid 
hormones (e.g. recombinant thyroid stimulating hormone – rhTSH) would be of interest in order 
to examine potential methods to achieve a high therapeutic ratio such as by prolonging the 
retention of rhenium in thyroid or benign lesion.  
Radiation damage to the salivary glands is one of the most frequently complications of 
radioactive iodine treatment. Salivary gland dysfunction has been reported with symptoms such 
as pain, swelling and xerostomia (dry mouth) (Liu et al., 2011). Therefore, it is important to 
estimate the absorbed dose to salivary glands in this therapeutic perspective. However, OLINDA 
excludes salivary glands. In this study, a single sphere was used to estimate the absorbed dose 
to the salivary gland with the approximation of a sphere with mass of 77 g for both male and 
female. Therefore, the salivary gland absorbed dose reported here was only based on self-
absorption. The validity of the assumption is supported by the human study of salivary gland 
absorbed dose by Liu et al (2011) which reported that the cross-photon radiation from brain or 
thyroid to the submandibular and parotid salivary gland were only 3.6 and 5.5 % respectively (Liu 
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et al., 2011). Therefore, this contribution should be smaller for rhenium as the gamma photons 
from both rhenium radioisotopes are gentler than 131I. Nevertheless, our results as shown in table 
4-9, indicate that the salivary glands absorbed dose from rhenium are higher than from 131I. 
Subsequently, this could be a limitation of using high activity of rhenium for therapy. However, 
numerous clinical studies have been published referring to methods such as using sour fruit or 
lemon juice for inducing the secretion of saliva and hastening the wash-out of the radionuclide 
from the salivary gland (Jentzen et al., 2010; Liu et al., 2011). Currently, there is still lack of data 
for radionuclide kinetics in the salivary glands, the resulting radiation exposure and cumulated 
absorbed dose from radiopharmaceuticals. Also, no data on dose limits and tolerance dose from 
131I-NaI therapy have been reported yet.  To the best of our knowledge the only data available are 
from external beam radiotherapy (EBRT) where the dose limit to the parotid gland is reported to 
be 23 Gy and a complication can occur at doses of 26-30 Gy whereas doses of 45-60 Gy can 
severely damage the glands (Liu et al., 2011). Therefore, the total salivary glands absorbed dose 
should be taken into account to prevent such complications and future clinical translation of 
therapy agents should be mindful of these issues.  
With regard to dosimetry in xenografts, our study calculated absorbed doses from 188Re-
perrhenate and 186Re-perrhenate based on99mTc-pertechnetate kinetics, since the 
pharmacokinetic properties of perrhenate were similar to pertechnetate while image quantification 
seems less problematic with 99mTc as mentioned in previous chapter. Besides, we used 123I-NaI 
kinetics for estimating dosimetric data of conventional 131I-NaI due to issues with 131I quantification 
(likely from septal penetration, uniformity map discrepancies and lack of optimisation of image 
reconstruction for high energy photons) as described in chapter 2. The human-equivalent 
dosimetric data (as shown in table 4-10) were estimated from the animal data with scaling to a 
reference standard adult male and female bearing a 2 g tumour. It is important to note that the 
NIS expression in these xenografts is unrealistically high as this model was genetically 
engineered with hNIS, but the comparisons between tracers are still valid. Also, the thyroid, 
salivary glands, stomach express endogenous mouse NIS (mNIS). Hence, this could have 
different substrate affinities from hNIS and this might explained the variation of uptake across 
organs and tumours in this xenograft model. Our results demonstrated that both rhenium isotopes 
delivered higher absorbed dose (per MBq administered) to tumour (6.33 and 8.68 times higher 
for 186Re and 188Re) compared to131I-NaI. Tumour to effective dose ratio for 186Re and 188Re were 
about 6.5 fold higher than 131I. Notably, the lower estimated effective doses from rhenium result 
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from the lower energy and lower abundance of gamma photons. Also, the perrhenate is not 
organified in, and hence does not give high dose to thyroid. These properties of rhenium isotopes 
make it a worthy candidate to investigate for treatment of non-thyroidal NIS expressing tumours.  
Several research groups have published data showing in vivo uptake of 188Re- and 186Re-
perrhenate with NIS gene therapy in extra-thyroidal tumours but only one included dosimetric data 
(Riesco-Eizaguirre and Santisteban, 2006). In support of our findings, results from our study 
agreed well with Dadachova et al (2005) which showed that 188Re-perrhenate delivers 4.5 times 
higher dose to a 2 g tumour in a human than 131I-NaI in a study of NIS-expressing mammary 
tumour mice (Dadachova et al., 2005). Another study by Shen et al. reported on the kinetics and 
dosimetry of NIS targeted therapy in a glioma-bearing rat model (F98 hNIS-transduced RG2 
gliomas). The study showed similar results to our kinetics and in particular that iodine isotope had 
a higher tumour uptake and cumulated activity when compared with 188ReO4 (authors co-injected 
dual isotopes of 125I-NaI and 188ReO4 in their study then applied physical decay factor of 188Re 
and 131I for dosimetric calculation). However, 188Re was more efficient than 131I in terms of dose 
delivery and prolonging the survival of rats bearing glioma (Shen et al., 2004). In addition, our 
dosimetry results also agree with human equivalent dosimetric estimations by Willhauck et al. 
using 188Re-perrhenate in nude mice transfected with NIS-expressing prostate cancer model 
(NIS-transfected LNCaP cells) (Willhauck et al., 2007). Authors reported the concentration of 
188ReO4 in tumours (% ID/g) was two times lower when compare with 131I. To compare dose and 
effectiveness of therapy, this study separated mice into 2 groups; small (tumour volume < 200 
mm3) and large tumour volume. In small tumours, 188Re showed similar therapeutic efficiency (in 
terms of tumour reduction) as conventional radioiodine. However, 188Re demonstrated a superior 
therapeutic effect in the larger tumour group due to their physical properties with greater range, 
higher energetic beta and “cross-fire” effect. (β Eaverage of 0.346, 0.764 and 0.182 MeV for 186Re, 
188Re and 131I respectively) 
Generally, thyroid acts as a sink during treatment with NIS-targeting radionuclide (also 
called “thyroid sink effect”), which refers to circumstances that most of the radionuclide is taken 
up in thyroid. In chapter 3, kinetic data illustrated that tumour uptakes were higher than thyroid. 
However, this might result from different affinity of endogenous and engineered NIS of this model. 
In addition, the dosimetric estimation in this chapter also showed that the tumour to thyroid ratio 
(figure 4-9) of rhenium isotopes was much higher than 131I. Hence, it demonstrated that rhenium 
produced less radiation damage to thyroid when treating non-thyroidal NIS tumour.  
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One of the limitations of this study is that we followed the kinetics of 99mTc and 188Re only 
up to 4 hours after injection due to technical limitations related to equipment sensitivity and 
radiotracer effective half-life. The extrapolation from the last imaging time point to infinity can 
introduce numerical errors in the estimation of accumulated activity. In addition, the limited 
number of animals was not adequate to fully understand sources of variability and to apply 
detailed statistics. Therefore, we have reported data in terms of average ± SD.    
In summary, this study indicates the potential for improved therapeutic effectiveness of 
rhenium isotopes compared to 131I in hNIS expressing tumours. The physical properties of 188Re 
and 186Re include emission of high energetic beta particles (Emean 0.764 MeV with βmean-range 3.10 
mm for 188Re, Emean 0.346 MeV with βmean-range 1.10 mm for 186Re compared to Emean 0.182 MeV 
with βmean-range 0.39 mm for 131I). Therefore with greater range, these rhenium isotopes may 
improve treatment efficacy when treating larger benign disease, tumours or extensive metastatic 
disease allowing a greater fraction of cells in large lesions which are not directly targeted to be 
irradiated by the “crossfire” effect of rhenium betas. 
Considering radiation protection and radiation safety, the shorter half-life of 188Re (17 h 
compared to 8 days for 131I) is a better match to its biological half-life in non-organifying tumours. 
The long half-life of 131I is ‘wasted’ in such tumours (unlike in thyroid tissue) and serves only to 
increase radiation dose to normal thyroid and whole body. Moreover, both rhenium isotopes may 
potentially be more cost effective due to reduced concerns about shielding and waste 
management for shorter lived isotopes. Additionally, the gamma photons from both rhenium 
isotopes have lower abundance and a more gentle profile (155 keV with 15 % abundance for 
188Re, 137 keV with 9 % abundance for 186Re compared to 364 keV with 82 % abundance for 131I). 
We have previously discussed that the gamma photons of 188Re emitted can be imaged 
quantitatively in clinical setting to provide data for dosimetry and therapy verification (Blower et 
al., 2000). Similarly, published data by other groups showed that 186Re is possible for imaging 
(Eary et al., 1990). 
In addition, the relative low gamma energy and short half-life (for 188Re) allow for 
outpatient treatment. This may alleviate the need for isolation and hospitalisation after treatment 
with substantial cost savings and more economical treatment for the healthcare system. Likewise, 
the shorter restriction period would allow patients to return to their lifestyle, and alleviate the 
negative impact of radionuclide treatment upon patients and their families. 
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Considering isotope production, 131I is produced from nuclear reactors, while 186Re can 
be produced by either cyclotron or reactor (Moustapha et al., 2006). In contrary, 188Re can be 
economically available daily from a generator that has a shelf life of 6 months. A single generator 
can provide treatments for many patients in a specialist centre at low cost. Availability from a 
generator also makes administration of fractionated doses practically feasible (Argyrou et al., 
2013). However, it is important to note that, the radiation activity required by 188Re is about 2 times 
higher than 131I to yield similar thyroid absorbed dose (based on our thyroid ablation calculated 
with eliminating activity in the stomach and urinary bladder).  
 
4.5.3 Impact of Partial Volume Effects in Preclinical Dosimetric Calculation 
In chapter 2, the quantification accuracy and the effects of PVE in preclinical imaging of 
small organs were evaluated using the micro hollow sphere phantom. Thus, the volume-specific 
correction factors determined could be used to correct our in vivo kinetic data in chapter 3. In this 
chapter, we examined the impact of quantification accuracy and PVE on dosimetry calculation in 
preclinical research based on defining VOI with integral method. 
As mentioned earlier, the mass of thyroid from dissection under the microscope was 
0.0169 ± 0.0052 g. Therefore, the volume of thyroid converted by using the thyroid tissue density 
(1.05 g/cm3) published in ICRU report no. 44, should be 16.10 ± 4.95 µl. However, the volume of 
thyroid obtained from CT images from our study was 22.07 ± 3.99 µl. Similarity with salivary 
glands, the volume converted from weight (density 1 g/cm3) is 116.50 ± 25.50 µl whereas the 
volume obtained from CT was 95.71 ± 8.36 µl. These volumes were inconsistent between 2 
methods and it was difficult to compare with other work as the organ volume and mass from this 
strain were not found published. We have listed the potential sources of error of these 2 
approaches: dissection-based   and CT image-based in the following table. 
In addition, the CT based volume of stomach and urinary bladder had a large standard 
deviation due to different amounts of stomach contents and urine across the animals. As 
discussed in chapter 2, the quantification of 123I was overestimated in large objects (over 125 µl), 
thus, this made correction factors for stomach and urinary bladder less than 1. We believe that a 
possible explanation might be that the nanoSPECT/CT only used 99mTc PSF (rather than isotope-
specific) modelling in image reconstruction. This will be addressed for further investigation in the 






Method to Obtain Volume of Organ Potential Error 
Weight (convert to volume) from organ 
dissection 
Human error - dissection skill 
Instrumental - weighing error 
Loss/Excess of body fluid during dissection (e.g. 
blood, urine, food in stomach) 
Tissue remaining in the body (e.g. isthmus) 
CT Image based VOI from in vivo 
imaging 
Human error – drawn ROI 
Instrumental  - Limited resolution of CT 
Acquisition and reconstruction parameters 
Time dependency - drawn single snapshot at last 
time-point of dynamic phase(~4 h PI) e.g. for 
fluid-filling organs 
 
In order to improve the accuracy of image-based VOI, alternative imaging techniques 
such as SPECT/MR or PET/MR should be investigated since those techniques can provide an 
improved soft tissue contrast which should make it easier to identify and distinguish the 



















In summary, preclinical spatio-temporal data were used to provide initial estimates and 
dosimetric comparison of the human-equivalent effective dose for diagnostic and therapeutic use 
of NIS radiotracers; 18F-tetrafluroborate, 99mTc-pertechnetate, 123I-iodide, 131I-iodide and 186Re- 
and 188Re-perrhenate. The dose comparison studies were conducted on the same strain sex- and 
age-matched animals to allow approximate comparison of radiation dose for tracer development. 
Our results indicate that radionuclide therapy of thyroid benign disease with rhenium 
isotopes (186Re- and 188Re-perrhenate) appears promising in some circomestances and worthy 
for further investigation in human. This study is the first in vivo kinetic study that provided 
dosimetry estimation and compared the therapeutic efficiency in treating thyroid benign disease. 
The preclinical dosimetric estimation demonstrated that rhenium isotopes were equally effective 
when excluding uptake in stomach and urinary bladder (due to large variations affected by subject 
conditions). The higher beta energies and longer ranges of rhenium isotopes may improve 
treatment efficacy when treating larger benign disease in which radioiodine therapy is less 
effective due to its shorter range. The less abundant of gamma photons emitted by 186Re and 
188Re are more favourable than those produced by 131I, reducing radiation dose to the whole body 
and to other people and thus reducing or eliminating the need for isolation. Based on our study, 
effective dose per administered activity from 186Re and 188Re was lower than conventional 
radioiodine. Also red marrow absorbed dose was about 1.5 and 3 times (for 186Re and 188Re 
respectively) lower than that produced by radioiodine. Furthermore, treatments could therefore 
be offered on outpatient basis at great cost saving, and patients can return to normal lifestyle 
earlier. These factors make 186Re- and 188Re-perrhenate promising therapeutic 
radiopharmaceuticals for thyroid disease.  
In xenograft bearing NIS adenocarcinoma tumours, our data indicated that both rhenium 
isotopes delivered higher absorbed dose to the tumour (6.33 and 8.68 times higher for 186Re and 
188Re) compared to 131I-NaI. Additionally, the therapy indexes (tumour to effective dose and 
tumour to thyroid ratio) for both rhenium isotopes were greater than that for 131I-NaI. Tumour to 
effective dose ratios for rhenium isotopes were about 5 - 7 times higher whereas tumour to thyroid 
ratio of both rhenium isotopes were about 7 – 9 time higher than for 131I-NaI . Furthermore, the 
red-marrow absorbed doses produced by rhenium were lower than radioiodine (~ 0.27 times for 
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186Re and 0.50 times for 188Re) so for the same effective dose to the whole-body, rhenium can 
deliver more dose to the tumour. 
Although it is difficult to estimate the human dosimetry by scaling from animal data this 
preclinical dosimetric study is an important phase for initial estimation of the therapeutic potential 
and application of these radiotracers clinically and it supports the idea of performing dosimetry 
imaging studies with Tc and Re in humans.  
It was demonstrated in this chapter that the quantification accuracy and partial volume 
effect in preclinical research can be evaluated and corrected for by using standard geometrical 
phantom data. Subsequently, data presented in this chapter shows the impact of these effects on 
dosimetry calculations in small organs (e.g. thyroid, salivary glands) and also influence on the 






Chapter 5  Tracer Localisation at Cellular Level and Small-Scale 
Dosimetry 
5.1 Introduction  
Organ-level macroscopic dosimetry has been extensively discussed in Chapter 4. 
However, in some cases there may be potential limitations from macroscopic dosimetry that may 
interfere with prediction of biological effects and treatment outcomes. Such limitations of 
macroscopic dosimetry are associated with several factors. One significant limitation is the 
assumption that the radionuclide distribution is homogeneous across an entire organ. Many 
studies showed that radionuclides may be inhomogeneously distributed in an organ (see next 
section). In addition, the radiation sensitivity for individual cells can be different and may depend 
on many factors (different cell types and cell cycle phases) (Goodhead, 1982). 
Moreover, the assumptions used in macroscopic dosimetry are invalid in some cases. 
For instance, macroscopic dosimetry schemes often assume that beta and alpha particles are 
non-penetrating radionuclides. So, the absorbed fraction from source to target organ ( ∅𝑡←𝑠) is set 
to zero for all beta and alpha emissions. However, this assumption is only valid when the size of 
organ is much greater than particle track ranges and can be incorrect when high energetic betas 
deposit their energy in small organs. 
Also at macroscopic level, the effects of secondary Auger electrons are taken into 
account but it are attributed to the whole organ so high LET (linear energy transfer) of the Auger 
electrons loses its significance. These high LET electrons have low energy but are deposited in 
very short range hence the localised effects might be strong. So, they can cause genetic damage 
if the energy deposition occurs at close proximity to the critical target (e.g. cell nuclei). Although 
macroscopic dosimetry only considers deterministic effects of radiation, small-scale dosimetry 
take into account the stochastic effects in the micro-volume as well.  
The determination of deposited energy by a small-scale dosimetry approach may provide a 
more accurate link to biological effects of radiation interactions which occur at the cell or organelle 




5.1.1 Tracer Localisation 
Tracer localisation is key to understanding the micro-dosimetric profile of radiotracers at 
cellular level. In general, macro-dosimetry (based on MIRD formalism) usually assumes a uniform 
distribution of the tracer over the whole organ and also that radioactivity is uniformly distributed 
throughout the tissue and cell compartments in that particular organ. However, this assumption 
is not always correct as some cell populations in the organ may contain very different amounts of 
radioactivity, and even some cells may not show uptake of the radiopharmaceutical. Furthermore 
at cellular level, radionuclides may get incorporated into intracellular structures and subsequently 
the toxicity of radiation may depend on the precise location of the radioactive decay within the cell 
(Farragi et al., 1994; Humm et al., 1993a). 
Various publications have reported that dose delivered to the cell is strongly dependent 
on sub-cellular distribution of radiotracers. For example, a study by Konijnenberg M et al. reported 
that ex vivo autoradiographs of the kidneys from patients who received 111In-DTPA-Octreotide 
showed very heterogeneous distribution of the radiotracer. Furthermore, the authors also 
calculated the iso-dose curves with dose-volume histograms (DVH) using MCNP simulations 
based on the autoradiography data in order to illustrate the impact of tracer distribution with 
different radionuclides; 90Y (β -emitter), 111In (Auger electron and ɣ-emitter) and 177Lu (β – and ɣ-
emitter) (Konijnenberg et al., 2007).  
Results (from Konijinberg et al) indicated that 111In-DTPA-Octreotide was 
inhomogeneously distributed in kidneys showing different patterns in the cortex and medullar 
areas. The DVH demonstrated that the inhomogeneous tracer distribution generated 
inhomogeneous dose distributions especially with low energy particle-emitters (177Lu and 111In) 




In the case of thyroid, iodide [I-] has been used widely in thyroid imaging and therapy (123I, 
124I, 125I and 131I-NaI). In normal thyroid, the thyroid follicular cells are formed from “colloid” 
surrounded by a single layer of thyrocytes (as shown in figure 5-2 a and b). Iodide is taken up into 
follicular cells by NIS-mediated active transport on the baso-lateral membrane. Iodide is driven 
into the apical membrane by an ion gradient and exported into the colloid via the exporter protein 
“pendrin”. Then, iodide is oxidized and organified to thyroid hormones which are stored in the 
colloid until exported (Champion et al., 2007a; Zuckier et al., 2004).   Champion et al. have 
demonstrated that iodine distribution is heterogeneous in the follicular cells, with most of iodine 




Figure 5-1 Ex vivo autoradiography of kidney section (section size of 0.37×0.37×10 mm3) showing 
inhomogeneous distribution of radiotracer. MCNP was used to generate the dose distributions based on 




(a) (b) (c) 
 
Perrhenate ion [ReO4-] is also a substarte of NIS but is not metabolised to produce thyroid 
hormones. Also, perrhenate is chemically and biologically analogous to pertechnetate [TcO4-], 
which is a well known single-photon imaging radiotracer (in the form of 99m TcO4-) for studying the 
‘trapping’ function of the thyroid glands. Therefore, we expect the perrhenate/pertechnetate to be 
located in the thyrocyte. However, no sub-cellular tracer distribution studies are available for 
perrhenate or pertechnetate (Puncher and Blower, 1994b).  
Hence, this study aims to evaluate the perrhenate/pertechnetate ion distribution in normal 
rodents (mouse/rat) thyroid cells by using transmission electron microscopy (TEM) and micro-
autoradiography techniques. Consequently, data on tracer distribution at the cellular level should 
lead to a realistic small-scale dosimetric assessment which can be used to evaluate and predict 









Figure 5-2 (a) follicular cell of normal thyroid by SIMS (secondary ion mass spectroscopy) (b) geometrical 
model, the thyroid follicular cells are formed from “colloid” surround by a shell of thyrocytes (c) digitized 
image with phosphorus (green) and iodine (red). The arrows show the different patterns of distribution (1) 
homogeneous with (2) and (3) inhomogeneous [Images modified from Champion et al] (Champion et al., 
2007b; Elbast et al., 2008a) 
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5.1.2 Transmission Electron Microscopy (TEM) imaging for tracer localisation 
Transmission electron microscopy is an imaging technique to probe the small-scale 
structure of materials. The basic principle of TEM is same as the light microscope but TEM uses 
electrons instead of light. The electrons have much lower wavelength than light (wavelength is 6 
pm for electrons and about 400-700 nm for visible light). This makes it possible to get much higher 
resolution when compared with the light microscope. TEM has the capabilities to investigate 
crystal structures, specimen orientations and also chemical composition and distribution of 
elements using the principles of diffraction pattern and/or X-ray/electron-energy analysis (Kazy et 
al., 2009).   
The detection in TEM is not related to radioactivity but rather uses the principle of 
interaction of an electron beam with the electronic structure of the sample. Thus, the non-
radioactive perrhenate compound (cold perrhenate) can be used instead of radioactive rhenium. 
A schematic diagram of the main components of TEM is illustrated in figure 5-3.  
 
The electron source (‘electron gun’) emits electrons which travel through a vacuum 
column. The electro-magnetic lens is used to focus the electrons into a very thin beam to travel 
through the specimen (as the term ‘transmission’ suggests). For imaging purposes, the sample 
can stop or deflect electrons on their path as they pass through the sample. Then, the deflected 
electrons are detected by means of the bright dots generated on the screen below the sample, 
on the other hand, dark areas result from regions where electrons stop in the sample. Hence, a 
 
Figure 5-3 Schematic diagram of TEM (modified from JFOL 2000FX Handbook) 
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wide range of grey scale values can be formed on the screen which refer to the different modes 
of interaction of the electrons with the sample e.g. deflection, scatter, transmission and stopping 
by the sample. There are many electron microscopy (EM) techniques that can be used to identify 
the elemental composition or localisation of the chemical map and/or chemical concentration in 
the sample. In our study, we used 2 techniques; STEM/HAADF (Scanning Transmission Electron 
Microscopy/High Angle Annular Dark Field) and EDX (Energy Dispersive X-ray Spectroscopy) 
(Nerl et al., 2011). For STEM/HAADF, the small-spot electron beams scan across the sample and 
then the HAADF images are formulated by gathering high-angle scattered electrons using an 
annular dark-field detector to collect those scattered electrons. The image contrast of HAADF 
images is strongly depended on the atomic number, hence, brighter spots in the image refer to 
areas composed of higher atomic numbers in the sample. 
 The fundamental principle of the EDX technique (also called EDS – Energy Dispersive 
Spectroscopy) uses a focussed electron beam bombarding the sample. The interactions cause 
characteristic X-rays which can be detected and measured by an energy-dispersive spectrometer. 
The spectra of characteristic X-rays refer to the energy difference between the two shells of the 
atomic structure of the sample. This spectrum is a unique characteristic for each element and this 
allows the qualitative and quantitative elemental analysis of materials (Kazy et al., 2009; 







Figure 5-4 Schematic diagram of EDX Technique. A solid sample is bombarded with electrons then it emits 
characteristic X-ray which result from the loss of electron from various energy shells (usually the K, L, M 
shells are primary interest) and we can analyse this as spectroscopy for elemental analysis (modified from 
(Goldstein et al., 2012) 
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5.1.3 Small-Scale Dosimetry 
Small-scale dosimetry most generally means measuring the energy deposited on a 
microscopic scale or a scale below the resolution of the scanner. More specifically, small-scale 
dosimetry studies the spatial-, temporal- and energy-dependency of radioactivity imparted in 
cellular and sub-cellular structures (Attix, 2007; Rossi and Zaider, 1991). Furthermore, small-
scale dosimetry takes into account the stochastic fluctuations in the micro volume. This contrasts 
with macrodosimetry, where the radiation absorbed dose is obtained by dividing the total energy 
deposited by the mass of that particular volume. The macrodosimetry calculation does not include 
the stochastic effects because of the large target volume of interest.  
To illustrate the importance of stochastic fluctuation, Humm et al. provided a schematic 
diagram of cells irradiated by alpha particle emitters. As shown in figure 5-5, some cells received 
multiple hits, while other might have received none at all (Humm et al., 1993b). 
 
Small-scale dosimetry in nuclear medicine is increasingly of interest because of the 
clinical application of high LET (LET ≥ 10-30 keV/µm) alpha emitting radionuclides e.g. 211At, 213Bi 
and 223Ra. Alpha particles have high energy but penetrate only less than 100 µm in tissue. Macro-
dosimetry does not describe the association between the range of the particle and target size 
(volume) (Rossi and Zaider, 1991). The definition of LET in conventional dosimetry is only based 
on the mean (linear average) of a fluctuating energy loss. However for alpha emitting 
radionuclides, LET might vary along the path so it is not sufficient to use average LET. Also the 
stochastic nature of the energy deposition for high LET has to be taken into account (Loncol et 
al., 1994).  
 
 
Figure 5-5 Schematic diagram of cells irradiated by alpha emitters (arrows are individual alpha particle 
emission), some cells received multiple hits, while other receive none at all (modified from (Humm et al., 
1993b; Roeske et al., 2008a)) 
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In addition, macro-scale dosimetry does not address the effects of delta rays. Delta rays 
refer to energetic electrons with sufficient kinetic energy to produce secondary ionisation. Delta 
rays occur when a charged particle (e.g. electrons, protons and alpha particles) penetrates matter 
and it loses energy by interaction with orbital electrons. The result of their interaction can be high 
enough for knocking orbiting electrons out of the atoms and the kinetic energy of those ejected 
electrons can be very high to cause further ionisation events, such energetic electrons are called 
“delta rays” (Attix, 2007; Cucinotta et al., 1998).  
For Auger electrons, there are emitted when an inner shell electron vacancy is created. 
The processes of vacancy are induced after electron capture and/or internal conversion. The 
spectra of electrons emitted are very multifaceted and include high LET particles with sub-cellular 
ranges (Stepanek et al., 1996). Therefore, these delta rays and Auger electrons are also attractive 
reasons for studying small-scale dosimetry (Makrigiorgos et al., 1990; Puncher and Blower, 
1994a). 
As there are many diagnostic radionuclides which emit Auger electrons, such as 51Cr, 
64Cu, 67Ga, 99mTc, 111In, 123I, 125I and 201Tl (Chen, 2008; Makrigiorgos et al., 1990).  The 
understanding of small-scale dosimetry is also important for diagnostic nuclear medicine (Humm 
et al., 1993b; Roeske et al., 2008a). Makrigiorgos et al. (1989) compared the estimated dose at 
the cellular level with the conventional organ-level dosimetry. Authors expressed their concern 
that conventional dosimetry may underestimate radiation effects by 2 to 25-fold for radionuclides 
that emit Auger electrons (Makrigiorgos et al., 1989).  
For illustration, another recently published study by Kassis et al. (2011) (Kassis, 2011) 
confirmed that high LET and Auger electron emitting radionuclides caused severe damage to 
sub-cellular structures. Kassis’s study also reported that the biological effect could be 10–100 fold 
higher than for electrons from conventional radioactive iodine, especially with the ionisations 
clustered within nanometre range from the decay site (as shown in figure 5-6). As a consequence 







Figure 5-6. LETs of Auger electrons as function of their energy. Arrows indicate their range. It can be seen 
that LET might vary along the path (modified from (Kassis, 2010)) 
 
There are two main methods for calculating the energy deposited on the cell nucleus. It 
is commonly accepted that the main cell compartment for radiation-induced cell killing is the cell 
nucleus. The S-value for calculating the average dose was firstly published in 1994 by Goddu et 
al. using analytical and experimental range-energy methods (Goddu et al., 1994). Goddu and his 
co-workers developed the model for calculating cellular dosimetry with cell radius ranging from 3 
to 10 µm and nuclei radius ranging from 1 to 9 µm. Goddu et al. proposed many source-target 
pairs for electron and mono-energetic alpha particle at cellular level for example cell to cell, cell 
to cell surface, nucleus to nucleus, cytoplasm to nucleus and cell surface to nucleus (Goddu et 
al., 1994; S. Murty Goddu, 1994).   
In 1997, the MIRD schema was extended to publish S-values for calculating cellular dose 
at the cellular level and also to provide a simple cellular model (Thierens et al., 2001). The model 
comprised two concentric homogeneous compartments representing cell and cell nucleus (as 
shown in figure 5-7). The cell radius (RC) and the cell nucleus radius (RN) ranged from 6 to 20 µm 
and 4 to 18 µm respectively (Bolch et al., 1999). The distribution of radionuclide activity was 
assumed to be uniform for the cellular compartment (e.g. uniform in whole-cell, nucleus or 
cytoplasm). The source regions in these models included the whole cell (C), cell surface (Cs), cell 
cytoplasm (Cy) and nucleus (N)(Roeske et al., 2008a). The example of cellular S-value for 90Y for 
















































Extensive tables of cellular S-value have been published for several radionuclides such 
as 32P, 35S, 86Rb, 89Sr, 90Y, 91Y, 114mIn, 131I including Auger electron-emitters 51Cr, 64Cu, 67Ga, 
99mTc, 111In, 123I, 125I ,201Tl and the alpha emitter 210Po and 211At for a range of sizes of cell, cell 
nuclei and a variety of source compartment (S. Murty Goddu, 1994; Stinchcomb and Roeske, 
1992). However, there are many restrictions and limitations with the cellular S-values and the 
MIRD cell model. The cellular S-value is only the self-absorbed dose; the cross-fire and bystander 
effect are not taken into account (Amin I, 2008). Additionally, the assumption of uniform tracer 
distribution in the source compartment is not a realistic assumption (Bardies and Pihet, 2000; 
Puncher and Blower, 1994a).  
 
 
Table 5-1 Cellular S-values for 90Y, Rc and Rn are radius of cell and nucleus, C, Cs, N, Cy are whole-cell, 
cell surface, nucleus and cytoplasm respectively (modified from (Roeske et al., 2008a)   
Figure 5-7 MIRD cell model, the model composes with nucleus, cytoplasm and cell surface (modified 
from (Goddu and Budinger, 2003)) 
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The second method for calculating small-scale dosimetry is analytical- or computational-
based methods. Typically, the micro-dosimetric spectra are given in terms of stochastic quantities 
and can be calculated by using analytical methods or Monte Carlo (Berger, 1970). 
For the analytical method, this calculation technique usually employs dose point kernel 
(DPK) convolutions of the single event spectrum to calculate multi-event distributions. Kellerer 
developed initial patterns of specific energy deposition for a single hit to determine the spectra of 
multiple hits via Fourier transform (Kellerer, 1981; Kellerer and Chmelevsky, 1975). In 1995, Giap 
et al. used this method with 3D voxel dose distribution and compared results with absorbed dose 
calculation by MIRD. They found a good agreement between the two methods (Giap et al., 1995). 
However, the computation time and limited source-target geometry often restrict this method 
(Gardin et al., 1995). 
With computational-based methods, Monte Carlo (MC) is a powerful computational 
technique to assess the dose at small-scale. The MC track structure randomly considers all 
generated particles event by event, incorporating the stochastic nature of radiation (Bardies and 
Pihet, 2000; Bousis et al., 2009). MC also provides more flexibility in inhomogeneous medium 
distributions while conventional analytic methods (such as dose point kernel-DPK) can be 
computed only in an infinite homogenous medium (usually water). The use of MC to evaluate 
charged particle interactions has been of interest and several codes have been published based 
on MC platforms for assessing small-scale dosimetry. The code was established in the 1960s by 
Berger and Seltzer (Berger and Seltzer, 1973). This code was used to calculate beta-particle 
dosimetry of 6 radionuclides in RIT (radio-immunotherapy). ETRAN improved dosimetry 
calculations from DPK in various processes such as in overcoming CSDA (continuously slowing 
down approximation) and also including electron stopping power and Bremsstrahlung cross-
section. 
In addition, small-scale dosimetry with MC simulations has been developed by many 
research groups. For example, full MC simulation of energy deposition at cellular level include the 
stochastic variation of astatine-211 (211As) (alpha emitter) published by Humm et al. (1987) (J.L, 
1987). Larson et al. conducted in vitro studies of the cytotoxicity to human glioma and melanoma 
cells from At-211 labelled chimeric monoclonal antibodies (Larsen et al., 1998). The authors also 
provided the micro-dosimetric analysis using MC and determined cell sensitivity response based 
on micro-dosimetric quantities. Akabani and Zalutsky used the digitised histological images to 
determine chord-length distribution of At-211 (Akabani and Zalutsky, 1997). A chord-length is 
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defined by the intersection of particle track within a sphere. In micro-dosimetry, it is an important 
parameter to obtain the distribution of particle energy within the medium. Also this parameter can 
be used to demonstrate the influence of cell conglomeration and activity distribution. Another 
example of MC-based estimation for small-scale dosimetry is the CELLDOSE software by 
Champion et al. (2008). CELLDOSE is Monte Carlo-based software for calculating cellular S-
values for I-131 in spheres of various sizes. Authors concluded that their S-values agreed well 
with published analytic methods (Champion et al., 2008).  
Small-scale dosimetry can also be calculated by the GEANT4 toolkit which is a C++ class 
library (Archambault et al., 2003). Initially, GEANT4 was developed for applications in high-energy 
physics but also provides low energy packages. An example of using this code is the work by 
Freudenberg and co-workers (Freudenberg and Kotzerke, 2010). The S-values of four 
radionuclides (131I, 188Re, 90Y and 99mTc) were computed for various activity distributions at cellular 
level. The authors also provided biological measurements of cellular survival curves by GEANT4 
(Freudenberg and Kotzerke, 2010). Subsequently, many groups used GEANT4 as a standard 
tool for small scale dosimetry in RIT. For example, Chouin et al. used GEANT4 to calculate 
microdosimetry for alpha emitting radionuclides (Chouin et al., 2009) and Chauvie et al. 
developed the GEANT4 codes for nano-scale DNA dosimetry; this GEANT4 package is called 
“Geant4 DNA project” (Chauvie et al., 2007).  
Along with the use of Monte Carlo in small-scale dosimetry, improvements were also 
developed in cellular geometrical modelling. A model published by Larsson used MC to study a 
realistic anatomical structure of testes including seminiferous lobules with interstitial tissue 
between them (Larsson et al., 2012). The model consists of an ellipsoid with mosaic pattern and 
hexagonal cylinders to characterize the complex structure of testicular lobule and seminiferous 







The understanding of radiation biological effects is the goal for studying radiation 
dosimetry. However, currently there is limited link between dosimetry and biological effects. The 
link is rather unclear and perhaps limited because it is only based on external gamma/X-ray 
exposure and atomic bomb survival data. At the macroscopic scale, the radiation toxicity relies 
only on whole-tumour/whole-organ absorbed dose, which might not be a trustworthy predictor of 
the biological effects of internalised radionuclides. Also, the assumptions that activity and energy 
deposition distributed uniformly are not generally valid. Hence, the actual biological effects among 
cells in the same tumour/organ may be varied and dependent on spatial distribution of 
radioactivity at the multi-cellular, cellular or sub-cellular levels.  
For small-scale dosimetry, the microscopic dose, energy deposition and stochastic nature 
of radiation can be considered. Goodhead (1982) stated that the micro-dosimetric properties are 
important factors in determining the biological effectiveness of radiation (Zaider and Brenner, 
1985). True absorbed dose (or specific energy distribution) can be calculated from the area under 
micro-dosimetric spectra curves, and this can be linked to other radiobiological parameters, for 
example relative biological effectiveness (RBE), tumour control probability (TCP), cell 
mutagenesis and cell survival curves (Alan, 1996; Roeske and Stinchcomb, 1996; Stinchcomb 
and Roeske, 1992).  
RBE can be used to compare the qualities of new radionuclides relative to reference 
radiation (in terms of producing similar biological damage). In nuclear medicine, several reference 
radiation emissions are used to compare the efficacy of radionuclide treatments with different 
biological end-points. The table below is an example of using RBE to compare the efficacy of in 
vivo alpha radio immunotherapy. 
Figure 5-8. Cross-section of testicular cell geometrical model, simulated using MC code (modified from 





Radionuclide Biological end-point Reference radiation RBE 
213Bi-(Fab΄) marrow 90Y- (Fab΄) ~ 1 
213Bi-(Fab΄) tumour growth delay 90Y- (Fab΄) 2 - 14 
211At- (IgG) WBC reduction Whole body Co-60 5.0 ± 0.9 
211At- (IgG) WBC reduction 99m Tc- ( F(ab΄)2) 3.4 ± 0.6 
211 At- ( F(ab΄)2) tumour growth delay Whole body Co-60 4.8 ± 0.7 
213Bi- (IgG) leukaemia reduction 90Y- (IgG) ~ 1 
 
Cell survival curves and the tumour control probability provide additional ways to predict 
the biological response of cells to radiation. The cell survival curve is a mathematical curve used 
to describe the survival of a population of irradiated cells. Generally, the cell surviving fraction is 
plotted in logarithmic scale on the y-axis against the dose on the x-axis. Several published papers 
have used microdosimetry to analyse cell survival curves (Roeske and Stinchcomb, 1996, 2000). 
Aurlien et al. used microdosimetry to analyse cell survival curves of human osteosarcoma and 
bone marrow cells in vitro (Aurlien, 2000). The experiments were performed to simulate the effects 
of alpha therapy, evaluated by Monte Carlo microdosimetry and clonogenic cell survival. The 
cumulated activity and absorbed dose were calculated from microdosimetric parameters of 
average specific energy by single event, number of hits and single-event frequency distribution. 
The survival fractions were estimated experimentally for each cell line. Thus, the cell survival can 
be plotted and can be used to predict the outcome of the therapeutic radiotracer for clinical study. 
The cell survival curves of two types of cell lines (OHS - human osteosarcoma and BM -
mononuclear bone marrow) from Aurlien et al. are shown in figure 5-9 (Aurlien, 2000).  
 
Table 5-2. RBE values for different alpha radio immunotherapy studies, in vivo (Sgouros et al., 2010) 
 




In light of the above arguments, this chapter aims to study the cellular distribution of 
radiotracer in a thyroid model. In the first part of this chapter, we aim to use EM and MAR to study 
the cellular distribution of non-metabolised tracers (pertechnetate/perrhenate) in rodent (rat and 
mouse) thyroid. In the second part of this chapter, we aim to apply small-scale dosimetry to 
consider the absorbed dose distribution when radionuclides were distributed in different locations 
within or outside the cell. The thyroid geometrical model and tracer distribution from MAR were 

























5.2 Materials and Methods 
5.2.1 Tracer localisation 
There were 2 methods that performed in this study; (1) Electron microscope and (2) 
micro-autoradiography 
 
5.2.1.1 Electron Microscope 
5.2.1.1.1 Animal samples 
Animal experiments were performed according to the licence under the United Kingdom 
(UK) Government Home Office and protocols were approved by the local ethic committee. TEM 
tracer localisations were initially performed using healthy BALB/c mouse (female, 4-8 weeks old, 
weight ~ 25 g.). Due to small size and difficulty in dissection of the mouse thyroid, we re-designed 
the study to use the larger rodent species. Hence, the Wistar rat (female, weight ~ 250 g.) was 
chosen to use in this study.  
 
5.2.1.1.2 Perrhenate Compound  
The detection principle of TEM is not related to radiation but uses the interaction of an 
electrons beam with the electronic structure of the sample. Hence in this experiment, the non-
radioactive compound (cold perrhenate [ReO4-]) was used instead of radioactive perrhenate 
(188ReO4-).  
Cold perrhenate (ReO4-) compound in form of sodium perrhenate (NaReO4) was 
purchased from Sigma-Aldrich (Gillingham, UK). There are no data in the literature about the 
concentration levels of perrhenate (or rhenium) that cause toxicity to the cell/animal. We have 
calculated that the amount of rhenium based on the activity of 100 MBq of 188ReO4- to be 
approximately 0.015 nM of rhenium. Then, we increased this concentration 100 times. Therefore, 
the compound was prepared in a phosphate buffer saline (PBS) with final rhenium concentration 
of 1 nM (186.21 pg/ml) and 10 nM (1862.10 pg/ml) for injecting to mouse and rat respectively.  
 
5.2.1.1.3 Experimental Protocol 
Cold perrhenate compound was injected into the animal via the lateral tail vein with 
volume of approximately 150 µl. Animals were terminated by exposure to carbon dioxide (CO2) 
(schedule 1-appropriate methods of humane killing) 1 hr after injection. This time-point was 
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determined based on spatio-temporal quantification in scid/beige mice with 99mTc-pertechnetate 
in Chapter 3, in which pertechnetate reached its peak (3.27 %ID) at 1.22 hr after injection, 
however due to limitations of time, we used 1 hr time-point as this point the uptake determined by 
imaging was just slightly lower than maximum uptake (uptake at 1 h PI was about 3.15 %ID 
compared to 3.27 %ID at 1.22 h PI) but more convenience for experimental management. 
   
5.2.1.1.4 Sample Preparation and TEM Imaging   
After the termination process, the thyroid gland was immediately dissected under a 
microscope due to its small size (diameter about 1 mm with about 3 mm long). Then, the sample 
was quickly clamped using the copper clad pliers cooled to liquid nitrogen temperature. This 
selected method can fix the element in the cell and can protect the sample from ice crystals. 
Frozen samples were stored in liquid nitrogen until they were cryosectioned. Samples were sent 
to analyse at the Centre for Ultrastructural Imaging, King’s College London, Guy’s Campus 
(London, UK). 
 
5.2.1.2 Micro autoradiography  
5.2.1.2.1 Animal samples 
Animal experiments were performed according to the licence under United Kingdom (UK) 
Government Home Office and protocols were approved by the local ethics committee. Female 
healthy Wistar rats (weight ~ 151-200 g) were selected to use in this study. Animals were housed 
in standard BSU conditions at BSU Unit (St Thomas Hospital, London, UK) with autoclaved water 
bottle and normal food (already irradiated). 
 
5.2.1.2.2 Radionuclide 
Clinical standard radiopharmaceutical 99mTc-pertechnetate was eluted as per clinical 
routine and dispensed from the Radiopharmaceutical Unit, Nuclear Medicine, Guy’s Hospital 
(Guy’s & St Thomas’ Hospitals NHS Foundation Trust, London, UK). 188Re-perrhenate was eluted 
from our on-site W-188/Re-188 generator (ITG-Isotope Technologies, Germany) using sterile 
normal saline for injection (Baxter Healthcare, Newbury, UK). The radiochemical purity of 188Re-




5.2.1.2.3 In vivo MAR protocol 
Activity of 100 MBq of 99mTc-pertechnetate diluted in normal saline with volume less than 
200 µl was injected into the rat via the lateral tail vein. For 188Re-perrhenate, activity of 100 MBq 
(volume less than 200 µl) was intravenously injected into the lateral tail vein.  
After injection under anaesthesia, the rats were sacrificed by schedule 1 (neck 
dislocation) at 1 hr after injection. This terminal time-point was based on spatio-temporal 
quantification of scid/beige mouse in Chapter 3, as discussed previously, taking into account 
practical limitations of time; Thus we chose the 1 hr time-point for our experiment (uptake about 
3.15 %ID and about 1.25 %ID at 1 hr PI for 99mTc-pertechnetate and 188Re-perrhenate 
respectively).   
 
5.2.1.2.4 Sample Preparation 
We tested our emulsion by preparing (A) positive control with 99mTc (B) negative control 
of cold 99mTc (10 half-lifes) and (C) negative control of PBS. Each tested sample was prepared 
by suspended (positive 99mTc or negative control of cold 99mTc or PBS) in 1 % agar, then snapped 
frozen with OCT (Optimal Cutting Temperature) tissue freezing medium at -170 Co in liquid 
nitrogen-cooled iso-pentane. Sectioning was performed in a cryostat (Bright Instrument Company 
Ltd, UK) with specimen and chamber temperature of -20 and -40 Co respectively. The sections 
were mounted on the emulsion coated slide for 24 hours then developed.   
For in vivo sample, thyroid with trachea was dissected immediately after animal 
termination, then the thyroid was separated from the trachea under microscope due to its small 
size. The sample was snapped and sectioned as explained above.  Thyroid sample was cut in 
sagittal section with thickness of 10 µm for 99mTc-pertechnetate and 7 µm for 188Re-perrhenate 
then placed on the slide (whether before or after emulsion coated – see next part).  
 
5.2.1.2.5 Emulsion 
Ilford emulsion (Agar Scientific, UK) was used in this study. The K-5 emulsion with crystal 
diameter of 0.2 µm was obtained in gel form. This product is offered for shorter exposure time 
and the K-series is better suited for light microscopy. The Ilford nuclear emulsions have highly 
uniform particle size, low background, long time stability, and consistent grain size. Typically, the 
emulsion (gel form) must be stored at 4 Co avoiding ambient exposure of background radioactivity.  
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In this study, we have performed experiments with 2 settings (a) Mounting section directly 
onto emulsion-coated slide and (b) Mounting section on plain slide then coat with emulsion. 
(a) Mount sample section directly onto emulsion-coated slide 
With this setting, the cryostat sectioning was performed in a dark room and the emulsion-
coated slide was prepared prior the experiment with these following steps:  
I. Microscope slides (Thermo Scientific Ltd., UK) were washed in chromic acid solution 
(10% K2Cr2O7, 10% H2SO4) for 2 hours, rinsed for 2 hours in running tap water then rinsed 
overnight in distilled water on the laboratory shaker.  
(Steps II to VI were performed in dark room with safelight while minimising other 
background radioactivity) 
II. K5 nuclear emulsion (in gel form) was melted in a pre-warmed measuring cylinder in a 
water bath at 40°C. The emulsion was diluted with deionised water (dH2O) for example 3 parts of 
emulsion and 5 parts of dH2O. Glycerol was also added to a final concentration of 0.01 %.  
III. Microscope slides were subbed in diluted emulsion (from step II) removing any excess 
emulsion from the other side that would not be used. Then, the emulsion coated slides were 
transferred onto a chilled aluminium plate for 15 minutes and then dried on a flat level surface 
with cool air for 1 hour. Generally, this dipping procedure provides about 1-2 µm thick of emulsion 
after drying. 
IV. Emulsion-coated slides were stored over desiccant at 4 °C until use.  
V. Frozen sample sections (10 µm thick) were mounted directly onto emulsion-coated 
slide and exposed for 24 h at 4 °C in the dark box while minimising ambient light and local 
radioactive background.  
VI. The mounted sample section on the plain slide was then coated with emulsion 
With the above method (mounting the sample section directly onto emulsion-coated 
slide), the major problem was the difficulty in sectioning tissue in the dark room. To solve this, the 
sample section was mounted on a plain microscope slide and then the slide was later coated with 
emulsion in the dark room. As there were many steps in the process for emulsion-coated slide, 
there was the risk that the tissue might be detached from the slide surface. Therefore, we used 
the adhesive charged slide (Super-Frost PlusTM, Thermo Scientific, UK) in order to adhesively 
bind the sample onto the slide surface. The processes for this method are listed below. Tissue 
section was placed onto positively charge slide 
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Slides were transferred to the dark room. Then, steps II – VI from previous method were 
repeated in dark room with safe-light 
The samples were exposed for 24 h at 4 °C in the dark box while eliminating ambient light 
and local radioactive background.  
 
5.2.1.2.6 MAR Processing 
After 24 hours, the slides were transferred to dark room. Then, the exposed MARs were 
developed in 16% Kodak D19 (Eastman Kodak Ltd, USA) for 5 min. This developing agent was 
made on the day of use. Additionally, the solution was protected from light as the latter would 
increase the chance of fogging artefact. The slides were placed in 1 % acetic acid (CH3COOH) 
for 5 minutes (to stop the developing process) and dipped in 0.5 % gelatine before being air dried 
for 30 minutes. Once dry, slides were fixed in 30% sodium thiosulphate (Na2S2O3) for 5 minutes 
and washed in running tap water for 10 minutes with final wash in distilled water. The slides were 
left until dry. 
 
5.2.1.2.7 DAPI Staining 
In this study, we stained MAR tissue with DAPI fluorescence staining agent after MAR 
developing process. DAPI can pass a cell membrane and bind to A-T rich regions in double-
stranded DNA. Hence, this allows to visualise the cell nucleus. DAPI can emit blue light (~ 460 
nm) using the ultraviolet light (UV) as excited source and a blue/cyan filter.  
 
5.2.1.2.8 Haematoxylin and Eosin (H&E) Staining  
We also stained thyroid tissue with H&E using following steps; 
I. After developing micro-autoradiograph slides  
II. Dehydrate (15 seconds for each step) 
a. 100% Ethanol alcohol 
b. 95% Ethanol alcohol 
c. 75% Ethanol alcohol 
d. dH2O (deionised H2O) 
III. Dipped slide in Haematoxylin for 10 minutes 
IV. Running in tap water for 15 minutes, then washed in dH2O  
V. Dipped slide in Eosin for 5 minutes 
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VI. Dipped in 100% ethanol (in separate container for avoid contamination of Eosin) 
VII. Dipped slide in 100% Histoclear® (Agar Scientific, Essex, UK) for 15 seconds  
VIII. Fixed and mounted slides with a synthetic resin using DPX (Sigma-Aldrich, 
Gillingham, UK)  
5.2.1.2.9 Silver Grain Cell Imaging and Post Processing Imaging Technique 
The tissue and emulsion were viewed under fluorescence microscope (EVOS® XL, Life 
Technology, UK). Silver grain and emulsion were on different layers, so, focus adjustment for 
each plane was necessary for interpretation of results. Silver grains were examined under bright 
field. Post processing technique was used to enhance silver grain by adjusting brightness, 
contrast and thresholding of image using the AMIDE (AMIDE is a Medical Image Data Examiner) 
software (version 1.0.4, http://amide.sourceforge.net). For tissue stained with DAPI, the slides 
were viewed in fluorescence mode with UV excited.  
 
5.2.2 Small-scale dosimetry 
5.2.2.1 Input data (models and assumptions) 
The fused image of MAR and DAPI (figure 5-10) was used as an input for simulation. The 
original dimension of this image was 110.67 µm (horizontally) × 76.67 µm (vertically) with 498 × 
345 pixels. The fused image was manually segmented using the ImageJ software version 1.48v 
(National Institutes of Health, USA). Pseudo orange areas refer to colloid and we assume rest of 
the images are follicular cell. 
 
 
Figure 5-10 Segmentation of fused image (MAR, and DAPI), the orange areas indicate the colloid. We 





The segmented image was digitised using MATLAB software version R2011b 
(MathWorks Inc., USA). We used a digitised number (0 and 1) to represent the location of 
radionuclide, “0” (white) means pixel element without radioactivity and “1” (dark) means pixel 
element with radioactivity. 
  
 
Ranges of electrons for both 188Re and 131I are far beyond the dimension of the original 
image. So, we propagated this image 5 times in both the X- and Y-axis, and also made the 
simulation 3D by overlapping 5 images in the Z-direction. The images below were propagated 5 
times in 3 dimensions and resized to an integer matrix of 128 × 128 × 5 voxel (volume element 
dimension 1.6 × 1.6 × 1.6 µm3). For interpolation, the “nearest neighbour” option was chosen to 
estimate an element value at a location in between original image voxel. With the “Nearest-
neighbour interpolation”, the output element was assigned the value of the voxel that the point 
falls within, no other voxels are considered.  
 
 
Figure 5-11 Digitised images (“0” represents pixel element without radioactivity and “1” represents pixel 
element with radioactivity). There are 2 main conditions; (left) radioactive uniformly distributed in colloid 
and (right) radioactive uniformly distributed in follicle.  
  
Figure 5-12 Simulation images after 5 times propagation in X-, Y- and Z-dimension. After resizing, the 
nearest option was used to interpolate the output element in between original image voxel 
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For micro-distribution of radiotracer, we initially set only 2 conditions (radionuclide in 
follicular cell or colloid, as shown in figure 5-12) with uniform distribution of the two radionuclides 
(131I and 188Re). Hence, we examined four scenario of tracer distribution for simulation.  
(A) 131I uniformly distributed in colloids, no radioactivity in other areas  
(B) 131I uniformly distributed in follicular cells, no radioactivity in other areas  
(C) 188Re uniformly distributed in colloids, no radioactivity in other areas 
(D) 188Re uniformly distributed in follicular cells, no radioactivity in other areas 
The scenario of radiotracer distribution was assumed based on our data from previous 
part and also published data of thyroid distribution in new-born mouse accessed using SIMS 
(Elbast et al., 2008b). The simulation was assumed to be reflect only 2 tissue types; thyroid and 
soft tissue.  Material compositions were taken from the ICRU report 44 (International Commission 
on Radiation Unit and Measurement, 1989) (Units and Measurements, 1989). Follicular cells were 
assumed to be of thyroid tissue composition whereas colloid was assigned to be of soft tissue 
composition from the available specifications of the ICRU report 44. The density of thyroid is 1.05 
g/cm3 and compositions in % of: hydrogen (H) 4, carbon (C) 11.9, nitrogen (N) 2.4, oxygen (O) 
74.5, sodium (Na) 0.2, phosphorus (P) 0.1, sulphur (S) 0.1, chlorine (Cl) 0.2, potassium (K) 0.1 
and iodine (I) 0.1. The density of soft tissue is 1.06 g/cm3 with compositions in % of: H 10.2, C 
14.3, N 3.4, O 70.8, Na 0.2, P 0.3, S 0.3, Cl 0.2, and K 0.3 (Ghorbani et al., 2014; Kramer et al., 
1997; Units and Measurements, 1989) 
 
5.2.2.2 Simulation  
The overview process of the simulation is shown in the figure below. The first step was 
the preparation of input files (segmented MAR, tissue composition, and tracer distribution map) 
as previously described. OEDIPE (French acronym means Tool for the Evolution of Personalised 
Internal Dose) is a user friendly graphical interface developed in IDL® Interactive Data Language 
(ITT Visual Information Solution, Colorado, USA). OEDIPE was used to design and create the 
Monte Carlo input file. For the simulation, the MCNPX version 2.5.0 was used to calculate small-
scale dosimetry in this study. In MCNPX, the electron and photon (Franck et al., 2007) cut-offs 





Once the simulation of the predefined event population is complete, OEDIPE was used 
to export the results. The dose calculations and absorbed dose distribution histograms were 















Figure 5-13 Schematic diagram of simulation in this study with OEDIPE and MCNPx (modified from 
(Franck et al., 2007)) 
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5.3 Results and Discussion 
5.3.1 Tracer localisation  
5.3.1.1 Electron Microscope 
5.3.1.2 Electron Microscope with Balb/C Mouse 
The mouse was injected with cold perrhenate compound and then culled at 1 hr after 
injection according to protocol stated above. The TEM, STEM/HAADF and EDX spectrum images 










The figure 5-14 A was taken with conventional TEM imaging, where the dense areas 
(arrow) are colloid. The figure 5-14B was imaged using the HAADF technique. As explained 
earlier, the contrast of HAADF represents the average atomic number in that particular area. For 
Figure 5-14 (A) Conventional TEM images, the dense area (arrow) represents colloid (B) HAADF (High 
Angle Annular Dark Field) technique. Spectra in figure (C) and (D) are correspond to the rectangular ROI 






elemental localisation with EDX, the ROIs were drawn on the dense blobs (rectangular area in 
figure 5-5B). The spectra show peaks of copper (Cu), rhenium (Re), phosphorus (P), potassium 
(K) and Titanium (Ti). The Cu, P and K were suggested to be natural endogenous elements in 
thyroid gland (Błażewicz et al., 2010). The sample holder was made from titanium, so, the titanium 
spectrum was observed as well. The weak signals of rhenium were observed in both areas but it 
just a few counts above the background. Also, the position of spectrum (characteristic X-ray) was 
very close to endogenous copper and phosphorus which complicate accurate detection of the 
characteristic rhenium peak.      
We have compared the size of thyroid from our images with the published work by 
Champion et al. The imaging study of newborn rat thyroid (Wistar, 7 day old) by Champion et al 
reported the size of colloid as 12 µm in diameter and for cellular shell (colloid + follicle cells) as 
20 µm in diameter using SIM (secondary ion mass spectroscopy). However, our colloid was 
approximately 1 µm which it quite small when compared with those published data.  
 
Hence, this observation limited our confidence in accurately sampling the required area 
with TEM imaging. Therefore, it was decided to repeat this experiment with larger species (easier 
to dissect the thyroid free from surrounding tissue) and to increase the concentration of cold 






Figure 5-15 (Left) TEM image from the Balb/C mouse experiment (Right) new-born rat thyroid with SIM 
technique (image taken from Champion et al) (Champion et al., 2007a). According to Champion et al, the 
size of new born rat colloid was about 20 µm in diameter while in our Balb/C images the colloid diameter 
was just about 1-2 µm.  
Colloid 
50 × 50 µm 9 × 9 µm 
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5.3.1.2.1 Electron Microscope with Wistar rat 
As mentioned in previous part, we changed to larger species of rodent (from 25 g Balb/C 
mouse to 250 g Wistar rat). The concentration of cold perrhenate compound was increased 10 
times (increased amount of cold perrhenate from 1 nm to 10 nm). All other protocol parameters 
remained as discussed in the previous section. The following figures demonstrate examples from 
TEM imaging of Wistar rat, where we also correlated this image with the schematic diagram of 
the microscopic structure of the thyroid gland.  
 
A TEM image from normal Wistar rat thyroid sample is shown in figure 5-16. The colloid 
diameter was approximately 30 to 40 µm; follicular cell dimension was 5-7 µm. However, it was 
not possible to lower magnification in order to obtain several follicles due to a technical problem 
of the microscope. To localise the elemental map, the STEM/HAADF and EDX spectra were used 





Figure 5-16 (Left) Schematic diagram of microscopic appearance of thyroid gland - modified from (Hall, 










   
                         (A)                                                                  (B)                                                             (C) 
 
The spectra of copper, potassium, sulfur, chlorine and phosphorus were observed in 
thyroid follicles, suggesting these to be natural elements in the thyroid. However, the sprectrum 
of rhenium could not be confirmed in both folicle and colloid due to this peak being located in 
close proximity to the peak of endogenous phosphorus. Additionaly, iodine was detected only in 
the colloid but not in thyrocyte areas which correlated well with the study by Champion et al.  and 
this confimed our initial hypothesis that most iodine is located in the colloid and not in the follicular 
cells (Champion et al., 2007a). However, the cost of this technique is high as it requires costly 
dedicated equipment.  
 Figure 5-17 Images were acquired with HAADF technique which the contrast depending on the average 
atomic number, the red rectangular area shows the region of interest for obtaining the spectra for 
elemental analysis 
Figure 5-18 The data generated by EDX technique showed several spectra corresponding to the elements 
making up the composition of the sample being analysed (figure 5-18 A and B) correspond to rectangular 
ROI 1 in figure 5-17 which are follicular cell (figure 5-18 C) correspond to rectangular ROI 2 in figure 5-17 
which is colloid. The rectangular red-dashed (figure 5-18 A) shown the primary peak of rhenium that located 
at a similar position as the endogenous phosphorus. The rectangular orange-dashed (figure 5-18 C) area 
presented the iodine spectrum in the colloid area but not found in the follicular cell.  







Energy (keV) Energy (keV) Energy (keV) 
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Further investigations are needed in order to confirm that rhenium is solely located in 
thyrocytes and not in the colloid, hence, we will use other techniques (e.g. micro-autoradiography) 
in order to prove this statement in the next section. 
 
5.3.1.3 Micro-autoradiography   
The figure below shows high magnification images (400x) under the following conditions 
(A) silver grain from 99mTc (10 µm section of uniform source suspended in 1 % agar) (B) negative 
control of cold 99mTc (10 µm section of cold (10 half-lifes) 99mTc suspended in agar) and (C) 
negative control (10 µm section of PBS suspended in 1 % agar). The sections were mounted on 
the emulsion coated slide for 24 hours then developed.   
 
                    (A)                                                  (B)                                                 (C) 
 
 
The slide in figure 5-19 (A) with 99mTc showed high density of silver grains as expected 
while cold 99mTc and PBS showed only a few grains visible which is likely a result from emulsion 
fog/background. For in vivo MAR, the thyroid was dissected immediately and then embedded with 
OCT and snap-frozen in liquid nitrogen cooled liquid propane. Sections were cut with a thickness 
of 10 µm in a cryostat. To confirm that we picked the right tissue, we stained our sample section 
with DAPI and also with H&E (haematoxylin and eosin). The section was placed on microscope 
slide (no emulsion coated). The image is shown in figure 5-20 below (captured by EVOS®XL). 
 
 
Figure 5-19 The sectioning of 10 um of (A) 99mTc (B) Cold 99mTc and (c) PBS suspended in 1 % agar then 







Figure 5-20 Wistar rat thyroid (Top) tissue stains with DAPI under fluorescence microscope (200x) (Bottom) 
H & E staining under bright field (200x). (1- Thyroidfollicular cell (thyrocyte), 2 – Colloid). It was important to 
note that images were from different areas.   
 
The images in figure 5-20 (top) and (bottom) displayed the 10 µm section of thyroid with 
DAPI and H & E staining. DAPI and haematoxylin stain the nucleus of thyroid follicular cells. The 
diameter ranges of colloid were 40 – 100 µm. The wall of follicular cells was not clearly seen from 
staining but the estimated sizes of the nucleus were about 5 × 5 µm (width × length). The 












Figure 5-21 showed the thyroid autoradiograph, the tissue section was placed on the 
slide and then the slide was transferred to the dark room for coating process. After exposure for 
24 hours, the MAR slide was developed using the protocol stated in previous sections. 
Additionally, we stained a sample with DAPI and also showed fusion of images in figure 5-21 
(bottom left). In figure 5-21 (bottom right), the digitised red dots indicate the grains. Interestingly, 
silver grains were observed only in thyrocyte areas but were not present in colloid. In vivo MAR 
with 188Re-perrhenate also showed similar findings (as illustrated in next figure).  
Figure 5-21. Wistar rat thyroid injected with 100 MBq of 99mTc-pertechnetate, tissue harvested at 1 h after 
injection. (Top Left) Micro-autoradiograph of 10 µm section, image with bright-field (200x). (Top Right) 
Image from similar area with DAPI under fluorescence microscope (200x). (Bottom Left) Fused image of 
micro-autoradiograph and DAPI. (Bottom Right) Grain enhancing from post processing technique, the red 





Figure 5-22 presented the thyroid autoradiograph, the tissue section was placed on the 
slide, the section was cut thinner (from 10 µm to 7 µm) in order to yield better resolution (Puncher 
and Blower, 1994b). Then, the slide was transferred to the dark room for coating process. After 
exposure for 24 hours, the MAR slide was developed using the protocol stated in previous 
sections. However, the DAPI staining was not performed due to technical problem.  
Based on this study, the findings support our initial hypothesis that non-metabolised 
tracers (e.g. pertechnetate, perrhenate) localise only in thyrocytes (not in colloid). In addition, we 
also performed a control experiment by mounting the non-radioactive thyroid (rat injected with 
150 µl of PBS) on the emulsion coated slide. This slide was also exposed for 24 hours with similar 







Figure 5-22 Wistar rat thyroid injected with 100 MBq of 188Re-perrheate, tissue harvested at 1 hr after 
injection. (Left) Micro-autoradiograph of 7 µm section, image with bright-field (200x). (Right) Image from 
similar area with grain enhancing from post processing technique, the red dots refer to the silver grain. 
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The control experiment (as illustrated in figure 5-23) showed no silver grain in both slides. 
These indicated that silver grains (as seen in figure 5-21 and 5-22) were produced from secondary 
electrons of 99mTc-pertechnetate and 188Re-perrhenate. In this study, we proved that radiotracer 
distribution of 99mTc-pertechnetate and 188Re-perrhenate in thyroid have similar patterns. This 
finding was supported our initial hypothesis.  
It was important to mention that according to the published literature pertechnetate 
provides a better resolution due to the short range of secondary electrons. As previously reported 
(Puncher and Blower, 1994b), 188Re provided a resolution of 3.9 µm whereas 99mTc gave 
resolution of 2.8 µm. It was important to clarify that the resolution value of MAR is usually 
expressed as the distance from the edge of uniform source to the point that grain density falls to 
half value over the source. With reference to the principle of silver grain forming, 99mTc has no 
beta emissions and the process only depends on secondary emissions of electrons (Auger and 
internal conversions). This is similar to 125I. In terms of exposure time, 99mTc has much shorter 
Figure 5-23 Thyroid of Wistar Rat injected with 150 µl of PBS (negative control). The tissue section was 
mounted on the emulsion-coated slide, then exposed and developed using similar protocol 
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half-life, so, exposure times longer than 24 h are meaningless. The additional advantages of 
99mTc-pertechnetate include that it is cheap, available daily, imparts very low radiation dose to 
user (compared with 188Re-perrhenate). 
The poorer resolution of 188Re results from its high-energy beta particles (penetrate longer 
range in emulsion). The thinner slide can improve the resolution, however, this was difficult to 
perform especially with a small tissue/organ (Puncher and Blower, 1994b). Also, we have not 
quantified the silver grain at this stage, this will be carried in future work. Further investigations 
(such as SIM-Secondary Ion Mass Spectroscopy) are needed in order to confirm this statement, 
also further MAR experiments ideally with 125I-NaI are required to prove that there is no stable 
iodine present in thyrocytes at equilibrium conditions.   
To conclude our assumption of tracer distribution, we need to combine the results from 2 
experiments (TEM and MAR). With TEM, the primary peak of rhenium could not be 
unambiguously detected because this peak is located close to that of endogenous phosphorus. 
However, iodine was detected only in colloid but not in thyrocytes. With MAR, pertechnetate and 
perrhenate were found present only in thyrocyte areas while no pertechnetate/perrhenate were 


















5.3.2  Small-scale dosimetry 
Graphs in figure 5-24 are plotted of the number of volume elements (no. of voxel) per bin 




These graphs indicate the population of voxels that received absorbed dose from different 
scenarios of tracer distributions. 131I in colloid and 188Re in follicle are biologically realistic, as both 
these two conditions were experimentally demonstrated in the first part of this chapter with 
transmission electron microscopy and micro-autoradiography techniques along with other 
published studies in the literature (Champion et al., 2007a; Elbast et al., 2008b). In addition, 131I 
located in colloid could also occur during the transition time of transferring iodide from the basal- 
to apical- membrane of NIS. As shown in a study by Champion et al (figure 5-10), the kinetic 
pattern of iodine in thyroid cells of new-born mice seems to indicate that there is no iodine 
observed in follicular cells at 1 hr post injection. Hence, we assumed that the transition of iodine 











































































Re-188 in folliocular cell
follicular cell colloid
Figure 5-24. Absorbed dose distribution in thyroid section, calculated by small-scale dose modelling with 
MCNPx. The graphs show the population of voxels that received absorbed dose with following conditons 
(a) 131I in colloids (top left) (b) 131I in follicular cells (top right) (c) 188Re in colloids (bottom left) and (d) 188Re 
in follicular cells (bottom right). There was assumed to be no radioactive elsewhere in each condition 
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Based on the graph, the total elements comprised 81920 voxels (128 × 128 × 5) of which 
60100 voxels (73.36 %) are assigned to colloid and 21820 voxels (26.64 %) are follicular cells. 
As seen from the graphs, the dose distribution spectrum was broader when the radionuclide was 
localised in colloid. The dose range was distributed from 0 mGy/MBq.s to 0.619, 0.457, 0.400 and 
0.304 mGy/MBq.s for 131I in colloid, 188Re in colloid, 131I in follicular cell and 188Re in follicular cell 
respectively. The dose which most voxels were found to absorbed (“mode” of absorbed dose in 
colloid) were 11.26mGy/MBq.s (2202 voxels) for 131I distributed in colloid, 16.93mGy/MBq.s (1785 
voxels) for 131I distributed in follicular cell, 11.14mGy/MBq.s (2032 voxels) for188Re distributed in 
colloid and 14.92mGy/MBq.s (1786 voxels) for 188Re distributed in follicular cell. However at this 
stage, we assumed that the cell nucleus is the biological target for cell killing and the nucleus is 
located in the follicular cell. Hence, we plot another graph (figure 5-25) to illustrate the absorbed 
dose distribution in follicular cells (i.e. excluding colloid voxels). 
 
Figure 5-25  Absorbed dose distribution to follicular cells 
  
Fig. 5-25 shows that both 131I and 188Re deliver higher dose to more thyrocytes if the 
radionuclide is located only in thyrocytes and not in colloid. However, only 188Re can show this 
advantage because only 188Re is in the thyrocytes. 
 
Considering only biologically realistic distribution scenarios, the mode of absorbed dose 
























Absorbed Dose to follicular cells
I-131 colloid I-131 follicular cell
Re-188 in Colloid Re-188 in Follicular Cell
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located in follicular cell and 131I located in colloid respectively. We considered only these two 
scenarios as the transit time of radioiodine in cell is very fast (less than an hour after administration 
based on the Champion study (Champion et al., 2007a)) compared with the half-life of 131I (8.01 
days).  
This preliminary finding indicates that most of follicular cells received high dose when 
188Re was located in follicular cells. Moreover, the absorbed dose spectrum from 188Re was 
narrower when compared with 131I located in the colloid.  
As a measure of the broadening of the absorbed dose distribution, the width of the 
histogram distribution at 50% of the maximum when 188Re being located in follicular cells was 
10.62 – 19.86 mGy/MBq.s compared with 6.03 – 17.78 mGy/MBq.s when 131I located in colloid. 
Broad dose distribution was observed when 131I located in colloid. The volume elements of 
follicular cell that received more than 17.78 mGy/MBq.s was 7848 voxels (35.97 % of follicular 
cells) but there were 1889 voxels (8.66 % of follicular cells) which received less than 6.03 
mGy/MBq.s. Conversely when 188Re was located in follicular cells, 77.80% of follicular cells 
received absorbed dose between 10.62 -19.86 mGy/MBq.s. Lesser absorbed dose and narrower 
range indicate more uniformly distributed dose which should make it easier to predict the 
biological effect on the cell or nucleus. On the other hand, it might be difficult to predict the 
radiobiological effect for broad dose distribution as some cells received high absorbed dose 
whereas there are some areas that received low dose. Also the lower energy limit on emission 
energies will cause underestimation of the advantage of the radionuclide being inside the cell.  
It is important to note that results of MCNPx simulations reported in this chapter are very 
preliminary. The main limitations of this work are the lack of rigorous validation of the simulation 
model in such a small region (micron level) and ideally with cross-validation with radiobiology 
experimental results (e.g. in vitro clonogenic cell survival assay)  and also the fact that beta ranges 
from both radionuclides (131I and 188Re) are far beyond the simulation space even if we already 
propagated our histology section in X-, Y- and Z-dimensions (3.35 × 10-7 cm3 calculated from 
voxel dimension of 128 × 128 × 5 with voxel size of 1.6 × 1.6 × 1.6 µm3). 
In addition, our simulated activity (0.01 MBq.s homogeneous distributed in the section) is 
generated the overestimation of activity when scaling this simulated volume (3.35 × 10-7 cm3) to 
average volume of human thyroid (average of 14.4 g for female age 20-96 years and assuming 
density of thyroid 1.05 g/cm3) (Pankow et al., 1985). The calculated human-equivalent activity 
from our simulation is 408.16 GBq whereas the clinical administered dosage ranges are 0.19 to 
187 
 
0.74 GBq for hyperthyroidism, 2.75 to 7.40 GBq for thyroid cancer. The initial choice of simulated 
activity was speculative in order to avoid issues of high noise levels though results can be scaled 
down to clinically applicable levels of administered activities. 
There are also some aspects where a deeper understanding of the biological and physical 
mechanisms are required in this simulation, for example, effects of radiation on colloid, loss of 
follicular structure in thyroid cancer, threshold dose for killing the cell or to produce DNA double 
strand break in the nucleus and also different patterns of dose distribution in colloid and follicular 
cells (e.g. homogeneous, heterogeneous or at the periphery of the cell). These will be factors to 
























Our initial assumption was that metabolised radiotracers (e.g. 123I-NaI, 131I-NaI) are taken 
up by NIS at the apical membrane, then oxidised and organified to thyroid hormone in thyrocytes, 
and stored in colloid until released to the bloodstream. In contrast, non-metabolised tracers (e.g. 
99mTc-pertechnetate, 188Re-perrhenate) are not involved in the processes of thyroid hormone 
synthesis and as such are expected to be solely localised in in thyrocytes. 
For tracer localisation with EM, the primary peak of rhenium cannot be detected in 
follicular cells due to limitations of detection sensitivity and the physical properties of rhenium 
(proximity of characteristic peak to other elements naturally present in the sample). Nevertheless, 
this work has shown the capability of EM as a tool for tracer localisation at cellular level and 
elemental analysis of high spatial resolution images of rat thyroid follicles.  
As shown in this work, the MAR technique can be used to determine the micro-distribution 
of radiopharmaceuticals at cellular level. Results showed that pertechnetate/perrhenate was 
located only in thyrocytes but was not present in colloid.  
It can therefore be concluded that non-metabolised tracers are only located in thyrocytes. 
To conclude our initial assumption, we need to combine the results from 2 experiments (TEM and 
MAR). This information was used as an input for small-scale dosimetry. 
The next part of this chapter described small-scale dosimetry. The work described in this 
study has been carried out to estimate the absorbed dose distribution among a population of cells 
at cellular level using MCNPx. The modelling information (cell geometry, radionuclide distribution) 
were experimentally derived from real histology sections and MAR of the rat thyroid as described 
in the first part of this chapter. Then the data formed the input to Monte Carlo simulations using 
the OEDIPE platform. These initial results demonstrated that 188Re-perrhenate, being localised in 
follicular cells, has dosimetric advantages over conventional131I-NaI localised in the colloid. By 
assuming follicular cells are targets for cell killing, the pattern of absorbed dose when 188Re 
distributed in follicular cells seemed to have some advantage as absorbed dose ranges were 
higher and also more uniform as about 80% of the cell population received dose within narrower 
range. On the other hand, the absorbed dose received by 131I located in colloid were 
inhomogeneous as only 65% of the follicular cells population was exposed to a dose range within 
the width of the histogram distribution at 50% of the maximum, whereas some cells received high 
and some cells received low dose which may be difficult to predict the range of biological effects. 
189 
 
These pilot data seem to support the macro-dosimetric estimation of possible advantages from 
using 188Re-perrhenate treatment of thyroid disease. However, further model validation together 
with deeper knowledge of radiobiological and physical modelling are needed for establishing 




























Chapter 6 Summary and Future Work 
6.1 Thesis Summary  
Work in this thesis investigated the isotopes 186Re- and 188Re- in the form of perrhenate 
as alternatives to conventional radionuclide 131I-sodium iodide for treatment of thyroid benign 
disease. Also, the potential of using these isotopes in non-thyroidal tumours has been discussed 
in this work.  
A general introduction of the sodium iodide symporter, basic anatomy, histology, 
physiology and system description of our preclinical scanners (nanoScan SPECT/CT and 
nanoScan PET/CT) were presented in chapter 1. The published literature relevant to the sodium 
iodide symporter (NIS), NIS in nuclear medicine, NIS radiotracers and the role of nuclear medicine 
imaging in the management of thyroid disease were also reviewed in the first chapter.   
 The first experimental part of this thesis reported on basic performance characteristics 
(uniformity, linearity, calibration factor) of the nanoScan SPECT/CT. In this chapter, we critically 
investigated the quantification accuracy of preclinical nanScan SPECT/CT (with 99mTc, 123I and 
188Re) and nanoScan PET/CT (with 18F) using the mouse size micro-hollow sphere phantom 
relevant to the in vivo imaging intended in this research project. The effects of object size, 
acquisition time and reconstruction parameters (number of iterations) on the image-based 
quantitative accuracy were examined. We also inspected the quantification accuracy with 3 
different methods; (a) large VOI with integral activity (b) large VOI with SUVmax and (c) automatic 
VOI with 42% thresholding SUVmean. The large VOI approach with integral activity within the entire 
organ seems the most suitable method for our in vivo experiments aiming at determining relative 
organ uptake. Subsequently, this work attempted to assess PVE from this method and correct for 
its effects using phantom-derived correction factors. Quantification results with 188Re showed 
poorest accuracy especially with the smallest phantom compartment (3.9 mm diameter sphere). 
However, our normalised results indicated that across different isotopes the influence of PVE 
remained comparable. Therefore, the poorer performance of 188Re compared with 99mTc and 123I 
is likely to be caused by other factors; physical properties of 188Re (scatter photon, septal 
penetration, Bremsstrahlung, low-abundant photons), limitations of instrument and reconstruction 
software (lack of high energy multi-pinhole collimation, no attenuation and scatter correction, 
unclear energy dependency of PSF model used during image reconstruction). For the effects of 
acquisition time and reconstruction iterations, varying acquisition time did not alter the 
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quantification accuracy for 99mTc and 123I, however, 188Re was more affected when acquiring 
shorter time frames and the effect was stronger in smaller spheres. Additionally, the quantification 
accuracy improved when changing from 6 to 9 iterations. When changing from 9 to 24 iterations, 
quantification accuracy depended on acquisition time (count levels). Hence, these errors are likely 
to be related to the influence of number of counts per projection. Furthermore, the quantification 
accuracy in the smallest microsphere was affected most strongly by the reconstructing 
parameters and acquisition times. In the later part of chapter 2, the quantification results from 
nanoScan SPECT/CT were compared with 18F data from the nanoScan PET/CT. The 
quantification of small objects from nanoScan PET/CT was more accurate than nanoScan 
SPECT/CT. Our PVE results were found to be somehow contradicting with the scanner spatial 
resolution as according to system specifications, the nanoScan SPECT/CT has a better spatial 
resolution than the nanoScan PET/CT. Therefore, the quantification of small objects from 
nanoScan PET/CT should be subject to stronger PVE than nanoScan SPECT/CT. However, this 
might be mainly due to the correction processes of attenuation, scatter and dead-time which are 
employed only in nanoScan PET/CT. Hence, these data are important to note when comparing 
results across different modalities.  
 In chapter 3, we presented a series of in vivo spatio-temporal quantification 
measurements with available SPECT NIS-radiotracers (99mTc-pertechnetate, 123I-NaI, 131I-NaI and 
188Re-perrhenate) in normal healthy and non-thyroidal NIS bearing tumour model. We also 
presented kinetic data to support a forthcoming clinical PET radiotracer 18F-BF4. This information 
afforded a side by side comparison of NIS radiotracers. In a healthy mouse model, we 
demonstrated distinct differences of uptake patterns in thyroid between metabolised (123I- and 
131I-NaI) and non-metabolised tracers (18F-tetrafluoroborate, 99mTc-pertechnetate and 188Re-
perrhenate), and also subtle differences between the supposedly non-metabolised tracers. In 
salivary glands, similar patterns of uptake were observed for all tracers with uptake increasing 
gradually over time then remaining steady and slowly washing out. Stomach uptake was high 
compared with other organs (thyroid, salivary glands, and urinary bladder) perhaps due to its 
large size and effect of anaesthesia. The uptake in stomach peaked at 4 h for metabolised 
radiotracers. In contrary, peak uptake in stomach was found at 8 h for non-metabolised 
radiotracers, except for 18F-BF4 which showed peak values at around 3 h after injection (as we 
collected data only up to 4 h). The activities in the urinary bladder indicated the excretion of 
radioisotopes via the genitourinary system. The maximum bladder activity was mostly observed 
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at 4 hr post injection because all animals were anesthetised during the imaging session then mice 
were awakened from anaesthesia and urinated. Activity in muscle (not expressing-NIS) and left 
ventricle (representing blood activity) was low and remained so over time for all tracers. In this 
chapter, we demonstrated the capabilities of the dedicated high-resolution preclinical systems 
which clearly distinguished and quantified the radioactivity accumulated in small organs such as 
the thyroid and salivary glands. The later part of this chapter described in vivo spatio-temporal 
quantification in a xenograft model. All radiotracers detected the tumour with high target to 
background ratio. However, perrhenate uptake in tumour was significantly low when compared 
with pertechnetate or iodide, with percentage uptake per gram of tumour at about 5 - 12 %ID/g 
for 188Re-perrhenate, 45-55 % ID/g for 99mTc-pertechnetate and 42-62 % ID/g for 123I-NaI). This 
work also showed kinetic data of the forthcoming PET radiotracer 18F-BF4 for imaging NIS-
expressing tumours, showing that 18F-tetrafluoroborate accumulated in tumour at about 4-8 % 
ID/g. This chapter has described the ability of 188Re-perrhenate for imaging with appealing 
therapeutic properties (shorter half-life, higher beta energy and lower energy gamma emission 
compared with 131I-NaI). However, it also brought up challenges with imaging 188Re such as 
increased image background.  
The human-equivalent effective dose for diagnostic and therapeutic use of NIS 
radiotracers (18F-tetrafluroborate, 99mTc-pertechnetate, 123I-iodide, 131I-iodide and 186Re- and 
188Re-perrhenate) have been reported in chapter 4 using the spatio-temporal data from chapter 
3. In the present work, the dose comparison studies were conducted on the same strain sex- and 
age-matched animals to allow approximate comparison of radiation dose for tracer development. 
Estimation of effective doses from our study varied from the ICRP and this can be attributed 
mainly to the bio-kinetic models used as a basis for the calculations. Nevertheless, these 
estimated values can still be practically useful for initial estimates and dosimetric comparison in 
the development of new radiotracers. For illustration, the findings from this work indicated the 
effective dose for 18F-BF4 as an initial approach for a forthcoming clinical trial of the radiotracer in 
thyroid disease. Based on our human-equivalent estimation, the effective dose from this new PET 
tracer was lower than conventional imaging agents (123I-iodide and 131I-iodide). However, the 18F-
BF4 estimated dose was still higher when compared with 99mTc-pertechnetate a long-established 
SPECT tracer. In the later part of the chapter, we presented the dosimetric feasibility of using 
rhenium isotopes (186Re- and 188Re-perrhenate) in treatment of benign nodular thyroid disease 
and non-thyroidal NIS-expressing tumours compared with conventional 131I-NaI. The preclinical 
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dosimetric estimation demonstrated that rhenium isotopes were equally effective when excluding 
uptake in stomach and urinary bladder (due to large variations affected by subject conditions such 
as food consumption and anaesthesia). Our results indicate that radionuclide therapy of thyroid 
benign disease with rhenium isotopes appears promising and worthy for further investigation in 
humans. This study is the first in vivo kinetic study that provided dosimetry estimations and 
compared the therapeutic efficiency in treating thyroid benign disease. The higher beta energies 
and longer range of rhenium isotopes may improve treatment efficacy when treating larger benign 
nodules in which radioiodine therapy may be less effective due to the shorter particle range. The 
lower abundance of gamma photons emitted by 186Re and 188Re is more favourable than those 
produced by 131I, reducing radiation dose to whole body and to other people (members of family, 
staff, general public) and thus reducing or eliminating the need for isolation. Based on our study, 
effective dose per administered activity from 186Re and 188Re was lower than conventional 
radioiodine. Also red marrow absorbed dose was about 1.5 and 3 times (for 186Re and 188Re 
respectively) lower than that produced by radioiodine. Furthermore, treatments might therefore 
be offered on outpatient basis at great cost saving, and patients could return to normal lifestyle 
earlier. These factors make perrhenate promising therapeutic substrates for the sodium/iodine 
symporter. In xenograft bearing non-thyroidal NIS adenocarcinoma tumour (hNIS-engineered 
model), our data indicated that both rhenium isotopes delivered higher absorbed dose to the 
tumour (6.33 and 8.68 times higher for 186Re and 188Re) compared to 131I-NaI. Additionally, the 
therapy indexes (tumour to effective dose and tumour to thyroid ratio) for both rhenium isotopes 
were greater than 131I-NaI. Tumour to effective dose ratio for rhenium isotopes were about 5 - 7 
times higher whereas tumour to thyroid ratio of both rhenium isotopes were about 7 – 9 time 
higher than 131I-NaI . The red-marrow absorbed doses produced by rhenium were lower than 
those produced by radioiodine (~ 0.27 times for 186Re and 0.50 times for 188Re) so for the same 
effective dose to the whole-body, rhenium can deliver more dose to the tumour. It was also 
demonstrated in this chapter that the quantification accuracy and partial volume effect in 
preclinical research can be evaluated and corrected for by using standard geometrical phantom 
data (MHS quantification data from Chapter 2). Data presented in this work show the impact of 
quantification accuracy and partial volume effect on dosimetry calculations in small organs (e.g. 




An investigation of the radionuclide distribution at the microscopic level in thyroid was 
critically examined in Chapter 5. It has long been hypothesised that metabolised radiotracers (e.g. 
123I-NaI, 131I-NaI) are taken up by NIS to thyrocytes, and stored in colloid until released to the 
bloodstream. In contrast, non-metabolised tracers (e.g. 99mTc-pertechnetate, 188Re-perrhenate) 
are expected to be localised only in thyrocytes. In this thesis, we used electron microscopy (EM) 
and micro-autoradiography (MAR) to study the tracer distribution at cellular level. With the EM 
technique, the spectra of copper, potassium, sulfur, chlorine and phosphorus were observed in 
thyroid follicles, suggesting these to be natural elements in the thyroid. Spectra of iodine were 
detected only in the colloid but not in thyrocytes. However, the primary peak of rhenium cannot 
be detected in follicular cells due to limitations of detection sensitivity and the physical properties 
of rhenium. This experiment has demonstrated the competence of EM as a tool for tracer 
localisation and elemental analysis at cellular level although rhenium is problematic. In the latter 
part of this chapter, the MAR technique was used to prove our hypothesis that non-metabolised 
tracers are present only in thyrocytes but not in the colloid. The results from this experiment 
indicated that pertechnetate/perrhenate was present only in thyrocyte areas while there was no 
pertechnetate detected in the colloid. It can therefore be concluded from these two techniques 
(EM, MAR) that non-metabolised tracers are only located in thyrocytes. This information can be 
used as an input for small-scale dosimetry. In the last part of this thesis, simulation work has been 
carried out to estimate the absorbed dose at cellular level using MCNPx. The modelling 
information (cell geometry, radionuclide distribution) was experimentally acquired from real 
histology section and MAR of rat thyroid, then the data input to Monte Carlo using the OEDIPE 
platform. By assuming follicular cells are the target for cell killing, the pattern of absorbed dose 
when 188Re distributed in follicular cells showed higher and also more uniform dose distribution 
as about 80% of the cell population received dose within narrower range. On the other hand, the 
absorbed dose delivered by 131I located in the colloid was more inhomogeneous as only 65% of 
the follicular cells population was exposed to a dose range within the width of the histogram 
distribution at 50% of the maximum, whereas some cells received high and some cells received 
low dose which may be difficult to predict the range of biological effects. These pilot data support 
the macro-dosimetric estimation from chapter 4 for using 188Re-perrhenate in treatment of thyroid 
diseases. The results suggested that both 131I and 188Re would be more effective if localised within 




In conclusion, the initial preclinical work and small-scale dosimetry have proved the 
hypothesis that the radioisotopes of rhenium (186Re- and 188Re-) in the form of perrhenate can be 
used as alternatives therapeutic radionuclide to conventional 131I-NaI. Although it is difficult to 
estimate the human dosimetry by scaling from animal data the preclinical dosimetric study in this 
thesis has formed an important step for initial estimates of the therapeutic potential and 
application of these radiotracers clinically and in support of methodology for performing kinetic 



























6.2 Recommendation for Future Work 
Although results presented here have demonstrated the capabilities of preclinical 
scanners in quantification, dosimetric profile estimation and the potential of using rhenium 
isotopes in benign thyroid disease, as well as the tracer distribution at cellular level and small-
scale dosimetry in the thyroid model, these issues could be further investigated and developed in 
a number of ways:  
 Attenuation correction for nanoScan SPECT/CT and 188Re scatter correction  
We did not correct for photon attenuation in our SPECT data. Hence, SPECT attenuation 
correction could be performed in order to improve the quantification accuracy in preclinical 
SPECT.  In addition, 188Re scatter correction needs further investigation with the development of 
software applicable to multi-pinhole reconstruction. Triple-energy window, Monte Carlo simulation 
using GATE or the convolution method with Matlab/IDL would lead to a better image quality and 
reduce scatter. Furthermore, the high energy multi-pinhole collimator could be employed to 
reduce septal penetration (Bernsen et al., 2014).  
 Improve accuracy of image-based VOI 
In order to improve the accuracy of image-based VOI analysis, alternative imaging 
techniques such as SPECT/MR or PET/MR should be investigated since those techniques can 
provide an improved soft tissue contrast which should make it easier to identify and distinguish 
the boundaries of small organs (e.g. thyroid, salivary glands) on the MRI images. Also, thyroid 
volume could be precisely estimated with preclinical 3D ultrasonography (Freesmeyer et al., 
2014; Nagarajah et al., 2011). 
 Tracer localisation at cellular level and quantification of micro-autoradiography 
As mentioned earlier, tracer localisation at cellular level is the key to understand small-
scale dosimetry. Further investigations with other techniques (such as SIM-Secondary Ion Mass 
Spectroscopy, or Confocal Fluorescence microscopy) are needed in order to improve the 
resolution and sensitivity (Koike et al., 2015; Tessier et al., 2012). In addition, further MAR 
experiments should be extended to cover silver grain quantification technique which may improve 
the realistic dose map for small-scale dosimetry (Lund Nielsen and Halkjær Nielsen, 2005; 





 In vitro- and in vivo treatment response of 188Re-perrhenate versus 131I-NaI 
In vitro dose validation using conventional clonogenic assays and in vivo treatment 
response (measuring level of thyroid hormones, determining thyroid/tumour volume and 
histopathological changing for pre- and post-treatment) need further work before using this 
rhenium isotope in human. 
 Small-scale dosimetry, Role of Auger electrons in small-scale dosimetry 
We performed pilot small-scale dosimetry with MCNPx in this thesis. However, small-
scale dosimetry can also be performed with other platforms for example PENELOPE, GATE, 
GEANT4. Additional comparison of simulation results should be also considered because 
different simulation platforms have different assumptions and physics processes (e.g. choice of 
tissue compartment, energy spectrum of radionuclide and cut-off simulation energy).  
Also due to limited time and resources, we did not validate our MCNPx simulation at such 
a small-scale. Further model validation together with deeper knowledge of radiobiological and 
physical modelling are needed for using this preliminary results for clinical translation. In addition, 
we did not include Auger electrons in our simulation due to the limitation of energy cut-off in 
MCNPx. This could be addressed by using the PENELOPE, GEANT4 or Monte Carlo 4 (MC4) 









Appendix A. Accuracy Calibration of Radionuclide Activity 
Calibrator 
In this study, the radionuclide activity calibrator was used as a standard measurement 
throughout the thesis. It is important to calibrate this equipment in order to ensure that the 
radionuclide calibrator provides a correct reading of activity within the required accuracy levels 
(Busemann Sokole et al., 2010). In the UK, the accuracy of radionuclide activity calibrator is 
calibrated against the NPL (National Physics Laboratory) as national standard using the MGPG 
9317 (Measurement Good Practice Guide No. 9317) as a guideline. The recommended accuracy 
deviation limit for high energy radionuclide (energy ≥ 100 keV) as stated by NPL is ± 2% from 
secondary standard source (Gadd et al., 2006).  
The radionuclide activity calibrators in the Department of Imaging Sciences and 
Biomedical engineering were annually calibrated using a standard source directly traceable to 
NPL. The calibration sources are sent to NPL immediately after completion of measurements with 
a number of calibrators, including at least one of the calibrators in the department Imaging 
Sciences and Biomedical Engineering. As NPL recommended, the radionuclide activity calibrator 
is checked and calibrated with at least two reference sources and local practice is to include 99mTc 
every year while varying the radionuclide of the second source. For example, in 2013, the 
calibration was performed on 31st July 2013 with 99mTc and 67Ga (as illustrated in figure A-1 and 
A-2) 
 
Figure A-1 The accuracy calibration of radionuclide activity calibrator with 99mTc in year of 2013. 







The test was performed in 2 modes of measurement; “preset” and “dial” (a manual mode 
allows the user to “dial in” conversion factors not available on the preset button). The percentage 
deviations of measurement from reference standard source for 99mTc and 67Ga were 0.96 and -
1.26 for “preset” setting and 0.98 and -1.20 for “dial” setting. Hence, the results showed that our 













Figure A-2 The accuracy calibration of radionuclide activity calibrator with 67Ga in year of 2013. The 
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